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Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in the 
western world and remains incurable. It is driven by as yet unknown (auto)antigens 
via the B cell receptor (BCR) and growth, survival and expansion signals it 
receives from the microenvironment through a range of cytokines and receptors, 
including Toll-like receptors (TLR). The role of the microenvironment in the 
development and progression of CLL is currently of major interest. Pathogen- and 
damage-associated molecular patterns (PAMPs and DAMPs, respectively) 
represent exogenous and endogenous microenvironmental factors acting via a 
range of receptors, including TLR. CD180/RP105 is a membrane-associated 
orphan receptor of the TLR family which is expressed on various cells of the 
immune system including macrophages, peripheral blood monocytes, dendritic 
cells, naive and mature B cells and marginal zone/mantle zone B cells driving 
normal B-cell activation and proliferation. However, it is not expressed on 
germinal centre (GC) B cells. CD180 is expressed heterogeneously on CLL cells, 
and predominantly on CLL with mutated IGVH genes (M-CLL). Although 
approximately 60% of CLL clones expressed CD180, only half responded to 
ligation with anti-CD180 monoclonal antibody (mAb) by activation, cycling, and 
reduced basal apoptosis. They were termed responders (R) and CD180+ CLL 
samples that failed to respond to anti-CD180 mAb despite expressing a high 
density of CD180 receptors, were termed non-responders (NR). 
Our group has previously demonstrated that CD180 ligation significantly induced 
phosphorylation of ZAP70/Syk, ERK, p38MAPK, and AKT in R-CLL cells whilst 
CD180-mediated signalling in NR CLL cells did not progress downstream from 
ZAP70/Syk phosphorylation indicating a block in activation of downstream protein 
kinases, and possible anergy. 
However, the responses were quite heterogeneous and to further understand the 
CD180-mediated signalling pathways in CLL; downstream signal transduction 
was studied by defining CLL samples into R and NR through their proximal ability 
to activate AKT. R-CLL cells could be divided into two categories as AKT 
signallers (AKT-S) and AKT non-signallers (AKT-NS) based on the ability to 
increase level of phosphorylation of AKT (Ser 473) compared with the basal 
levels. AKT-NS showed a significant increase in p38MAPK-P and this group was, 
therefore, re-categorised as p38MAPK signallers (p38MAPK-S). A small cohort 
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of patients showed phosphorylation of both AKT and p38MAPK and they were 
categorised as double signallers (DS) whereas the remaining CLL samples which 
showed a decrease in percentages of both AKT-P and p38MAPK-P expressing 
cells and were categorised as non-signallers (NS). Ligation of CD180 with mAb 
on CLL cells can activate two alternative signalling pathways, one being pro-
survival and operating through activation of protein kinases (PK) BTK-AKT (AKT-
signallers); and the second - predominantly pro-apoptotic, operating through 
activation of p38MAPK (p38MAPK-signalers) but not through BTK. This may 
have implications for CLL therapy where BTK inhibitors are being used. 
To assess cross-talk between CD180 and BCR (sIgM) signalling pathways in 
CLL, the effect of pre-engagement of CD180 on sIgM-mediated signalling was 
investigated. While sIgM ligation with goat anti-human IgM F(ab)2 alone led to a 
significant activation of pro-survival BTK-AKT pathway, pre-treatment with anti-
CD180 mAb redirected pro-survival signalling mediated through BCR towards 
pro-apoptotic p38MAPK pathway. Application of specific inhibitors of AKT and 
p38MAPK signalling pathways confirmed that, in many of the CLL samples, 
activation of AKT and p38MAPK pathways is exclusive. This dichotomy appears 
to be a feature of CLL cells, and not of normal B cells that responded to CD180 
ligation as double AKT/p38MAPK signallers. 
It is becoming apparent that the clinical outcome of patients with CLL is 
significantly affected by intraclonal diversity. CLL clones which can respond more 
vigorously to external stimuli may gain selective advantage for growth and 
survival and perhaps promote clonal evolution. That CD180 expression 
modulates in some categories of CD180+ CLL cells suggests a possible link 
between dynamic expression of CD180 and CD180-mediated intracellular 
signalling, survival or apoptosis. Finding on rewiring of signalling pathways from 
BTK/AKT pro-survival circuit to p38MAPK pro-apoptotic pathway in AKT-S CLL 
cells may suggest a possible cross-talk between CD180 and BCR in AKT-S is 
consistent with that CD180+sIgM+ CLL cells may receive simultaneous signals 
through both receptors in vivo and microenvironment plays a major role in the 
survival of CLL cells. Hence, this study helped defineify mechanisms leading to 
the expansion of the leukaemic cells and thus contribute to development of novel 
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1.1 Epidemiology and aetiology of Chronic Lymphocytic Leukaemia 
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in 
Western countries mainly affecting elderly individuals. It presents with 
progressive accumulation of leukaemic B cells in the blood, bone marrow and 
lymphatic tissues (Dighiero, 2005). CLL is most frequently diagnosed among 
people aged 65-74 with the median age at diagnosis being 71 years. The highest 
frequency of deaths from CLL is found among people aged 75-84 with a median 
age at death of 80 (www.seer.cancer.gov). Between 7% and 20% of patients with 
CLL in European population are <55 years. These younger patients have adverse 
prognosis markers with Immunoglobulin Heavy Chain Variable (IGHV) unmutated 
status (U-CLL), expression of ZAP-70 and more likely to have early stage of 
disease (Parikh et al., 2013). The time to treatment was shorter in patients ≤55 
years than in those older than 55 years (4.0 years versus 5.2 years; P=0.001). 
And also, CLL patients who were ≤ 55 years had longer survival than patients 
who were > 55 years (12.5 years versus 9.5 years; P<0.0001). However, patients 
≤55 years had significantly shorter survival than the age- and sex-matched 
normal population (12.5 years versus not reached; P<0.0001) (Parikh et al., 
2013). The disease rarely is diagnosed in people <30 years of age (Morrison and 
Nowakowski, 2016).  
The incidence of the disease shows significant geographical differences. CLL is 
much less common in the Far East than the Western countries.  It is possible to 
suggest that genetic and environmental factors may play a role in geographical 
differences since the incidence in the Asian population in the USA seems to be 
lower as well (Morrison and Nowakowsk, 2016). When evaluating the average 
incidence of CLL in Taiwan during the period from 1986-1990 to 2001-2005, there 
was a drastic increase of CLL incidence in both males and females. However, the 
incidence remained stable for both sexes for Caucasian Americans, suggesting 
the involvement of lifestyle and environmental factors in the development of CLL 
in Taiwanese (Wu, 2010). Eastern CLL patients have been reported to progress 
earlier, to have a shorter time-to-first-treatment than western patients. They also 
required treatment twice as often as Caucasian patients in the same hospital 
suggesting that the outcome difference might be less associated with the 
availability of medical care or therapeutic medicines but due to the existence of 
ethnic differences in the disease development (Wu et al., 2013). 
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Gender is also an important factor as the incidence of the disease is different 
among males and females. The incidence of CLL in the USA is 6.75 and 3.65 
cases per 100,000 population per year in males and females respectively, 
resulting in a ratio of 1.7:1 between males and females (Morrison and 
Mayakovski, 2016).  Catovsky et al., (1989) were the first to report that women 
with CLL had a better overall survival (OS) independently of age and the stage of 
the disease. A statistically significant inferior survival for men compared to women 
was shown by Kristinsson et al., (2009) in all age groups of CLL patients. Recent 
clinical trials demonstrated that women had a better overall response to treatment 
than men although they experienced greater gastro-intestinal toxicity (Catovsky 
et al.,2014).  
CLL cells express mostly CD19+ B cell lineage phenotype hence the disease is 
also called B-cell chronic lymphocytic leukaemia (B-CLL). The prediagnosis 
aetiology of CLL remains unknown. A CLL patient with at least one affected 
relative is considered familial and approximately 5% of patients have family 
history of leukaemia (Goldin et al., 2010). One in every ten patients with CLL has 
either a family history of CLL or another lymphoproliferative disorder and there is 
a 30-fold increase in the risk of CLL in first-degree relatives of patients (Greer et 
al., 2009). Several studies have been done to analyse the variations between 
familial and sporadic CLL. Some studies involving multiplex families have shown 
familial CLL to have an earlier age at diagnosis compared to sporadic CLL. 
However opposite results have been demonstrated by some studies based on a 
large population of CLL patients, by not finding differences in age at diagnosis 
between two categories. A higher proportion of female cases is shown among 
familial compared to sporadic CLL (Goldin et al., 2010).  
Studies on familial CLL have not discovered genes to clearly relate with the 
pathophysiology of CLL although the characteristic expression markers of CLL 
have been found in family members of patients (Goldin et al., 2010). Familial and 
sporadic CLL cases have shown similar shorter telomeres or CD38 positivity 
which is a prognostic marker of CLL (Ishibe et al., 2002). The frequency of IGVH 
mutation was significantly higher in familial CLL (in 327 cases) compared to 
sporadic cases (in 724 cases) (Crowther-Swanepoel et al., 2008). It is also found 
that B-lymphocyte stimulator levels (BlyS, also known as B-cell activating factor, 
BAFF) were higher in familial CLL cases than sporadic CLL cases or controls 
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(Novak et al., 2006). Another small study has shown similar results with higher 
levels of BAFF in familial CLL than sporadic CLL cases, but the level of 
expression was significantly lower in the combined group of CLL patients than 
controls (Molica et al., 2009).  
Kristinsson et al., (2008) have observed 3-fold increased risk of non-Hodgkin 
lymphoma (NHL) and CLL among first-degree relatives of lymphoplasmacytic 
lymphoma (LPL)/Waldenstrom macroglobulinemia (WM) patients. Although CLL 
shows substantial geographical variations with a 40-fold difference in rates (the 
highest among Caucasians in North America and Europe and very low in Asians), 
environmental risk factors associated with CLL have not been identified (Goldin 
et al., 2011).   
Most chronic lymphoproliferative disorders (CLPDs) are B cell origin. Cases of 
chronic lymphoid leukaemia of T-cell origin have been reported to account for 
less than 5% of the total number of CLPDs (Jandi, 1987). A subtle proportion of 
CLL cases belongs to T lineage, and it is known as T-cell Chronic Lymphocytic 
Leukaemia (T-CLL). T-CLL accounts for less than 1% of all CLPDs and consists 
of mature T-lymphocytes with immunophenotype of CD2+, CD3+, CD7+, and 
CD4+/CD8-ve (Hoyer et al., 1995). The presence of lymphadenopathy, 
organomegaly and infiltrating monoclonal B cells with same CLL 
immunophenotyping, but lack of peripheral blood lymphocytosis is known as 
small lymphocytic lymphoma (SLL). SLL has been considered as an equivalent 
form of CLL, but currently, they are regarded as different manifestations of the 
same entity. The clinical outcome of CLL is extremely heterogeneous as some 
patients show very indolent disease while others have a more aggressive disease 
(Santos and O’Brien, 2012). 
 
An increased risk for CLL among individuals with a history of pneumococcal 
pneumonia has been reported. Those studies have found that pneumonia 
remained marginally associated with increased risk of CLL for more than a 5-year 
period after pneumonia episode. The presence of an extended latency period 
over several years in those individuals could be explained by suggesting that 
undiagnosed CLL may cause pneumonia (Anderson et al., 2009). Other 
respiratory tract infections such as sinusitis also increased the risk of CLL. B-cell 
immunity seems to be important in protection against Streptococcus pneumoniae 
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and Haemophilus influenza which involve with respiratory tract infections 
(Anderson et al., 2009). Some evidence has shown a connection between skin 
infections like cellulitis and herpes zoster (caused by Staphylococcus aureus or 
Streptococcus pyogenesandvaricella zoster virus respectively) and the increased 
occurrence of CLL (Anderson et al., 2009). There are few explanations for these 
interactions. Common community acquired disease such as pneumonia may 
promote the transition from Monoclonal B-cell lymphocytosis (MBL) to CLL. Since 
CLL cells have VH gene mutations, the importance of antigenic stimulation in CLL 
can be suggested (Kienle et al., 2006). Since encapsulated bacteria are 
responsible for causing respiratory tract infections it is also possible to suggest 
that these bacteria may play a role in the development of CLL. The disruption of 
immunity in CLL patients before they are diagnosed could be the cause for the 
frequent presence of community-acquired infections (Anderson et al., 2009). 
1.2 Diagnosis and clinical staging  
CLL is described as leukaemic, lymphocytic lymphoma by the World Health 
Organization and it is distinguishable from SLL by its leukaemic appearance. 
Several diagnostic parameters are used to confirm that the patient has CLL and 
no other lymphoproliferative disease such as hairy cell leukaemia, or leukaemic 
manifestations of mantle cell lymphoma, marginal zone lymphoma, splenic 
marginal zone lymphoma with circulating villous lymphocytes or follicular 
lymphoma (Hallek et al.,2008). 
1.2.1 Diagnosis in blood 
The presence of more than or equal to 5×109/L B lymphocytes (5000/μL) in the 
peripheral blood for the duration of at least three months indicates diagnosis of 
CLL.  The clonality of the circulating B lymphocytes can be confirmed by flow 
cytometry analysis. The leukaemic cells are characteristically small, mature 
lymphocytes with a narrow border of cytoplasm and a dense nucleus lacking 
discernible nucleoli with partially aggregated chromatin (Hallek et al., 2008).  
1.2.2 Diagnosis by Immunophenotyping 
CLL cells are characterised by the co-expression of T-cell antigen CD5 and B-cell 
surface antigens CD19, CD20 and CD23. The levels of expression of CD19 and 
CD20 are lower compared with normal B cells. Almasri et al., (1992) 
demonstrated that low CD20 expression is a unique feature of CLL/SLL cells. 
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Cells showing intense expression of CD20 antigens in a small number of CLL/SLL 
cases could be due to the presence of biologically or clinically different disorder. 
The absence of FMC7 and CD22 is also used as a routine diagnostic criterion in 
patients with CLL (Ibrahim, 2001). 
 
1.2.3 Clinical staging 
There are two staging systems for CLL depending on clinical characteristics - Rai 
staging and Binet staging.  
Table 1.1: Rai staging (Rai et al., 1975).  
Clinical stage Clinical characteristics 
Low risk (stage 0) Lymphocytosis (increase in the 
proportion of lymphocytes) in blood 
and/or bone marrow. Absolute 
lymphocytes count is 15,000/mm3 or 
more in blood, with 40% or more 
lymphocytes in the marrow. 
Intermediate risk (stage I or stage II) Lymphocytosis with enlarged lymph 
nodes, enlarged spleen 
(splenomegaly) or liver 
(hepatomegaly) or both (stage I) and 
nodes may or may not be enlarged 
(stage II). 
High risk (stage III) Lymphocytosis with anaemia, 
haemoglobin (Hb) less than 11 g/100 
ml or haematocrit less than 33%. 
Nodes, spleen or liver may or may not 
be enlarged. 
High risk (stage IV) Lymphocytosis-with-




When comparing the survival of patients in different stages according to Rai 
staging system, Rai et al., (1975) reported that out of 125 patients analysed, all 
stage IV patients died within 3.5 years from diagnosis and only one patient in 
stage II survived for five years. The overall survival (OS) of patients in stages II, 
I and 0 was longer than stage IV and some patients in stage 0 could survive for 
23,24 and 32 years after diagnosis.  
Binet et al., (1981) proposed a new staging system by analysing two series of 
patients (a total of 295 patients). They have used a survival method which 
enabled to identify factors affecting survival. The new staging system has 
categorised CLL patients into three groups as low-, intermediate- and high-risk 
patients. The new system was simpler and required only clinical examinations 
and routing haematological analysis. 
Table 1.2: Binet staging (Binet et al., 1981). 
Clinical stage  Clinical characteristics 
Stage A No anaemia, no thrombopenia, less 
than three involved areas*. Hb 100 g/L 
(10 g/dL) or less, platelets 100x109/L or 
more and any two of the 
organomegalies- (splenomegaly or 
hepatomegaly).  
Stage B  No anaemia, no thrombopenia, three or 
more involved areas* Hb 100 g/L (10 
g/dL) or less and platelets 100x109/L or 
more. 
Stage C Anaemia (Hb less than 10 g/dL) and/or 
thrombopenia (platelets less than 
100,000/mm3), irrespective of 
organomegaly. 
*The following areas of involvements are considered for staging; 
1. Head and neck, including the Waldeyer ring (this counts as one area, even if 
more than one group of nodes is enlarged). 
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2. Axillae (involvement of both axillae counts as one area). 
3. Groins, including superficial femorals (involvement of both groins counts as 
one area). 
4. Palpable spleen. 
5. Palpable liver (clinically enlarged). 
The median survival for the patients at Binet stage A or Rai stage 0 (low risk) is 
over 10 years, 5-7 years for patients in Binet stage B or Rai stage I-II 
(intermediate risk) and 2-3.5 years for Binet stage C or Rai stage III-IV (high risk) 
(Cramer and Hallek, 2010). 
1.3 Prognostic markers 
CLL patients show clinical heterogeneity having some patients die soon after 
diagnosis despite aggressive treatments whereas the other group can survive for 
a prolonged period without requiring definitive treatment. Rai and Binet staging 
systems above mentioned, provide valuable information on survival of patients; 
however, they are unable to predict which patients will experience an indolent or 
an aggressive form of the disease especially in early stage or intermediate risks 
patients. Therefore, the use of several prognostic factors which enable to identify 
favourable versus poor prognoses is necessary to manage patients clinically. 
These prognostic markers include Immunoglobulin (Ig) heavy (H) chain gene 
(IGVH) mutational status, expression of CD38, lymphocyte doubling time, 
circulating levels of β2 microglobulin and soluble CD23, serum thymidine kinase 
levels, bone marrow history, expression of ZAP-70 and cytogenetic abnormalities 
(Damle ,1999).  
1.3.1 Immunoglobulin (Ig) heavy (H) chain gene (IGVH) mutational status 
B cell Immunoglobulin genes undergo somatic hypermutations during germinal 
center reaction to diversify the antibody repertoire resulting in improved affinity of 
an antibody towards an antigen. Although the early studies suggested that CLL 
cells did not show somatic mutations in complementarity-determining regions of 
the antibody genes, Cai et al., (1992) were the first to show that the VH and Vc 
genes rearranged and/or expressed in CLL cells have few and random mutations. 
They described unmutated CLL cases being “preantigen” and the mutated CLL 
being “postantigen”. Hamblin et al., (2002) demonstrated that out of total number 
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of 38 patients 45.2% showed >=98% sequence homology with the nearest 
germline VH genes (considered “unmutated, U-CLL”) whereas 54.8% showed 2% 
somatic mutations (considered “mutated, M-CLL”) arguing that U-CLL cells arise 
from pre-germinal centre naïve B cells whilst M-CLL cells arise from post-
germinal centre memory B cells. Patients with U-CLL showed significantly worse 
survival irrespective of the stage as well they showed the progressive disease, 
advanced stage, atypical morphology and trisomy 12. CLL patients with somatic 
mutations showed abnormalities at 13q14 and it has been previously shown that 
patients with trisomy 12 had poor clinical outcomes than patients having 13q14 
abnormalities (Juliusson, 1990). 
The observation that females have a more favorable clinical outcoms than males 
was further confirmed by Damle et al., (2004) who demonstrated that about 10% 
of women showed unmutated IGVH genes and ≥ 30% CD38 expression and  poor 
outcomes and about 50% had mutated status and <30% CD38 expression with 
good outcomes. They also demonstrated that those CLL cells expressing ≥30% 
CD38 and with unmutated status display surface markers which are characteristic 
of B cells that have not entered a germinal centre (GC). 
There are approximately 51 VH genes in the repertoire available for 
recombination to generate functional VH-DH-JH transcriptional units. Normal B 
cells are stimulated by antigens and enter the lymphoid follicle after genetic 
recombination. Point mutations in the variable region genes can cause somatic 
hypermutations arising the differentiation process. Selection of V gene 
sequences in the presence of limited antigens to increase affinity can lead to an 
increase in the replacement amino acids in complementary-determining regions 
(CDRs). Fais et al., (1998) indicated that the VH genes of approximately 50% of 
the IgM+ B-CLL cells and approximately 75% of the non-IgM+ B-CLL cells can 
exhibit somatic mutations. Somatically mutated CLL cases may have arisen from 
B cells that have undergone mutational events but without losing expression of 
IgD or not having isotype-switch before entering to the blood (Oscier, 1997). 
Unmutated VH genes were significantly associated with V1-69 and D3-3 usage, 
with atypical morphology; isolated trisomy 12, advanced stage and progressive 
disease. However, the reason for this biased association is not known (Hamblin, 
1999). Similar results were published earlier by Fais et al., (1998) showing that 
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the use of VH gene among CLL patients is not random. The expression of VH and 
VL genes among CD5+ normal B cells and CLL cells was different. They found 
that VH 4-34, 3-07 and I-69 were the most commonly expressed VH genes in CLL 
cells. They also found that mutation frequencies vary depending on the VH family 
expressed by the CLL cells. The presence of somatic mutations in approximately 
50% of IgM+ CLL cells and approximately 75% of non-IgM+ cells suggests that 
these cells have been exposed to antigens previously and they are “experienced” 
or “memory” CD5+ B cells. CLL biased differential expression of immunoglobulin 
genes among M-CLL and U-CLL cells was also reported by Dal-Bo in 2011. He 
observed that certain immunoglobulin genes such as IGHVI-69, IGKVI-33/ID-33, 
and IGLV3-21 are more commonly found in nonmutated rearrangements 
whereas other genes such as IGHV4-34, IGKV2-30 and IGLV2-8 are more 
frequent in the mutated rearrangement.  
The presence of homologous (“stereotyped”) complementarity-determining 
regions 3 (CDR3) sequences in both mutated and unmutated cases of CLL 
patients has been reported by several groups. Stamatopoulos et al., (2007) 
described 48 different subsets of IGHV-D-J sequences with homologous heavy-
chain CDR3 (HCDR3) among 916 CLL patients of Mediterranean origin and they 
were named ‘subset #1’ to ‘subset #48’. By analysing the association between 
stereotyped BCR and clinical/phenotypic features or outcome for selected 
subsets of CLL patients it was suggested that specific antigen binding sites might 
be important in determining clinical presentation and prognosis. Oxidised low-
density lipoproteins (oxLDL) may be formed by the conjugation of metabolites of 
lipid peroxidation and can be found on apoptotic cells and microbial surfaces. It 
was recently reported that mAbs from CLL cases of subset # 1 and subset # 32 
could recognise malondialdehyde (MDA)-modified oxLDL epitopes. Non-
stereotypical CLL mAbs from IGHV3-21UM, IGHV1-2UM and IGHV3-30M could 
recognise these epitopes suggesting most CLL mAbs have the capacity to bind 
different epitopes, all of which may be derived in oxidation processes 
(Myhrinder,2008; Rosen,2010). 
Most U-CLL cells express low-affinity BCRs that are polyreactive to self- and exo-
antigens such as DNA, lipopolysaccharide (LPS), insulin, apoptotic cells, oxLDL 
and the cytoskeletal antigens myosin and vimentin whereas M-CLL BCRs are 
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generally not polyreactive (Herve,2005; Catera,2008; Chu,2008; Binder,2010). 
Βeta-(1,6)-glucan is a polysaccharide found in the cell wall of certain yeast, 
filamentous fungi, Basidiomycetes and bacteria. It was identified that a subset 
defined as V3-7Sh (a subset of patients expressing mutated IGHV3-7 and semi-
identical IGKV2-24 genes) could recognise β-(1,6)-glucan. Mutated V3-7Sh 
accounted for 0.3% of all CLL cases and responded to the natural antigenic 
determinant shared by some pathogens such as commensal yeast species of 
Candida, Trichosporon, Malassezia and Saccharomyces, filamentous fungus 
Aspergillus, spores and conidia of Aspergillus fumigatus, Penicillium 
chrysogenum, Fonsecaea pedrosoi, and Rhizopus oryzae (Hoogeboom,2013). 
Monoclonal antibodies found in CLL patients were found to be similar to natural 
IgM Abs with low affinity to microbes, lacking somatic hypermutation and with 
autoreactivity/polyreactivity. Auto- and polyreactivity is conversely associated 
with the mutational load of immunoglobulin genes in BCR.  It was observed that 
by reversing the amino acid structure in monoreactive M-CLL Ab into germline 
genes, the monoreactivity can be converted into polyreactivity. This suggests that 
most CLL B cells derive from normal B lymphocytes with poly- or autoreactive 
BCRs (Herve, 2005, Hoehn, 2010). sIgs of CLL showed reactivity against certain 
Gram-positive and Gram-negative bacteria such as Streptococcus pyogenes, 
Enterococcus faecium, Enterococcus faecalis and Enterobacter cloacae. IGHV1-
69 UM mAbs particularly had higher binding capability for the antigens from those 
bacteria. Certain viral infections were also associated with CLL and associations 
were observed between subset # IGHV-34 with persistence infections with 
Epstein-Barr virus (EBV) and cytomegalovirus (CMV) and some CLL cases with 
hepatitis C virus (HCV) (Gunnarsson,2011; Kostareli,2012). Moreover, 
respiratory tract infections (Anderson, 2009), sinusitis, pneumonia (Landgren, 
2007), skin infections such as cellulitis and herpes zoster (Landgren, 2007; 
Anderson, 2009) have shown that there is a possibility of having an association 
of these infections with CLL, suggesting the importance of antigenic stimulation 




Figure 1.1: Model to explain the derivation of CLL cells via T cell-dependent 
and T cell-independent manner. The mutated CLL cell derives from a B cell 
stimulated by T-cell-dependent antigens which activate the cell to undergo classical 
germinal centre (GC) reactions. The U-CLL cell derives from a marginal zone (MZ) B cell 
by a T cell-independent process (Chiorazzi et al., 2003). 
The phenotypic differences observed between the B-CLL cells and their putative 
progenitors is a significant factor to explain the model shown in figure1.1. If these 
progenitors are the IgM+, IgDlow MZ B cells, the process of activation to which the 
B-CLL cells are subjected, either by self antigen stimulation and/or leukemic 
transformation, may induce the appearance of new surface markers. Activation 
of resting MZ B cells induces the expression of a number of activation markers 
including CD5, CD23, and CD38. Considering this, the phenotypic profile of the 
two subgroups suggests that the mutated and ummutated B-CLL cases are 
frozen at different degrees of activation (Damle et al., 2002). It becomes more 
challenging to explain the phenotypic differences If one assumes that mutated 
and ummutated B-CLL cases are generated by different progenitors and that the 
mutated cases derive from memory B cells, especially considering that memory 




Figure 1.2: Model to explain the derivation of CLL via T cell-independent 
pathway. IgM+IgDlow subset of MZ B cells is stimulated by autoantigens in T cell-
independent manner. Some of these cells undergo somatic hypermutations via V gene 
differentiation pathway and/or isotype class switching and others do not develop 
mutations to become U-CLL clones (Chiorazzi et al., 2003).  
However, these two models are not mutually exclusive, and therefore the mutated 
B-CLL cells could follow either of the two differentiation pathways explained. 
Indeed, the segregation of B-CLL cases into two subgroups defined by the 
presence or absence of V gene mutations may be too simplistic, and additional 
subgroups within these two larger groups may exist. Because the MZ contains 
three B cell subsets defined by the surface expression of IgD (memory B cells 
and the two subsets of MZ B cells), further distinction at the gene expression level 
may reveal more subsets (Chirazzi et al., 2003) 
It was demonstrated that Binet stage A CLL patients more frequently had VH 
mutated status (91 of 112 at the less than 97% and 106 of 132 at the less than 
98% VH homology cut off) with good clinical outcome whereas the patients 
diagnosed at the same Binet stage A, but with unmutated VH status had inferior 




1.3.2 Expression of surface CD38 
CD38 (T10 antigen) was initially characterised as a T cell differentiation antigen 
expressed on T cells and in different haematopoietic and non-haematopoietic 
tissues such as CD34+ progenitor cells, germinal centre B cells, activated mature 
lymphocytes, plasma cells and myeloid precursors (Ibrahim, 2001). It is a type 2 
trans-membrane glycoproteinype II membrane which is similar to the type I class 
in that they span the membrane only once, but they have their amino terminus on 
the cytoplasmic side of the cell and the carboxy terminus on the exterior and acts 
as a complex ecto-enzyme with adenosine diphosphate-ribosyl cyclase activity 
to catalyse the conversion of nicotinamide adenine dinucleotide (NAD) into cyclic 
Adenosine diphosphate ribose (cADPR). This causes an inositol 1,4,5-
trisphosphate (IP3) independent mobilisation of intracellular Ca2+. Exposure of 
murine B cells to anti-CD38 mAb caused IP3-independent Ca2+ reflux further 
confirming the involvement of CD38 in lymphocyte activation and proliferation 
(Zupo,1994).  CD38 also has cyclic adenosine diphosphate-ribose hydrolase 
activities (Howard, 1993).  
CD38 is expressed at different stages of B cell development especially when cell-
to-cell interactions are significant (Hamblin et al., 2002). Immature B cells, 
germinal centre (GC) B cells and plasma cells in humans have a high level of 
expression of CD38 whereas mature resting B cells show negativity for CD38 
expression or very weak level of positivity. Since they are highly expressed in GC 
B cells, it can be suggested that CD38 may be involved with the selection process 
of GC B cells (Zupo,1994). It has been demonstrated that anti-CD38 in GC B 
cells could prevent apoptosis and increase the expression of B cell lymphoma 2 
(bcl-2) proto-oncogene expression. Deaglio et al., (2010) studied the signalling 
mechanism mediated by CD38 in human B cells and found that it was driven via 
three stages. Firstly, CD38 interacts with CD31, a non-substrate ligand 
surrogated by ligation with agonistic monoclonal antibodies, then localisation of 
the receptor-ligand complex into membrane lipid rafts and finally the generation 
of functional associations with other proteins CD19/CD81 complex. 
CD38 is expressed heterogeneously among CLL patients. It is highly expressed 
in lymph nodes compared with bone marrow or peripheral blood. Ozren (2004) 
demonstrated that there was no significant difference in CD38 expression 
between peripheral blood and bone marrow. Another study by Khoudoleeva 
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(2011) showed that expression of CD38 on CLL cells varied from almost 
negligible to 100%.  Depending on the level of CD38 expression, they observed 
different subgroups of CLL patients as follows: patients with 30% or more B cells 
with CD38 are positive, 30%-80% intermediate positive, more than 80% high 
positive and those with less than 30% CD38 expressed B cells are negative. 
Damle et al., (2007) demonstrated that U-CLL cells were characterised by high 
levels of CD38 expression (30% or more cells in a clone), and this was associated 
with the more aggressive disease with a worse prognosis. CD38 expression on 
M-CLL cells was low and this was associated with indolent disease and with 
significantly longer survival times with good prognosis. 
There is an elevated level of ZAP-70 expression in CD38+ CLL clones compared 
to CD38neg CLL clones and this may contribute to the increased ability of BCR 
mediated signal transduction which is associated with ZAP-70 (Damle, 2007). 
They also have shown a correlation between CD38 expression and Ki-67, a 
cellular marker of proliferation in CLL cells suggesting CD38+ CLL clones enter 
the cell cycle more frequently than CD38neg CLL clones. Khoudoleeva (2011) has 
demonstrated that although there is a significant correlation between CD38 
expression and Ki-67 expression in the bone marrow, the relationship between 
the expression of CD38 and Ki-67 in lymph nodes and the spleen was more 
complicated. Combined analysis of CD38 and ZAP-70 enabled categorisation of 
CLL patients into three subgroups: CD38neg/ZAP-70neg with good prognosis, 
patients with discordant CD38/ZAP-70 (CD38+/ZAP-70neg or CD38neg/ZAP-70+) 
results in an intermediate prognosis and CD38+/ZAP-70+ results in poor 
prognosis. When concordant CD38+/ZAP-70+ and discordant patients were 
compared with concordant CD38neg/ZAP-70neg patents, the presence of other 
negative prognostic markers such as 17p13 deletions, 11q22-23 deletions and 
trisomy 12 was significantly higher (Schroers, 2005). Genetic analysis by Damle 
et al., (2004) showed that CD38/CD31 interaction could lead to upregulation of 
genes controlling leukocyte transendothelial migration, actin cytoskeleton and 
focal adhesion and downregulation of genes controlling interactions with 
extracellular matrix and coding for cell adhesion molecules. This suggests that 
the long-term interaction of CD38/CD31 modulate CLL cells competence to grow 




Stromal derived factor-1α (SDF-1α)/CXCL12, which is mainly produced by 
stromal and nurselike cells (NLCs), is effective in recruiting circulating CLL 
lymphocytes toward secondary lymphoid organs via the specific CXCR4 receptor. 
CD38+/ZAP-70+ patients are characterized by enhanced migration toward SDF-
1α. Suggesting the association between CD38 and ZAP-70. In ZAP-70+/CD38+ 
CLL patients, activation of CD38 results in the phosphorylation of ZAP-70 
suggesting CD38 mediated signalling depends on the presence of ZAP-70. This 
was further confirmed showing CD38+/ZAP-70neg CLL patients were consistently 
unable to signal via CD38 (Deaglio, 2007). Correlation between the expression 
of CD38 and the concentration of β2-microglobulin or sCD23 in a distinct subset 
of B-CLL has been reported by Poeta (2001). There are some controversial data 
on CD38 expression and apoptosis showing CD38+ CLL cells undergo apoptosis 
quickly after treatments with anti-immunoglobulin antibodies whilst CD38neg cells 
are resistant to these antibodies suggesting receptor stimulus can lead to either 
apoptosis or survival (Zupo, 1996). Previous studies also have demonstrated 
similar results showing that expression of CD38, enabled to identify different CLL 
clones that show either increased or decreased chance of survival by transducing 
signals via CD38 (Zupo,1994).  
CLL cells of some patients are homogeneously negative or positive for CD38 
whereas, in a proportion of patients, leukaemia cells show concomitant presence 
of CD38 leading to bimodal distribution (Scielzo et al., 2007). In CLL, expression 
of CD38 above the threshold level, expression of protein kinase ZAP-70 and 
absence of mutations in the IGVH gene are considered as reliable negative 
prognostic markers (Deaglio, 2010). Several studies have shown a correlation 
between CD38 expression and poor clinical outcomes of CLL patients. One study 
demonstrated that CD38+ patients required more frequent treatments than 
CD38neg patients (Domingo-Domenech, 2003). A higher percentage of CD38 
correlated with lack of complete responses to six courses of fludarabine 
monophosphate as first line approach (Del Poeta, 2001). However, as a surrogate 
marker, the association between CD38 and IGVH mutational status is not 
considered as absolute (Cramer and Hallek, 2010). Oscier et al., (2002) 
suggested that CD38 expression can be used to give additional information in 
patients with an established mutational status but cannot be used as an 
independent marker.  
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1.3.3 Expression of intracellular ZAP-70 
ZAP-70 (zeta-associated protein-70) is a receptor-associated protein tyrosine 
kinase expressed by T lymphocytes, natural killer (NK) cells, activated tonsillar 
and splenic B cells and U-CLL cells. The role of ZAP-70 in CLL cells is related to 
the enhancement of BCR-mediated signalling, promoting survival and/or 
proliferation. Expression of ZAP-70 is a negative prognostic marker for CLL 
(Catherwood et al., 2006) as ZAP-70 is an essential signalling molecule in T 
lymphocytes and natural killer cells (Chen, 2002;2005). CD38 ligation resulted in 
phosphorylation of ZAP-70 in Jurkat T cells showing the importance of ZAP-70 in 
CD38 mediated signalling pathway (Zubiaur, 1997). ZAP-70 is a member of the 
Syk-ZAP-70 protein kinase family and its function in normal T cells and natural 
killer cells is to play a critical role in development and differentiation. ZAP-70 is 
not expressed in normal B lymphocytes (Hus,2005). It was reported that the 
expression of ZAP-70 is superior in the prediction of the time to first treatment 
when compared with the expression of CD38 or IGVH mutational status. Also, 
ZAP70 expression was 5.54-fold higher in U-CLL cells compared to M-CLL 
(Cramer and Hallek, 2010). There was a strong correlation between the presence 
of IGVH mutations and the percentage of leukaemic cells expressing ZAP-70. 
Moreover, there was 100 percent probability (95 percent confidence interval, 89 
to 100) of the absence of somatic hypermutations in the presence of more than 
20 percent ZAP-70 positive CLL cells and 87.5 percent probability of IGVH 
mutations in the presence of a low percentage of ZAP-70 positive cells. The 
reason for this correlation is unknown. The level of expression of ZAP-70 did not 
change over time and the presence of ZAP-70 was associated with rapid 
progression and poor survival. Therefore, analysis of expression of ZAP-70 could 
be used as a simple and reliable surrogate marker to identify IGVH mutations 
(Crespo, 2003; Schroers, 2005). Studies using DNA microarrays have shown a 
way to distinguish U-CLL from M-CLL by the differential expression of a small 
number of genes including the gene which encodes the ZAP-70 protein 
(Rosenwald, 2001; Wiestner, 2003). 
Additionally, Sabattini (2007) assessed the role of ZAP-70 on bone marrow 
biopsy specimens of CLL patients using immunohistochemistry and confirmed 
the potential for ZAP-70 as a surrogate marker for mutational status. This study 
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also demonstrated a small subset of discordant cases with unmutated status and 
low expression of ZAP-70 had more favourable clinical outcomes.  Hus (2006) 
demonstrated that a significant difference between ZAP-70 positive and ZAP-70 
negative patients in terms of CLL prognostic parameters such as stage of the 
disease, WBC count, lymphocytosis, platelet count (PLT), haemoglobin level and 
lactate dehydrogenate (LDH) serum level compared with CD38 positive and 
negative patients (WBC count, lymphocytosis and LDH activity). Another study 
performed by Krober (2006) found a correlation between the presence of 
prognostic genetic features and discordant ZAP-70 and VH mutational status, 
moreover, 25% of cases studied had discordance ZAP-70 expression and VH 
mutation status. Subgroups with V3-21 usage and 17p or 11q deletion had a 
higher proportion of discordant cases (39%). ZAP-70 positive/VH mutated cases 
had a higher usage of V3-21 (89%). The association between ZAP-70 expression 
and VH mutational status was stronger in cases without V3-21 usage, 17p 
deletion, or 11q deletion (84%) and the distribution of ZAP-70 positive/VH 
mutated vs. ZAP-70 negative/VH unmutated cases were balanced (55%, vs. 
45%). It is found that the percentage of ZAP-70 positive B cells in the peripheral 
blood of CLL patients ranged from 0% to 85.4% and the level of expression was 
significantly higher in B lymphocytes taken from lymph nodes and spleen of CLL 
patients (Khoudoleeva, 2011).  
1.3.4 CLL cell kinetics 
The time taken to double the absolute lymphocyte count is known as lymphocyte 
doubling time (LDT) and it reflects the disease activity in CLL. An LDT of less 
than 12 months is associated with an aggressive course, decreased progression-
free survival (PFS) and OS. If the lymphocyte count increases more than 50% in 
2 months, or the LDT is less than six months then the patient is considered to 
have a status of active disease and treatments are needed as per the guidelines 
published by International Workshop on CLL (IWCLL) (Cramer and Hallek, 2010).  
Some studies have shown that there is a correlation between in vivo LDT and 
telomere length and telomerase activity. Patients with shorter LDTs (less than 12 
months or more) had significantly higher telomerase activity than patients who 
had longer LDTs (Damle, 2002). CLL kinetics has been measured using 
deuterated water to see the incorporation of 2H into the deoxyribose moiety of 
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DNA of newly divided CLL cells. This method has demonstrated that the 
leukaemic cells of each patient had definable and substantial lymphocyte birth 
rates varying from 0.1% to greater than 1.0% of the entire clone per day. The 
patients who had lymphocyte birth rates higher than 0.35% per day showed more 
active disease and developed progressive disease than those who had lower 
lymphocyte birth rates (Messmer,2005). The doubling time (DT) of total tumour 
mass (TTM) which is measured using the square root of the number of peripheral 
blood lymphocytes per nl, the diameter of the largest palpable lymph node in 
centimetres, and the enlargement of the spleen below left costal margin in 
centimetres (Jaksik and Vitake, 1981) in untreated patients was found to be 
associated with the type of response to treatment and prognosis (Jaksic, 1981). 
Molica and Alberti (1987) demonstrated that the trends in LDT could be used as 
a proper parameter to predict the progression of the disease. Their findings 
suggested that higher the LDT, longer the survival. Also, many of patients who 
had higher LDT did not have treatments indicating slower progression of the 
disease. 
1.3.5 Serum markers 
Serum β2-microglobulin (B2M), serum thymidine kinases (sTKs) and soluble 
CD23 (sCD23) are the most important serum prognostic markers in CLL. sβ2m is 
an extracellular protein which is non-covalently bound to the β-chain of the class 
I MHC (major histocompatibility complex). Increased level of sβ2m is linked with 
adverse prognostic features such as the expression of CD38 and ZAP-70 
(Schroers et al., 2005). sTK involves with salvage pathway for DNA synthesis 
and is found only in dividing cells and its elevated levels are associated with rapid 
disease progression.  
sCD23 (Soluble CD23) 
CD23 is expressed by mature B cells, antigen presenting cells and platelets. It is 
a 45KDa transmembrane protein and a low-affinity IgE receptor. CD23 is 
proteolysed into soluble CD23 (sCD23) molecules of variable molecular weight. 
Elevated levels of its soluble form are characteristic of CLL exclusively and are 
associated with reduced survival (Cramer and Hallek, 2010). Several biological 
activities of CD23 and its soluble factor have been reported. This includes 
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regulation of normal B and T cell proliferation (Swendeman,1987; 
Armitage,1989), control of synthesis of human IgE (Sarfati,1988), proliferation of 
myeloid precursors (Mossalayi,1990) and the rescue of germinal centre B cells 
from apoptosis (Liu,1991). Synergistic effect of CD23 and IL-1 had been found 
on the maturation of prothymocytes (Mossalayi, 1990). CD21 which is the 
receptor for the EBV is the ligand for CD23 and CD21/CD23 interaction involves 
in cell adhesion of human B-lymphocytes (Aubry, 1992). The expression patterns 
of CD23 in CLL have been studied using immunohistochemistry and found that 
CD23 is more strongly expressed in the proliferating cells from the splenic white 
pulp and lymph nodes than in the small CLL cells outside the proliferating centres 
(Lampert, 1999). Lopez-Matas et al., (2000) demonstrated that compared to 
normal B lymphocytes, CLL cells have low expression of CD21 and ncreased 
levels of CD23 facilitates normal B-cells entering the cell cycle explained by the 
higher expression of CD23 in CLL (Fournier,1994). Moreover, CD23/CD21 
interaction plays a major role in B cell activation and proto-oncogenes expression 
such as c-fos leading to cell proliferation and tumour mass formation 
(Luxembourg,1994). 
Reinisch (1994) demonstrated that there is a significant reciprocal relationship 
between serum sCD23 and LDT in CLL. Serum deoxythymidine kinase activity 
and TTM score but not absolute lymphocyte count were positively correlated with 
sCD23. The cross-linking of the CD23 molecule delivered a negative growth 
signal to the leukaemic B cells and the CD23 gene was abnormally regulated in 
CLL (Foumier,1992).  The doubling time of sCD23 level has been to be 
prognostically significant for OS of the entire group of patients studied and for 
disease progression among stage A patients. The doubling of sCD23 level 
increased the risk of death of the whole population of CLL patients analysed by 
3.2 times (Sarfati, 1996). 
Serum thymidine kinase (sTK) 
Thymidine kinase is an enzyme involve with pyrimidine metabolic pathway and 
has a significant role in the complementary alternative salvage pathway of DNA 
synthesis and conversion of deoxythymidine into deoxythymidine 
monophosphate is catalysed by this enzyme (Hallek, 1992; Hannigan, 1993). 
There are two different isoenzymes of TK in mammalian cells which are cytosolic 
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TK (TK1) accounting for 95% of serum TK activity and mitochondrial TK (TK2). 
TK1 levels vary throughout the cell cycle and the highest activity is seen at the 
G1/S boundary (Wintersberger, 1992; Johansson, 1997). Elevated TK activity 
was found in patients with unmutated IGHV status, poor prognostic chromosomal 
abnormalities such as trisomy 12, del11q23, del17p13, ≥15% CD38 expression 
and adverse clinical outcomes with aggressive and progressive disease. The 
level of TK was elevated in ZAP-70 positive patients compared to ZAP-70 
negative patients and significantly higher levels of TK were found in different VH 
gene usage subgroups of patients with VH4-39, VH1-69 and VH3-2 than other 
gene usage subgroups (Matthews, 2006). Furthermore, Levy et al., (1999) 
showed that both p27kip1, the cyclin-dependent kinase inhibitor and s-TK levels 
were strongly associated with either LDT or disease progression. Magnac et al., 
(2003) demonstrated that s-TK indicates the proliferative potential of the 
malignant clone and a predictor of mutational status. sTK levels correlated with 
the proliferative activity of CLL cells and related with number of dividing tumour 
cells (Hallek, 1999). 
Serum β2-microglobulin 
β2-microglobulin (B2M) is a polypeptide with 11.6 kDa which stabilises the tertiary 
structure of the MHC-I molecules present on cell surface of nucleated cells 
(Bjorkman and Burmeister, 1994). The use of B2M as a prognostic marker is very 
useful over other prognostic markers due to its cheapness, easiness to implement 
and availability in many non-specialised laboratories. B2M levels are influenced 
by patient’s renal function (Filler et al., 2002). As the B2M level approximately 
correlates with tumour mass, it can be suggested that the levels could vary with 
the progression of the disease and relatively low level in the early stage when the 
tumour mass is low. Gentile et al., (2009) demonstrated that B2M levels and 
CD38 expression were correlated in 128/219 CLL cases studied by having both 
B2M positivity and CD38≥ 30%. Furthermore, B2M level was correlated with 
IGVH mutational status in 125/195 CLL cases (64.1%) by having B2M+/IGVH 
unmutated status and 29/62 (46.8%) B2M-/IgVH mutated cases. B2M negative 
cases had a significantly higher treatment-free survival (TFS) compared to B2M 
positive cases.   
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There are possible explanations for the mechanism of increased level of B2M in 
CLL cases. Lymphocytes continuously shed B2M and hence with the progressive 
expansion of leukaemic clone, the level of B2M also increases showing a close 
correlation between CLL stage and B2M level. Contrast to that; there was a 
substantial population of CLL patients in Binet stage A with high levels of B2M 
suggesting those cells are more activated in vivo and shed more B2M (Gentile et 
al., 2009). Molica et al., (1999) studied the combining effect of sCD23 and B2M 
to verify whether these two markers have an additive effect. They integrated the 
levels of B2M and sCD23 into Binet staging system and stratified patients 
belonging to the Binet low and intermediate risk categories as low risk group, 
stage A (low B2M <3mg/dl, low sCD23 <2300 U/ml or one increased), 
intermediate risk group, stage A (high B2M >3mg/dl/high sCD23 >2300U/ml) 
stage B (B2M/sCD23 both low or one increased), high risk group, stage B 
(B2M/sCD23 both increased) and Stage C. However B2M levels also rise with 
worsening renal dysfunction, leading some investigators to suggest a measure of 
B2M adjusted for glomerular filtration rate (GFR-adjusted B2M) (Delgado et al., 
2009). 
1.3.6 Chromosomal aberrations 
Interphase fluorescence in situ hybridization (iFISH) analysis shows that CLL 
cells from 80% of patients have at least one cytogenetic abnormality. These 
abnormalities include deletion of the long arms of chromosome 13 (del[13q]), 
chromosome 11 (del[11q]) and chromosome 6 (del[6q]), deletion of the short arm 
of chromosome 17 (del[17p]), trisomy of the long arm of chromosome 3 (trisomy 
3q), chromosome 8 (trisomy 8q), chromosome 12 (trisomy 12q) and translocation 
14q32. The worst prognosis is associated with del(17p) followed by del(11q) 
which is related to removal of TP53 locus and Ataxia telangiectasia mutated 
(ATM) gene respectively (Cramer and Hallek, 2010). 
Stilgenbauer et al., (1999) demonstrated that among 285 CLL patients, 21 cases 
(7%) had del[6q]. Those patients had adverse clinical parameters such as higher 
white blood cell counts and more extensive lymphadenopathy. However, there 
was no significant difference in the OS and the treatment-free intervals between 
CLL patients who had del[6q] compared to the normal chromosome. Krober et 
al., (2006) analysed chromosome aberrations among CLL patients and detected 
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72% of patients (104 of 144) had chromosome aberrations with most common 
13q deletion (52%) followed by 11q deletion (21%), 17p deletion (12%), trisomy 
12 (8%),14q involving aberrations in 4% and least of 1% 6q deletion of cases. 
They observed that the association between ZAP-70 expression and VH 
mutational status differed significantly depending on presence or absence of 
additional genetic high-risk features. The subgroups with V3-21 usage and 17p 
or 11q deletion had a large proportion of discordant cases and the cases with V3-
21 usage were almost ZAP-70 positive/VH mutated. The cases without V3-21 
usage, 17p deletion or 11q deletion had a stronger association between ZAP-70 
expression and VH mutation status. They observed that the CLL cases using V3-
21 with ZAP-70 expression predicted poor clinical outcomes regardless of IGVH 
mutational status but the majority who had unmutated IGVH with 11q or 17p 
deletions did not predict unfavourable clinical outcomes. Therefore, it was 
proposed that high-risk genomic aberrations are independent prognostic factors 
in addition to mutational status and ZAP-70 expression. 
Byrd et al., (2006) demonstrated that CLL patients with high-risk interphase 
cytogenetics such as del(11q22.3) or del(17p13.1) representing one-fifth of the 
patients studied showed significantly shorter PFS and OS. Compared with other 
cytogenetic abnormalities, all patients with del(17p13.1) responded to rituximab 
and fludarabine therapy partially with a shorter duration and had a short 
remission. Following autologous transplantation, patients with del11q23 is usually 
associated with bulky lymphadenopathy and high incidence of residual disease 
(Dohner et al., 1997). Patients with normal karyotype or deletion of 13q14 had a 
better prognosis than those with a complex karyotype or deletion of 11q23 or 
17p13 (Stilgenbauer et al., 2000; Shanafelt et al., 2006). They identified a 
commonly deleted segment in band 11q22.3-923.1 which contains the genes 
encoding for ATM, radixin (RDX) and ferredoxin (FDX1). CLL patients with 17p13 
deletion resist to purine analogues due to loss or mutation of the p53 gene (El et 
al., 1993; Dohner et al., 1995). CLL patients with 17p deletion affecting TP53 had 
failure after treatment with alkylating agents, purine analogues and rituximab 
(Dohner et al., 1995). Mutations of TP53 have been found in 4% to 37% of 
patients with CLL (Catovsky et al., 2007: Grever et al., 2007). Moreover, Zenz et 
al., (2008) showed the equal poor survival of CLL patients with 17p deletion plus 
TP53 mutation, TP53 mutation only and 17p deletion only. 
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10% to 15% of CLL patients have shown structural alterations and point 
mutations of p53 tumour-suppressor gene (Rouby et al., 1992). It was reported 
that wild-type p53 protein represses the activity of the human multidrug resistant 
(MDR1) gene promoter in vitro whereas it is stimulated by mutant p53 protein 
(Chin et al., 1992). Deletion of the p53 locus is associated with poor prognosis 
and p53 mutant CLL cells could cause a more aggressive disease (Rosenwald 
et al., 2004). Sandoval et al., (1996) and Genini et al., (2000) demonstrated that 
p53 and p53-dependent target genes can be activated by incorporating 
triphosphate of fludarabine into the DNA of CLL cells during DNA repair which 
could lead to killing of CLL cells. However, the significance of intact p53 is 
controversial as p53-independent killing in some CLL cases has been reported 
(Gartenhaus et al., 1996; Johnston et al., 1997). Rosenwald et al., (2001) found 
that fludarabine could activate a p53 response in all CLL patients studied 
suggesting the potential to select for outgrowth of p53 mutant subclones that are 
cross-resistant to many of other chemotherapeutic agents. Rouby et al., (1993) 
demonstrated an association between p53 gene mutations and an aggressive 
form of CLL characterised by advanced Rai stage, rapid LDT, increased drug 
resistance as measured by a poor response to chemotherapy and shortened 
survival duration.  
The most common chromosomal abnormality is trisomy 12. However, the 
structural aberrations involving long arm of chromosome 13 also frequent among 
CLL patients. Juliusson et al., (1990) analysed abnormal karyotypes in CLL 
patients using data from five collaborating European centres and found that 
almost half the cases had trisomy 12 and aberrations of chromosome 13 as single 
aberrations suggesting their involvement in the pathogenesis of the disease. 
Others have reported that important genes are localised on bands q13 to q22. 
The retinoblastoma gene may be involved on chromosome 13 as most of the 
aberrations were deletions of q14 and adjacent bands or translocations involving 
13q14. They also confirmed the position of trisomy 12 as a prognosis marker and 
association with survival was observed only in patients with single aberrations. 
The presence of trisomy 12 in complex karyotypes had not shown a clinical 
significant. Several studies have demonstrated that trisomy of chromosome 12 
derives from the duplication of one chromosome rather deletion and triplication 
of the other chromosome (Einhorn et al., 1989). Patients with other adverse 
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prognostic markers such as ZAP-70 expression or unmutated IGVH genes have 
higher chromosomal instability and show a greater risk of acquiring chromosomal 
aberrations leading to an aggressive form of the disease during the course of the 
disease (Shanafelt et al., 2006).  
As mentioned earlier although the reasons for the better outcome of CLL in 
women remain unclear, better prognostic factors have been identified in women. 
These include significantly higher incidence of mutated IGHV genes, lower 
expression of CD38 and ZAP-70, lower beta-2 macroglobulin levels and fewer 
cytogenetic abnormalities such as TP53 deletion/mutation and/or 11q deletion 
(Catovsky et al.,2014). Genotypic male: female ratios have been studied in 4698 
patients and found significantly higher male: female ratio (2.5) in patients with 11q 
del, alone or other abnormalities than in patients with trisomy 12, 13q del or 17p 
del (1.5). The exact reasons for different prognostic factors between men and 
women not known (Cantu et al., 2013). Even though those data supported the 
association of prognostic factors and sex, the prevalence of good prognostic 
factors in women does not solely account for better outcomes in women, 
underpinned by the findings that even women with unmated IGHV genes had 
longer survival than their male counterpart (Catovsky et al.,2014).  
1.4 Resistance to apoptosis 
It has been documented that CLL cells expressed high levels of Bcl-2 protein and 
associated with resistance to apoptosis. CLL cells are characterised by the 
increased Bcl-2/Bax ratio which favours cell survival (Pepper et al., 1999). CLL 
cells are generally resistant to apoptosis induced by tumour necrosis factor 
(TNF)-family death ligands, such as TNF-α, Fas ligand (FasL), and TNF-related 
apoptosis-inducing ligand (TRAIL) (Pedersen et al., 2002). MDM2 (Mouse double 
minute 2) is a negative regulator of an important apoptosis regulator protein p53, 
and it is over expressed in many human cancers including CLL (Vassilev et al., 
2004). Also, some cytokines such as IL-1, IL-6, IL-8, and interferon-γ are known 
to be produced by CLL cells and apparently could act in an autocrine fashion 
enhancing survival from apoptosis (Aguilar-Santelises et. al., 1999). 
 
Peripheral blood CLL cells are mostly non-proliferating and arrested in G0/G1 
phase of the cell cycle suggesting CLL is a malignancy of failed apoptosis 
whereas cell division occurs in proliferation centres in some patients causing an 
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increase in the tumour load (Burger et al., 2002; Hallek et al., 2010). The 
mechanism of apoptosis can be explained by using three pathways. The 
commonly described pathways are the intrinsic (or mitochondrial) and extrinsic 
(or death receptor), and the less well-known initiation pathway is the endoplasmic 
reticulum pathway. Caspases act as both initiators and executioners in apoptosis 
pathways (Wong, 2011). 
 
In extrinsic pathway (Figure 1.3), ligands such as TNF and FasL bind with their 
respective death receptors, type 1 TNF receptor (TNFR1) and a related protein 
called Fas (CD95). Intracellular death domain associated with these death 
receptors recruit adaptor proteins such as TNF receptor-associated death 
domain (TRADD), and Fas-associated death domain (FADD). This ligand-
receptor-adaptor protein complex is known as the death-inducing signalling 
complex (DISC) (Wang, 2011). FasL is expressed mainly by activated T cells and 
natural killer cells (Watanabe et al.,2002) whereas TNF-α is produced 
predominantly by activated monocytes/macrophages and lymphocytes (Klener et 
al.,2006).  This DISC complex recruits and assembles initiator caspases 8, a 








Figure 1.3: The extrinsic or death receptor (DR) pathway of apoptosis. 
Binding of pro-apoptotic ligands, death signals and Fas ligand (FasL) to Fas or TNFRs, 
groups the death domain (DDs) of DRs and form a binding site for an adaptor molecule. 
Death-inducing signalling complex (DISC) is formed by the ligand-receptor-adaptor 
protein complex and the initiator caspase-8 is recruited and assembled to release active 
caspase enzyme molecules into the cytosol. The activated effector caspases-3 and -7 
causes nuclear protein cleavage and the initiation of apoptosis (O’Brien and Kirby, 2008). 
 
Initiation of the intrinsic mitochondrial pathway of apoptosis happens within the 
cell in response to cellular stresses such as DNA damage, radical oxygen 
species, radiation, hormone or growth-factor deprivation, chemotherapeutic 
agents, cytokines and glucocorticoids (O’Brien and Kirby, 2008). This initiation 
can eventually release pro-apoptotic proteins from the mitochondria to activate 
caspase enzymes and trigger apoptosis (Figure 1.4). The intrinsic pathway 
depends on the balance of activity between pro-apoptotic and anti-apoptotic 






Figure 1.4: The mitochondrial or intrinsic pathway. When p53 is induced by DNA 
damage, the pro-apoptotic proteins Bcl-2-associated X protein (Bax) and BCL2 
antagonist/killer (Bak) are activated. This activation is done through the conversion of 
Bcl-2 homology 3 (BH3) interacting-domain (Bid) to tBid by caspase-8 or -10 and through 
activation of p53 upregulated modulator of apoptosis (PUMA), Noxa or other BH3 initiator 
proteins. Oligomerisation of activated Bax and Bak at the mitochondrial membrane 
causes the mitochondria to release mitochondrial factors including cytochrome c. It 
combines with apoptotic protease activating factor 1 (Apaf-1) and procaspase-9 to form 
apoptosome. Caspase 3 and 7 are activated by activated caspase 9 allowing apoptosis 
to proceed. Second mitochondria-derived activator of caspase/direct inhibitor of 
apoptosis-binding protein with low pI (Smac/DIABLO) proteins inactivate inhibitor of 
apoptosis protein (IAP) and EndoG and apoptosis inducing factor (AIF) stimulate 
apoptosis independent of caspase (O’Brien and Kirby, 2008). 
 
Kerr et al., (1972) suggested the importance of apoptosis for eliminating 
potentially malignant cells, hyperplasia and tumour progression showing the vital 
role of reduced apoptosis or its resistance in carcinogenesis. The Bcl-2 family of 
proteins contain both pro-apoptotic and anti-apoptotic proteins that regulate 
apoptosis (Gross et al., 1999). Bcl-2 is the leading member of this protein family 
which is coded by the BCL2 gene. Members of the Bcl-2 family can be further 
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divided into three groups based on their functions and Bcl-2 homology (BH) 
domains. The first group consists of anti-apoptotic proteins such as Bcl-2, Bcl-xL, 
myeloid cell leukaemia 1 (Mcl-1), Bcl-w, Bcl-2-related protein A1 (BCL2A1/Bfl-1) 
and Bcl-B/Bcl2L10. The second group consists of BH-3 only proteins which act 
as pro-apoptotic proteins such as BH3 interacting-domain (Bid), Bim, PUMA, 
Noxa, Bcl-2 associated death (Bad), Bcl-2 modifying factor (Bmf), Harakiri, BCL2 
Interacting Protein (Hrk) and BCL2-interacting killer (Bik). The third group also 
consists of pro-apoptotic proteins but with all four BH domains. Some examples 
are Bcl-2-associated X protein (Bax), Bcl-2 antagonist/killer (Bak) and Bcl-2 
related ovarian killer/ Matador (Bok/Mtd). Dysregulation of apoptosis can happen 
due to disruption in the balance of anti-apoptotic and pro-apoptotic members of 
Bcl-2 family. This can be due to overexpression of one or more anti-apoptotic 
proteins or under expression of one or more pro-apoptotic proteins or both 
(Dewson and Kuc, 2010). Another mechanism in apoptosis which leads to 
carcinogenesis is the low levels of caspases or impairment in caspase function. 
It was also suggested that abnormalities in death receptor pathway also leads to 
evasion of the extrinsic apoptosis pathway and hence leads to carcinogenesis 
(Wong, 2011). 
 
The p53 protein is also known as tumour protein53 (TP53) is a tumour suppressor 
protein. The tumour suppressor gene TP53 located on the short arm of 
chromosome 17 (17p13.1) encodes for p53. The p53 protein plays a role in the 
induction of apoptosis, cell cycle regulation, development, differentiation, gene 
amplification, DNA recombination, chromosomal segregation and cellular 
senescence (Oren and Rotter, 1999). More than 50% of human cancers are 
associated with defects in the p53 tumour suppressor gene (Bai and Zhu, 2006). 
Apoptosis, cytokinesis and signal transduction can be regulated by a group of 
structurally and functionally similar proteins called the inhibitor of apoptosis 
proteins (IAPs) and eight IAPs have been identified. IAPs inhibit caspase activity 
by binding to their conserved baculoviral IAP repeat (BIR) domains to the active 
site of caspases which leads to promoting degradation of caspases and prevent 
the binding of substrates to caspase active sites (Wei et al., 2008). Abnormalities 
in death signalling pathways have been identified which lead to evasion of 
apoptosis intrinsic pathway. Also, Friesen et al., (1997) demonstrated that CD95-
resistant and doxorubicin-resistant leukaemia and neuroblastoma cells displayed 
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resistance for induction of apoptosis in vivo and it was associated with reduced 
expression of CD95. Evasion of the death signalling pathway in various cancers 
is also related to reduced membrane expression of death receptors and abnormal 
expression of decoy receptors (Fulda, 2010).  
In CLL, cells express high levels of anti-apoptotic proteins of Bcl-2 and low levels 
of pro-apoptotic proteins such as Bax in vivo. Activation of the Bcl-2 pathway in 
CLL cells was confirmed by the examination of caspase-8 and caspase-9 levels. 
Inhibition of caspase-9 by LEHD, a cell permeable irreversible inhibitor of 
caspase 9, could inhibit the activation of caspase-3 in the apoptotic cells. 
Nevertheless, there was a preferential activation of caspase-9 over caspase-8 in 
CLL cells further confirming that the Bcl-2 pathway is functional in apoptosis of 
CLL cells (Goolsby et al., 2005). It was demonstrated that CD40L ligation in CLL 
cells upregulates the expression of the anti-apoptotic proteins, Bcl-XL and Mcl-1 
(Kitada et al.,1999). Robertson et al., (1996) analysed the survival of 33 untreated 
CLL patients and revealed significantly poorer survival in patients with higher 
expression levels of Bcl-2. The relationship between drug-induced apoptosis to 
p53 gene mutation and Bcl-2/Bax proteins was analysed in CLL patients after 
inducing apoptosis with a camptothecin analogue, 9-amino-20(s)-camptothecin, 
or a purine analogue, fludarabine. They found that drug-induced apoptosis was 
p53 independent whereas the cells with none to low Bcl-2/Bax ratios were 
sensitive to the drug compared to drug-resistant CLL cells with intermediate to 
high ratios (Thomas et al.,1996).  
It was thought that combination of Mcl-1 and Bcl-2 has an additive effect on CLL 
cells to protect against apoptosis induced by chemotherapeutic drugs in vivo. In 
vivo dynamics of CLL cells may regulate Mcl-1 and Bcl-2 genes to have either 
Bcl-2 or Mcl-1 but not both anti-apoptotic proteins, so the CLL cells which express 
both genes have an additional advantage to confront with anticancer drugs. 
Higher levels of Mcl-1 were significantly associated with failure to attain complete 
remission (CR) (Kitada et al., 1998). Bcl-2 binding protein, BCL2 Associated 
Athanogene 1 (BAG-1) expression was found to associate with failure to attain 
CR and poorer in vivo response to chemotherapy suggesting BAG-1 can interact 
with Bcl-2 to give an additive effect to enhance the resistance to apoptosis. 
Circulating CLL cells expressed Bcl-2, Mcl-1, BAG-1, Bax, Bak and Caspase-3 





The effect of antitumour triterpenoids, CDDO (triterpenoid 2-cyano-3,12-
dioxoolean-1,9-dien-28-oic acid) has been observed in CLL cells in vitro and 
found to induce apoptosis through different mechanisms than those induced by 
cytotoxic chemotherapeutic agents. Triggering of CLL cells by CDDO activated 
caspase-8 followed by activation of caspase-3 suggesting CDDO triggers the 
same pathway of apoptosis as TNF/Fas-family cytokine receptors (Pedersen et 
al., 2002).   
MicroRNAs (miRNA) are small non-coding RNAs involved in several cellular 
processes and expressed in a tissue-specific manner. They regulate gene 
expression, and their deregulation can alter expression levels of genes involved 
in development/progression of tumors. miRNA can function as oncogenes or 
tumor suppressors in CLL and can also serve as markers for CLL 
onset/progression. Another study has shown that downmodulation of miRNA, 
miR-15a and miR-16 which act as negative regulators of anti-apoptotic proteins, 
has been correlated with expression of anti-apoptotic proteins such as MCL1 in 
CLL (Calin and Carlo, 2009). Bcl2 expression in CLL was to found inversely 
correlated with the expression of miR-15a and miR-16 as they negatively 
regulated Bcl2 at a posttranscriptional level (Cimmino et al., 2005). It was 
demonstrated that Bcl-2-IP3R interaction could be disrupted by an IP3R- derived 
peptide (IPD) and high amplitude Ca2+ elevation and thereby apoptosis was 
induced in primary CLL cells in vitro (Zhong et al., 2011). Miyake et al., (1994) 
demonstrated that novel mAb RP/14 could protect B cells from irradiation-
dependent apoptosis by delivering signals to block apoptosis in mice. Several 
mechanisms which lead to evasion of apoptosis and carcinogenesis are 




Figure 1.5: Summary of the mechanisms that contribute to evasion of apoptosis 
and carcinogenesis (Wang, 2011). 
 
1.5 Microenvironmental signals 
Leukaemic B lymphocytes which show prolonged survival and persistence in 
vivo, usually undergo apoptosis when cultured in vitro suggesting the importance 
of other factors probably originating from the microenvironment for in vivo 
accumulation. Stromal cells/“nurse-like cells” and T-lymphocytes are two 
potential cellular components in their microenvironment. It was shown that in vitro 
spontaneous apoptosis of CLL cells can be prevented by the co-culture with 
nurse-like cells or stromal cells or activated autologous T cells (Gionnoni et al., 
2014). The action of T cells can be replaced by the presence of T cell-derived 
cytokines (IL-4) and soluble CD40 ligand (sCD40L). CD40 stimulation also 
induced CLL proliferation and activation reflected in upregulation of CD80, CD86 
and CD95 (Porakishvili et al., 2011). CLL cells recruit accessory cells to create a 
microenvironment which supports their survival. Increased number of CD3+ T 
cells with CD40L+ and CD4+ could stimulate CLL cells by interaction between 
CD40 and CD40L and it could be synergised with BCR signalling (Scieizo et al., 
2011). This ligation could lead to activation of NF-κβ/Rel transcription factors and 
Janus-activated kinase 3 (JAK3), signal transducer and activator of transcription 
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3 to induce high levels of the anti-apoptotic proteins BCL-XL and MCL-1 (Totero 
et al., 2006). Stimulation of CD40 in CLL cells could increase their proliferation. 
CLL cells produce chemokines such as CCL3, CCL4, CCL22 and interleukin-8 to 
interact with accessory cells such as T cells and monocytes to ensure the 
presence of signals for malignant growth and survival (Oppezzo and Dighiero, 
2013). Activation-induced cytidine deaminase (AID) expression results mainly 
from signals received through CD40-CD40L pathway. It was demonstrated that 
AID expression was restricted to a subpopulation of CLL cells which undergoes 
class switch recombination and aggressive course of the disease suggesting B 
lymphocytes are being constitutively activated in specific tumour 
microenvironment (Oppezo et al., 2003). CLL progression was favoured by 
stimulation of CLL cells through BCR which is considered as another possible 
mechanism of the microenvironmental impact (Ghia et al., 2008). This was 
confirmed by the evidence that CLL cells possess phenotyping profiles of 
activated B cells via antigen (Ag) interactions (Damle et al., 2002) and expression 
of antigen-experienced B lymphocytes gene profiles (Klein et al.,2001). 
 
Figure 1.6: Molecular crosstalk between CLL B cells and the 
microenvironment. Interactions between CLL cells and nurse-like cells/ lymphoma-
associated macrophages (NLCs/LAMs) or Mesenchymal stem cells (MSCs) is 
established and maintained by chemokine receptors and adhesion molecules. CLL cells 
are attracted by NLCs expressing chemokines CXCL12, CXCL13 and MSCs expressing 
CXCL12 via G protein-coupled chemokine receptor CXCR4 and CXCR5 expressed on 
CLL. They also make cell-to-cell adhesion with stromal cells using integrins such as very 
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late antigen 4 (VLA-4) integrins (CD49d) present on CLL cells and respective ligands 
such as vascular cell adhesion molecule 1 (VCAM-1) and fibronectin/FN present on 
stromal cells. Interactions between TNF family members BAFF and proliferation-inducing 
ligand on NLCs and corresponding receptors BCMA, TACI and BAFF-R provide survival 
signals for CLL. CLL cells also interact with NLCs and stromal cells via CD38 ligand and 
its ligand CD31 expressed on those cells which activates ZAP-70 and downstream 
signalling pathway. Stimulation of BCR and CD79a, b complex induces downstream 
signalling by activation spleen tyrosine kinase (Syk) and ZAP-70 enhancing the higher 
secretion of CCL3 and CCL4 to attract T cells thereby CD40L+ T cells found in 
proliferation centres (pseudofollicles) interact with CLL cells via CD40. Cytokines 
produced by T cells and CLL cells also act as an important survival regulator in CLL cells 
(Burger et al., 2009). 
 
CLL cells mainly reside in the spleen, lymph nodes and bone marrow where they 
receive microenvironmental support for expansion. Antigenic stimulation 
upregulated CD40L on T cells and initiated antibody production. B cell migration 
to the germinal centre in B cells was stimulated by CD40/CD40L interactions 
which lead to somatic hypermutations and class switch recombination (CSR) 
(Schatner et al., 2000: Grdisa et al., 2003). Stimulation of CLL cells led to up-
regulation of apoptosis protein, survivin confirming the dependence of CLL cells 
on CD40/CD40L microenvironment (Granziero et al., 2001). Kostareli et al., 
(2012) found that mutated and unmutated cases of CLL are different by having 
distinct Tall like receptors (TLRs). They also demonstrated that TLRs functional 
in CLL cells in a heterogeneous manner in stereotyped subsets.  As an example, 
CLL subset # 1 is aggressive and subset #4 is indolent as well as they have 
different gene expression profiles in TLR signalling pathway and responsiveness 
to TLR ligands indicating CLL cells receive both BCR dependent and independent 
pro-survival signals from its microenvironment. 
Giannoni et al., (2011) observed that hepatocyte growth factor (HGF) and C-X-C 
motif chemokine 12 (CXCL12) were highly produced by stromal cells which can 
give survival signals to CLL via ligation to HGF receptor, c-mesenchymal-
epithelial transition factor (c-MET). Levels of HGF in sera of CLL patients were 
higher than normal controls. Giannoni et al., (2011) also showed that HGF/c-MET 
interaction could activate signal transducer and activator of transcription 3 
(STAT3) phosphorylation in nurse-like cells together with activation of 
Indoleamine-2,3-dioxygenase enzyme in monocytes which modulates T-cell 
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proliferation and IL-10. Both nurse-like cells and monocytes in CLL patients 
significantly inhibited T-cell proliferation suggesting the dual pathophysiological 
function of HGF either directly through enhancement of survival of the leukaemic 
clone and indirectly by favouring T-cell immunosuppression. 
Normal activated CD3+, CD4+ and CD40L+ T cells are mainly gathered into 
proliferation centres (PC) in CLL, which is a characteristic structure of CLL 
suggesting T cell-mediated activation in CLL in vivo. CLL cells produce selected 
chemokines such as CCL22/MDC and CCL-17/TARC which can recruit activated 
T lymphocytes to provide favourable growth and survival signals (Ghia et al., 
2008). C-X-C motif chemokine receptor 4 (CXCR4) expressed highly on CLL cells 
may be used to move away from T cells towards stromal cell-derived factor-1 
(SDF-1) which is also known as C-X-C motif chemokine ligand 12 (CXCL12) 
produced by stromal cells to avoid T-mediated limit of expansion. It was also 
observed that co-culturing of CLL cells with marrow stromal cells secreting 
CXCL12 induced CLL cell migration beneath the stromal cells. CLL cells are 
attracted by NLC via CXCR4 and protect them from spontaneous or drug-induced 
apoptosis in a contact-dependent manner. This suggests the role of CXCR4 in 
CLL trafficking and recirculation between blood and the bone marrow or lymphoid 
tissues (Figure 1.7) (Bleul et al., 1996; Burger et al., 1999). Therefore, CXCR4-
CXCL12 axis acts as an important therapeutic target in CLL and Burger et al., 
(2004) demonstrated that small peptide antagonists of CXCR4 could block 
CXCL12 induced activation, migration and signalling of CLL cells. An activated 
fibroblast cell type, mesenchymal α-smooth muscle actin+ (α-SMA+) stromal cells 
in stromal compartment secrete CXCL12 to promote tumour growth and 
endothelial progenitor recruitment (Orimo et al., 2005; Ruan et al., 2006). It was 
demonstrated that Phosphatidylinositol 3-kinase (PI3K) inhibitors can effectively 
inhibit the signals derived from CXCL12 and CLL-MSC interactions for migration, 
survival and drug-resistance showing the importance of microenvironment 





Figure 1.7: Role of the CXCR4 chemokine receptor in the homing of 
haematopoietic stem cells and leukaemia cells to the marrow 
microenvironment. Both, haematopoietic stem cells and leukaemia cells expressing 
CXCR4, which directs chemotaxis of haematopoietic progenitor cells (HPC) and 
leukaemia cells from the circulation to the marrow along the gradients of CXCL12 (SDF-
1). There is a vascular network called ‘sinusoids' locating reticular stromal cells which 
HPC migrate in to. Leukaemia cells can adopt this mechanism to access niches that 
generally are restricted to HSC and to get favourable conditions for their survival. Another 
mechanism to explain the cross-talk of HSC and leukaemia cell in the marrow 
microenvironment is that providing a niche for HSC is by mesenchymal-derived 
osteoblasts which are specialised fibroblasts secreting CXCL12 (Burger et al., 2007). 
 
1.6 Treatment of CLL 
The stage of the disease and prognosis determine the necessity of treatment in 
CLL. There are several treatment options as follows.  
 
1.6.1 Chemotherapy 
The common nitrogen mustard alkylating agents used for CLL treatment are 
chlorambucil and cyclophosphamide to induce cell death through p53 
independent pathway. Induction of apoptosis by chlorambucil was related to 
increasing p53 and MDM-2 proteins whereas patients who had p53 mutations, 
increased cell apoptosis via p53 independent manner (Begleiter et al.,1996). The 
combination of chlorambucil and prednisolone produced initial response rates 
between 60%-90% and complete remission in 60% of patients analysed (Keating 
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et al.,1998). Particularly patients who are resistant to alkylating agents are treated 
with fludarabine, which is a purine analogue and potent inhibitor of DNA repair 
(Dillman et al.,1989). Moreover, it was reported that combination of fludarabine 
and cyclophosphamide (FC) give a higher response rate than fludarabine alone 
(O’Brien,1998). Rai et al., (2000) reported that fludarabine was superior to 
chlorambucil in previously untreated CLL patients in terms of rate of complete 
remission, overall rate of response, duration of response and progression-free 
survival. Another group has demonstrated that 2-chlorodeoxyadenosine (2-
CDA)+prednisolone is an effective treatment for CLL patients who resist to 
chlorambucil+predinisolone and for patients who had early relapse after treating 
with alkylating agents (Robak et al., 2000). Fludarabine had a superior activity 
compared to CAP regimen (cyclophosphamide, doxorubicin and prednisone) and 
chlorambucil in terms of complete remission rate and remission duration (Dilman 
et al., 1989; Rai et al.,2000).  
Chemotherapy treatment of CLL was reported to relate with p53 mutations and 
selective drug resistance mainly associated with alkylating agents (Sturm et al., 
2003). They suggested that p53 mutations may be related to DAN-damaging 
therapies which result in p53 inactivation. In vitro or in vivo drug resistance can 
be caused by several biological factors including abnormal p53 function, 
overexpression of bcl-2 and incubation of tumour cells with interleukin-4 (IL-4) 
(Dohner et al.,1995; Thomas et al., 1996). It was reported that chlorambucil could 
delay the disease progression whereas no effect on survival. However, analysis 
of the percentages of chlorambucil treated and untreated CLL patients 
progressed into stage B suggested that early exposure to the drug may select for 
resistant clones which may be related to poor prognosis of patients who have no 
response to early therapy (Dighiero et al., 1998).  
 
1.6.2 Immunotherapy 
Receptors on CLL are targeted via antibody-dependent cellular cytotoxicity 
(ADCC), causing apoptosis of CD20+ B cells and clearance of immune complexes 
(Shaw et al., 2003). Rituximab is the first monoclonal antibody approved for CLL 
treatment directed to CD20 phosphoprotein. Due to low density of CD20 on CLL 
cells, Rituximab treatment has a weak response in CLL patients (O'Brien et al., 
2001). CD52, a ubiquitous antigen in CLL with heterogeneous density is targeted 
by Campath-1H (alemtuzumab). Campath-1H has a significant effect on CLL cells 
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in the blood and bone marrow, but its effectiveness on targeting cells in secondary 
lymphoid tissues is lower confirming their protection by microenvironmental 
interactions with NLC and other stromal cells (Bentz et al., 1995). CD52 is 
expressed by both B and T lymphocytes and monocytes. It is reported that 
Campath-1H is concomitant with a significant incidence of opportunistic infections 
associated with T-cell immunodeficiency. Monoclonal antibodies are effective in 
the management of minimal residual disease (MRD) and the administration of 
moderate amounts of Campath-1H can clear residual tumour (Montillo et al., 
2002; Ferrajoli et al., 2003;). Furthermore, when CD20 monoclonal antibody, 
rituximab is used as a single agent, it can induce only partial responses. The 
response is mainly limited to the lymph nodes and of short duration (Itala et al., 
2002; Hainsworth et al., 2003). Therapeutic outcome of rituximab can be 
improved when it is used with other drugs such as fludarabine mono-phosphate 
(fludara) or fludara and cyclophosphamide (Ferrajoli et al., 2003). 
 
1.6.3 Haematopoietic stem cell transplantation 
Allogenic and Autologous stem cell transplantation (SCT) are increasingly 
considered for treatment of patients with CLL. Autologous stem cell 
transplantation (ASCT) may increase the response rate and prolong the time to 
progression, but in comparison with chemotherapy, it does not show a longer 
survival (Sutton et al., 2011). Since they have done their trial before monoclonal 
antibodies are started to use, it is important to analyse whether incorporation of 
rituximab into front line therapy can improve the results or including rituximab as 
an additional treatment after ASCT. The efficacy of ASCT depends on the 
administered cytotoxic therapy and it can improve patients' outcome with defined 
poor-risk features (Dreger and Montserrat, 2002). Allogenic stem cell 
transplantation from related and well-matched or partially matched unrelated 
donors could increase long-term MRD-negative survival in 50% of poor-risk CLL 
patients studied independently of the underlying genomic risk profile (Dreger et 
al., 2010). 
1.6.4 Novel therapies  
Recent studies have shown that autologous CD19 redirected T cells expressing 
genetically modified chimeric antigen receptor (CART19) (Figure 1.8) are very 
effective in targeting CD19 on CLL cells through transduction of chimeric antigen 
receptor linked to potent signalling domains (Porter et al., 2011).  A patient's T 
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cells are genetically modified and transferred back to the patient's body mediating 
killing of malignant and normal B cells (Davila and Brentjens, 2013). It was 
reported that CLL patients with TP53 deletions have short remissions after 
standard therapies (Dohner et al., 1995) and for CLL patients who have advanced 
stages of the disease, the only approach is allogenic bone marrow transplantation 
to induce long-term remission (Gribben et al., 2011). However, allogenic bone 
marrow transplantation is associated with potent graft-versus-tumour effect 
contributing to morbidity especially in older patients (Sorror et al., 2008; Gribben 
et al., 2011). Genetically modified autologous T cells may avoid this limitation and 
unlike antibody-mediated therapy, chimeric antigen receptor modified T cells 
have the potential to replicate in vivo. This can lead to long-term persistence and 
sustained tumour control (Porter et al.,2011). 
 
Figure 1.8: The chimeric antigen receptor (CAR). Most CARs consist of three 
parts, the antigen binding domain of a scFv, transmembrane region (TM) of a protein 
such as CD8 and a signal transduction domain associated with a T cell receptor. Antigen 
binds with scFv and the two signal transaction domains mediate T cell activation (Davila 
and Brentjens, 2013). 
 
1.7 BCR-mediated signalling in normal B cells and CLL cells 
BCR consists of membrane immunoglobulin IgM, IgD homodimers and non-
covalently bound heterodimers Igα/Igβ (CD79a/CD79b) which are essential for 
receptor expression and signal transduction. When IgM is ligated with a soluble 
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or membrane bound antigen, the activated BCR recruits Src family kinases 
Lck/Yes novel tyrosine kinase (Lyn) and spleen tyrosine kinase (Syk).  Activated 
BCR phosphorylates the tyrosine residues in the cytoplasmic immunoreceptor 
tyrosine-based activation motif (ITAM) portion of CD79a and CD79b (Choi et al., 
2012).This phosphorylation activates Bruton's tyrosine kinase (BTK) and PI3K 
which in turn induces the mobilization and activation of other downstream kinases 
such as protein kinase C-β (PKC-β), mammalian target of rapamycin (mTOR) 
and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated 
kinase (ERK) to recruit the signalosome. Dual phosphorylation of CD79a/CD79b 
performed by Syk and Lyn provides continued amplification of the BCR by 
recruiting protein kinases and forming complex with CD19 and other co-
stimulatory molecules. Antigen ligation results in BCR aggregation and 
microcluster formation in lipid rafts. This cascade activation promotes survival 
and proliferation of B cells by upregulating transcription factors such as nuclear 
factor kappa light-chain enhancer of activated B cells (NF-κβ). Negative 
regulators of BCR signalosome such as CD22, CD5, CD72 and FcγRIIB control 
the duration and intensity of BCR signalling (Stevenson et al., 2011). BCR is 
critical for normal B lymphocyte survival and is retained in most B-cell 
malignancies. Low expression of BCR compared to normal B cells is a 
characteristic feature of CLL cells (Oppezzo and Dighiero, 2013). U-CLL cells are 
characterised by significantly higher levels of the expression of sIgM compared 
to M-CLL cells (Porakishvili et al., 2005) and better BCR-mediated responses 
(Guarini et al., 2008). Guarini et al., (2008) showed that increased expression of 
genes involved with ERK and JNK (Jun amino-terminal kinases) MAPK 
pathways, downmodulation of genes expression in p38MAPK pathway, 
upregulation of genes expression for proteins involved in cell proliferation and 
genes related to anti-apoptotic pathway in U-CLL cells upon BCR ligation. The 
BCR of different CLL patients are often structurally very similar either in antigen 
binding site contributed by VH, DH, JH genes or the entire antigen binding site 
coded by both H and L chains suggesting their binding with similar and relevant 
antigens for the pathogenesis of the disease (Chiorazzi et al., 2005). BCR 
response might be heterogeneous among CLL patients due to the variable levels 




Figure 1.9:  B-cell receptor (BCR) mediated signalling. The BCR complex 
consists of surface Ig and accessory molecules CD79a and CD79b, which are 
phosphorylated in response to antigen binding, and recruit signalosome molecules to 
promote cell survival and proliferation by various downstream pathways (Choi et al., 
2012). 
Figure 1.9 shows the structure of B-cell receptor complex and major protein 
kinases involve with BCR signalling. They are further described below. 
1.7.1 Bruton tyrosine kinase (BTK) – BTK is a non-receptor tyrosine kinase 
belongs to Tec kinase family which is primarily expressed in hematopoietic cells 
particularly B cells. It is also expressed on mast and myeloid cells but not 
expressed on T cells and plasma cells (Genevier et al., 1994). Mutations in the 
gene encoding BTK result in B cell deficiency disease X-linked 
agammaglobulinemia (XLA) in human and X-linked immunodeficiency (xid) in 
mice demonstrating the importance of BTK in B cell development. XLA is 
associated with absence of peripheral B cells, decreased levels of serum 
immunoglobulin and increased susceptibility to infections whereas xid is 
associated with reduced mature B cell numbers in murine counterpart (Rawlings 
et al., 1993; Tsukada et al., 1993; Ventrie et al.,1993). Tyrosine kinases, such as 
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Lyn and Syk activate BTK, upon BCR activation in turns activate transcription 
factors needed for B cell proliferation and differentiation (Petro et al., 2000). BTK 
involves in other receptor-mediated signallings such as chemokine receptors, 
CXCR4 and CXCR5 which are needed for B cell migration and adhesion 
(Spaargaren et al.,2006; Ortolanno et al.,2010). Syk plays a major role in 
activation of BTK and it was reported that BTK activity in Syk negative cells is 
significantly reduced (Kawakami et al., 2000). Y551 (site 1) within the Src 
homology type 1 (SH1) domain is phosphorylated by Src-kinases Lyn and/or Syk 
in BTK, significantly increasing its BTK kinase activity. SH3 domain contains a 
second phosphorylation site at Y223 which is autophosphorylated by BTK. BTK 
is activated not only by BCR but also a wide array of receptors can activate BTK 
in B cells and other cell types including activated G-protein coupled receptors, 
IgE receptors on mast cells, cytokines and their cytokine receptors and CD40 
stimulation (Muller et al., 2004). 
It was demonstrated that BTK plays a significant role in BCR/NF-κ signalling axis 
using a BTK-deficient B cell line and primary B lymphocytes isolated from BTK-
deficient mice. Moreover, BCR could induce degradation of inhibitor of kappa B 
(IκBα). Nevertheless, NF-κB required BTK and the activity of IkB kinase (IKK) 
which frequently targets the NF-κB inhibitor IκBα for degradation was stimulated 
by BCR induction in BTK+ cells whereas it was not observed in BTK-deficient B 
cells in mice (Petro et al., 2000). The importance of BTK in chemokine-mediated 
homing and adhesion of B cells was also reported by Spaargaren et al., (2003).  
In BCR signalling, BTK is recruited to the membrane-bound signalosome in the 
early stage of B-cell activation and following phosphorylation by Syk and Lyn, 
phospholipase C gamma 2 (PLCᵞ2) is phosphorylated which leads to production 
of the second messengers, diacylglycerol (DAG) and inositol-1,4,5-triphosphate 
(IP3). In CLL this pathway is amplified and leads to pro-survival signals through 
its effects on PI3K, PLCᵞ2, and NF-kB. Inhibition of BTK by ibrutinib interrupts 
BTK autophosphorylation after IgM ligation hence reduces the expression of 
downstream targets of BCR activation including ERK, NF-kB, and v-AKT murine 
thymoma viral oncogene homolog (AKT) (Ringshausen et al., 2002; Herman et 
al., 2011). Several studies demonstrate that BTK involves with MAP kinase 
activation. Hence it plays a role in the activation of ERK2, JNK and p38 (Kurosaki, 
1999; Kawakami et al., 1997). Involvement of BTK in several constitutively active 
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pathways of CLL survival was reported by Petro et al., (2000; 2001). PCI-32765 
is a potent inhibitor of BTK which binds specifically and irreversibly with cysteine 
residue in the BTK protein and inhibits its phosphorylation on Tyr223, therefore, 
the enzymatic activity (Honigberg et al., 2010). PCI-32765 can increase 
favourable clinical outcomes of CLL patients in terms of rapid resolution of 
lymphadenopathy and/or organomegaly (Advani et al., 2010; Burger et al., 2010).  
1.7.2 AKT – One of the targets of PI3K is the serine-threonine kinase c-AKT. It is 
also known as PKB (protein kinase B) and RACPK (related to A and C protein 
kinases) (Bellacosa et al.,1990; Jones et al., 1991). AKT kinases belong to the 
AGC kinase family, related to AMP/GMP kinases and protein kinase C. The three 
conserved domains they consist of are an N-terminal pleckstrin homology (PH) 
domain, a central kinase catalytic (CAT) domain, and a C-terminal extension 
(EXT) containing a regulatory hydrophobic motif (HM). The PH domains are 
~80% identical among AKT isomers and ~30% identical to PH domains in 
pleckstrin and other proteins. The PH domain is connected to the CAT domain by 
the linker (LINK) region which is poorly conserved among the AKT isoforms (17–
46% identical) and has no significant homology to any other human protein 
(Kumar and Madison, 2005). The consensus CAT domains are ~90% identical 
among the AKT isoforms and are closely related the PKC, protein kinase A (PKA), 
serum-and glucocorticoid-induced protein kinase (SGK), and S6 sub families of 
the AGC kinase family whilst the C-terminal EXT is ~70% identical among the 
AKT isoforms and is most closely related to the PKC family (Kumar and Madison, 
2005). AKT is regulated by both phosphorylation and the direct binding of PI3K 
lipid products to its PH domain. However, PI3K independent mechanisms to 
activate AKT have been identified as well (Burgering and coffer,1995; Franke et 
al., 1995).  
Phosphorylation of phosphatidylinositol-4,5-biphosphate (PI3,4,5-P2) by PI3K 
generates phosphatidylinositol-3,4,5-triphosphate (PI3,4,5-P3) which in turns 
binds with PH domain of AKT protein and phosphatidylinositol-dependent protein 
kinase (PDK1) recruiting them to the membrane. Akt activation involves the 
phosphorylation of two residues, Thr308 and Ser 473. Thr308 is phosphorylated 
by PDK1 in the activation loop and Ser473 is phosphorylated by PDK2 localising 
into c-terminal HM (Franke, 2008). mTOR forms part of two different complexes 
which are mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) 
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needed for regulating different proteins. Upstream mTORC2 is essential to 
phosphorylate AKT whereas mTORC1 acts downstream of AKT (Zoncu et al., 
2011). AKT inhibits its substrates including the members of the Forkhead family 
of transcription factors and glycogen synthase kinase-3 (GSK-3). Inhibition of 
GSK-3 induces the up-regulation of the anti-apoptotic protein MCL-1 (Maurer et 
al., 2006).  The phosphorylation of the Forkhead family member FoxO3a and 
GSK-3 is induced and MCL-1 protein is increased by the activation of PI3K/AKT 
pathway in CLL. Inhibition of PI3K induces loss of cell viability, dephosphorylation 
of FoxO3a and GSK-3, and decrease in the level of MCL-1 protein (Ringshausen 
et al., 2002; Petlickovski et al., 2005). Higher capacity for cell cycle progression 
is associated with a stronger activation of AKT pathway in CLL cells from patients 
with progressive disease (Longo et al., 2007). This group has demonstrated the 
importance of activation of AKT in cell cycle progression and proliferation of CLL 
cells. When specific pharmacological inhibitors are used for PI3K/AKT/mTOR, 
ERK and JNK pathways, the complete inhibition of the proliferative response was 
observed indicating the importance of these signalling pathways in cell survival 
of CLL. Nevertheless, constitutively activated AKT kinases can increase 
leukaemic cell viability and expression of the anti-apoptotic proteins Mcl-1, Bcl-
xL and X-linked inhibitor of apoptosis protein (XIAP). Longo et al., (2007) also 
demonstrated that the strength of AKT, ERK and/or JNK activation determines 
the different proliferative responses in various CLL subsets. Survival of CLL cells 
is also promoted by AKT upon activation by several pro-survival signals such as 
IL-4, phorbol ester, human albumin and immobilised anti-IgM (Barragan et al., 
2002; Jones et al., 2003). AKT phosphorylation was inhibited by PI3K inhibitor, 
LY294002 and PKC inhibitor suggesting the existence of two different pathways 
for AKT phosphorylation in CLL cells (Barragan et al., 2006).  
AKT is expressed on macrophages regulate their survival pathway. AKT-1 is 
constitutively activated in human macrophages and the addition of PI3K inhibitor, 
LY294002 suppressed the activation of AKT-1 and induced cell death confirming 
constitutive activation of AKT was regulated by PI3K serine/threonine kinase. It 
was also reported that inhibition of PI3K or use of a dominant negative (DN) AKT-
1 to suppress AKT-1 resulted in loss of mitochondrial membrane potential and 
thereby activation of caspase-9 and -3 and DNA fragmentation in mice (Hongtao 
et al.,2001). PI3K/AKT signalling pathway is also present in the lipid rafts of 
mantle cell lymphoma (MCL) and survival of MCL cells depends on raft-mediated 
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AKT activation. The synthetic antitumour lipids (ATLs), are a family of compounds 
which can induce apoptosis in tumour cells and they could inhibit PI3K/AKT 
survival signals by dephosphorylating AKT and displacing AKT and key enzyme 
regulators from lipid rafts (Reis-Sobreiro et al., 2013). AKT inhibitors are used to 
inhibit the phosphorylation of AKT thereby to inhibit cell survival and cell cycle 
progression. A-443654 is a potent, ATP-competitive and reversible inhibitor of 
AKT catalysed phosphorylation activity. It is a pan-AKT inhibitor which effect on 
AKT1, AKT2 or AKT3 (Luo et al., 2005; Shi et al., 2005). It was reported that A-
443654 inhibits other protein kinases as well including PKA, protein kinase C-
related kinase 2 (PRK2), mitogen- and stress-activated protein kinase1 (MSK1) 
and dual-specificity tyrosine-phosphorylated and -regulated kinase1A (DYRK1A) 
showing less selectivity. An ATP non-competitive AKT inhibitor, Akti-1/2 is a highly 
selective AKT inhibitor, which blocks AKT1 and AKT2 but not AKT3 activity. Akti-
1/2 requires the PH domain for its activity (Barnett et al., 2005; Logie et al., 2007). 
Novel specific inhibitor AiX can antagonise AKT activation by direct blockade and 
induces apoptosis in U-CLL cells (Hofbauer et al., 2010). 
1.7.3 Phosphatidyl-inositol-3-kinases (PI3Ks) - PI3Ks consist of a lipid kinase 
family characterised by its ability to phosphorylate inositol ring 3'-OH group in 
inositol phospholipids. There are three primary groups of PI3Ks depending on 
their structure and substrate specificity and the most important group involve with 
B cell response is class I PI3Ks. These are heterodimers composed of a catalytic 
(CAT) subunit of 110-120 kDa (i.e., p110) and associated an adaptor/regulatory 
subunit (i.e., p85). There are three catalytic subunits in mammalian PI3Ks sharing 
42-58% amino acid sequence identity called p110α, p110β and p110δ in subclass 
IA which are activated by receptors with protein tyrosine kinase activity. Their 
regulatory subunits are p85α, p85β and p55δ. The subclass IB (PI3K) is activated 
by receptors coupled with G proteins (Fruman et al.,1998). 
Upon activation of growth factor receptor protein tyrosine kinases, 
autophosphorylation on tyrosine residues takes place to recruit PI3K to the 
membrane by directly binding to phosphotyrosine consensus residues of growth 
factor receptors or adaptors using one of the two SH2 domains in the adaptor 
subunit. This activates CAT subunit and activation of PI3K leads to the production 
of the second messenger PI3,4,5-P3 from the substrate PI-4,5-P2. PI3,4,5-P3 
then recruits a subset of signalling proteins with PH domains to the membrane, 
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including PDK1 and AKT (Fruman et al., 1998; Fresno-Vara et al., 2004). AKT 
activates a positive regulator of the survival factor NFkB which is IKK (Hussain et 
al., 2012). It was reported that inhibition of PI3K by wortmannin and LY294002 
could block induction of cyclin D2 and impaired phosphorylation of activation 
residues in BCR-mediated mitogen-activated protein/extracellular signal-related 
kinase kinase (MEK)1/2 and p42/44ERK in splenic B cells (Piatelli et al., 2004). 
Sirinivasan et al., (2009) analysed the role of PI3K in ‘tonic' BCR signalling, which 
is likely to be antigen-independent. They have performed in vivo BCR ablation 
which leads to rapid cell death of mature B cells but it was prevented by 
constitutive PI3K activation.  
 
Figure 1.10: The role of PI3K in the biology of B cells. The PI3K/AKT/mTOR 
pathway controls most hallmarks of cancer, including cell cycle, survival, 
metabolism, motility and genomic instability (Ortiz-Maldonado et al., 2015) 
The PI3K-AKT-mTOR pathway controls most hallmarks of cancer (Figure 1.10). 
(Hanahan and Weinberg, 2000; Fruman and Rommel, 2014). PI3K receives 
signals through CD40, IL-6. BCR, CXCR5 and integrin. Only Class I isoforms of 
PI3K have an important role in cancer. PI3Kα is a frequent genetic driver, while 
PI3Kβ is usually found in tumours with loss of phosphatase and tensin homolog 
(PTEN) (Jia et al.,2008). PTEN is an enzyme with opposite action of PI3K which 
70 
 
dephosphorylates PIP3. PI3Kδ is more specific for leukocytes and has a major 
role in the survival of normal B cells. It acts as a second messenger of many cell 
receptors such as BCR, CD40, IL-6 and CXCR5 for cell survival, proliferation, 
chemokine secretion, motility and adhesion to endothelial and stromal cells 
(Marshall et al., 2000; Davies et al., 2004).  PI3Kγ is found in leukocytes, but it is 
mostly involved in inflammation (Baracho et al., 2011). Moreover, PI3Kγ is also 
important in supporting the growth and survival of lymphoid malignancies, 
particularly in response to chemokines (Liu et al., 2007; Konrad et al., 2008). 
Idelalisib is one of the most advanced clinically developed PI3Kδ inhibitor, 
formerly known as GS-1101 or CAL-101. It is a selective inhibitor of the δ isoform 
that promotes apoptosis in primary CLL cells ex vivo despite adverse prognostic 
factors such as 17p or 11q deletions. The effectiveness of Idelalisib in M-CLL cells 
mostly dependent on tonic BCR signalling and in U-CLL cells, it relies primarily 
on chronic active BCR signalling pathways (Herman et al., 2010).  
1.7.4 Mitogen-activated protein kinases (MAPKs) – MAPKs are a family of 
conserved protein kinases that phosphorylate specific serine and threonine 
residues of target protein substrates and regulate many cellular activities such as 
gene expression, mitosis, cell movement, metabolism, cell survival and 
apoptosis. MAPK activity is regulated through three-tiered cascades composed 
of a MAPK, Mitogen-activated protein kinase kinase (MAPKK, MKK, or MEK) and 
a MAPK kinase kinase or MAPK/ERK kinase (MAPKKK or MEKK) (Chang and 
Karin, 2001). In mammals, there are at least four distinct groups of MAPKs are 
expressed which are extracellular signal-related kinases (ERK)-1/2, Jun amino-
terminal kinases (JNK1/2/3), p38 proteins (p38α/β/γ/δ) and ERK5. ERK1/2 are 
phosphorylated by specific MAPKKs, Mitogen-activated protein kinase kinase 1 
(MKK1) and Mitogen-activated protein kinase kinase 2 (MKK2). Upstream 
MAPKKKs such as rapidly accelerated fibrosarcoma (RAF) proteins activate 
MKK1/2 via retrovirus-associated DNA sequences (Ras)/ Rapidly accelerated 
fibrosarcoma (Raf)/MEK pathway and those Ras protein functions are regulated 
by many growth factors and the proto-oncogene RAS. Three JUN-amino-terminal 
kinases (JNK1/2/3) and four p38 protein kinases (p38α/β/γ/δ) are phosphorylated 
by MKK4/7 and MKK3/6, respectively in response to stress stimuli. Several 
MEKKs for JNKs and p38 protein kinases have been identified and some activate 
both JNK and p38 cascades. A fourth MAPK, ERK5, is exclusively activated by 
MEK5, which can be phosphorylated by two MAPKKKs, MEKK2 and MEKK3 
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(Chang and Karin, 2001). Several authors have reported that constitutive 
activation of p38 MAPK in B-cell tumours can contribute to B-cell tumour growth. 
p38 has shown to have a role in cytokine-dependent cell growth and cell survival. 
Inhibition of p38 activity has demonstrated inhibition of proliferation in 
erythropoietin (EPO)-dependent erythroid cell line HCD57 cells but did not protect 
cells from apoptosis induced by EPO withdrawal (Jacobs-Helber et al., 2000). 
Korus et al., (2002) demonstrated that NF-kB activation by Bcr, the oncogenic 
fusion protein was not mediated by nuclear translocation, but rather by p38MAPK 
dependent modification of the RelA/p65 transactivation domain. 
It was reported that the Noxa/Mcl-1 ratio strongly correlates with sensitivity to 
ABT-737, a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w in CD40-stimulated 
CLL cells and both the NF-kB and p38 MAPK signalling pathways involve in 
regulating Noxa and Mcl-1 levels in CD40-stimulated CLL cells and can, 
therefore, modulate sensitivity for ABT-737. This was confirmed by the 
observation that both Noxa and Mcl-1 levels declined in the presence of the p38 
inhibitor SB203580 (Tromp et al., 2011). Various treatments in cancer cell lines, 
including bortezomib, UVB irradiation, and cisplatin, have shown activation of the 
p38 MAPK signalling to induce Noxa. Muzio et al., (2008) demonstrated that 
MAPK ERK is constitutively phosphorylated in a proportion of CLL patients who 
did not show respond to BCR triggering in vitro. They suggested that MAPK 
pathway may be regarded as a potential target for new therapeutics in a selected 
cohort of patients. Their findings indicated that constitutive activation of MAPK 
signalling pathway together with nuclear factor of activated T cells (NF-AT) 
transactivation in the absence of AKT activation represent the molecular 
characteristics of anergic human B lymphocytes. CLL cells consistently express 
high levels of tumour suppressor Mda-7/IL-24 protein, melanoma differentiation-
associated gene-7 (mda-7) and IL-24 mRNA. p38 MAPK is shown to be activated 
by endogenous Mda-7/IL-24 protein or by exogenous IL-24 in CLL (Sainz-Perez 
et al., 2006). Pro-apoptotic activity of p38 MAPK was reported in some cell lines. 
Inhibition of p38 MAPK by its specific inhibitor SB203580 abrogated the induction 
of apoptosis by mda-7 (IL24) antibody in several model systems and human 
melanoma cells (Sarkar et al., 2002). However, an upstream activator of p38 
MAPK, MKK6b overexpression could lead to induction of apoptosis in Jurkat T 
cells. Furthermore, MKK6b activity was found to be required for Fas-induced 
apoptosis (Huang et al., 1997) suggesting the type of stimuli and cell type, 
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activation of the SAPK/p38 MAPK pathways may be sufficient to induce cell 
death.  Sainz-Perez et al., (2006) reported that p38 MAPK does not have pro-
apoptotic activity in CLL cells since fresh cells express p38 MAPK. Use of the 
p38MAPK inhibitor SB203580 and silencing of Mda-7/IL-24 induced apoptosis in 
CLL cells showing its role in cell survival. Graves et al., (1998) demonstrated the 
functional role of p38 MAPK to regulate transcriptional or translational events 
needed for BCR induced apoptosis by showing SB203580 inhibited BCR-induced 
apoptosis but not apoptosis induced by cross-linking Fas in two human B cell 
lines B104 and BJAB. p38MAPK also activates NF-κB which resulted in 
oncogenic transformation by the oncogenic fusion protein p210 Bcr-Abl (Korus et 
al., 2002). 
1.8 Toll-like Receptors (TLRs) 
TLRs are expressed by different types of leukocytes and in some non-immune 
cells present in sites of barrier function such as intestinal and airway epithelial 
cells. Their key roles are regulating innate immunity by recognition of exogenous 
pathogen-associated molecular patterns (PAMPs) and endogenous danger-
associated molecular patterns (DAMPs) (Muzio et al., 2012). TLR4 was first 
identified as a mammalian homologue of Drosophila Toll receptor which is needed 
for induction of genes involved in inflammatory response and later several 
proteins which are structurally similar to TLR4 have been identified and named 
TLRs. The TLR family consists of 10 members designated TLR1-TLR10 in human 
and 12 in mice. TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10 are present on the 
cell surface whereas TLR3, TLR7, TLR8 and TLR9 are localised into intracellular 
vesicles such as endosomes (Takeda and Akira, 2004; Muzio et al.,2012). The 
cytoplasmic domain of the TLR, Toll/IL-1 receptor (TIR) domain) has similarity 
with IL-1 receptor family. TLRs have leucine-rich repeats (LRRs) in the 
extracellular domain differ to Ig-like extracellular portion of IL-1 receptors. Each 
TLR can recognise specific components of pathogens playing a significant role in 





Figure 1.11: Different types of TLRs, TLR specific ligands and their 
signalling complexes in normal and malignant human B cells (Chiron et al., 
2008). TLR3, 7, 8 and 9 recognise highly conserved viral structures and 
TLR1,2,4,5,6,7,8,9 recognise bacterial structures. Heterodimerization of TLR2 with TLR1 
or TLR6 is triggered by bacterial lipopeptides, whereas TLR3 is activated by double-
stranded RNA. TLR4 is activated by LPS, TLR5 is activated by flagellin, TLR7 and TLR8 
are activated by single-stranded RNA (ssRNA), and TLR9 is activated by unmethylated 
CpG DNA motifs. TLRs are also activated by endogenous ligands released during 
cellular stress or matrix degradation such as heat-shock proteins, fibronectin, heparin 
sulphates (Rifkin et al., 2005). The ligand for TLR10 is not identified yet and it may 
functionally have a link to specific naïve and memory B cell actions rather function to 
recognise pathogens (Domer et al., 2009).  Several studies have demonstrated that 
peripheral blood–derived naive and memory B cells express distinct levels of TLR6, 7, 
and 9. Circulating naïve B cells do not express TLR6, 7, 9, and 10 (Bernasconi et al., 
2003) whereas memory B cells display a higher sensitivity to TLR activation with a 
concomitant higher capacity for differentiation into plasma cells. Therefore, the sensitivity 
of naive B cells to circulating PAMP is very low and to mature them to plasma cells they 
require additional signals. High expression levels of TLR are found in naive, germinal 
centre, and memory B cells in the tonsils suggesting human B cell localisation influences 
expression of TLRs (Mansson et al., 2006). It was also reported that TLR4 is also 
expressed in CD4+ T cells and involve with CD4+ T-cell proliferation and survival in vitro. 
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These CD4+ T cells and δγ T cells are activated by TLR4 which contributes to 
autoimmune inflammation (Reynolds et al., 2012). 
A fraction of circulating B cells which are IgG- and CD27-  with intermediate 
expression levels of CD19 and CD69 and most tonsillar B cells express TLR2 
(Mansson et al., 2006; Ganley-Leal et al., 2006). Increased TLR expression in 
tonsillar B cells may be caused by local infections. Expression of TLR7, 9 and 10 
in resting B cells is increased by the activation via the BCR and/or CD40L, or by 
CpG, oligodeoxynucleotides (ODNs) (Bernasconi et al., 2003, Bourke et al., 
2003). Furthermore, TLR7 and MyD88 expression in naive peripheral blood B 
cells are activated by type I interferon (IFN) produced by pDCs during infections 
(Bekeredjian et al., 2005). CD180 (Radio protective 105, RP105) structurally 
resembles TLRs but lacks a TIR domain and promotes LPS-driven B-cell 
responses in mice whereas it acts as a negative regulator of TLR4 signalling in 
monocytes and DCs (Divanovic et al., 2007). Expression of TLRs in CLL is 
heterogeneous, but most of CLL cases express TLR1, TLR2, TLR6, TLR10 on 
the cell surface, and TLR7, TLR8, TLR9 within endosomes resembling 
expression patterns in normal mature B cells (Muzio et al., 2009). The level of 
expression of TLR7 and CD180 is high, TLR1, TLR6, TLR10 is intermediate and 
TLR2, TLR4, TLR8 and TLR9 is low in CLL cells at cohort levels.  TLR7 and TLR8 
levels are varied among different samples and there is an up-regulation of TLR8 
and down-regulation of TLR4 mRNA in the unmutated subgroup (Arvaniti et 
al.,2011). Oncogenic mutations were identified in MyD88 in different B cell 
malignancies. Single point mutations were found in 29% of ABC type diffuse large 
B cell lymphoma cases (Ngo et al., 2010), 13% of splenic marginal zone 
lymphoma cases (Yan et al., 2012), 36% of primary central nervous system 
lymphoma cases (Montesinos-Rongen et al., 2011) and 3-10% of CLL cases 
(Puente et al., 2011; Wang et al., 2011).  Since these mutations may affect 
specific signalling pathways in leukaemic cells, they are considered as novel 
therapeutic targets. Stimulation of TLR7 increases the expression of 
costimulatory molecules such as CD25, CD80, CD86 on leukaemic cells and 
produces inflammatory cytokines such as TNFα and IL-6 (Spaner et al., 2005). 
TLR9 ligand CpG induces the production of TNFα, IL-10, IL-6 and CD25 
expression (Decker et al., 2000; Rozkova et al., 2010). Therefore, agonists of 
both TLR7 and TLR9 have been studied for immunotherapy approaches in 
preclinical models of CLL in vitro (Hoogendoorn et al., 2004; Spaner et al.,2006). 
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Primary B cells are activated by antigens and LPS to upregulate CD69 expression 
and co-engagement of these two receptors induces a synergistic B cell response 
suggesting a cross talk between TLR4 and BCR (Minguet et al., 2008).   
Triggering of BCR of naive B-cells can lead to a rapid up-regulation of TLR9 
expression suggesting the synergism of two receptors (Bernasconi et al., 2003). 
However, to induce full activation, proliferation and differentiation of naive B-cells, 
co-stimulation with three different signals from BCR, CD40 and TLR (Muzio et al., 
2012) and cytokines (Porakishvili et al., 2011) are required. Comparison of M-
CLL and U-CLL showed up-regulation of TLR8 mRNA and down regulation of 
TLR4 in U-CLL (Muzio et al., 2012). Some studies have reported that TLR9 
induction via CpG-B oligonucleotides may induce apoptosis in M-CLL and 
proliferation in U-CLL samples (Muzio et al., 2012) as well as upregulation of the 
expression of CD40 suggesting the synergy with IL-2 and/or CD40L (Chiron et 
al., 2008). To summarise, there is an evidence of the role of TLRs as 
microenvironmental sensors (Miyake et al., 1994, 1995; Chan et al., 1998; Miura 
et al., 1998; Roshak et al., 1999; Yazawa et al., 2003). Since there is increased 
frequency and severity of infections and autoimmune complications in CLL 
patients, it can be suggested that inflammation or autoimmunity mediated by 
distinct TLR may also involve with regulating the development, progression 














1.9 TLR-mediated signalling 
 
Figure 1.12: Schematic representation of TLR mediated signalling pathway. 
When TLRs are stimulated by their respective ligands, they dimerize and recruit 
downstream adaptor molecules, such as myeloid differentiation primary-response 
protein 88 (MyD88), MyD88-adaptor-like (MAL), Toll/interleukin (IL)-1 receptor, TIR-
domain-containing adaptor-inducing interferon-β (TRIF), TRIF-related adaptor molecule 
(TRAM), which activate other downstream molecules leading to the activation of 
signalling cascades that converge at the nuclear factor-kB (NF-kB), interferon (IFN) 
response factors (IRFs) and mitogen-activated protein (MAP) kinases. Transcription of 
several pro-inflammatory molecules, such as interleukin (IL)-6, IL-8, IL-12, and tumour 
necrosis factor a (TNF-α) are induced by those molecules. The secretion of these 
molecules is responsible for attacking microbes and helps activate other immune 
components.  (Anwar et al., 2013). 
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TLR signalling pathway is activated from the cytoplasmic TIR domain which acts 
as a binding site for downstream adaptor molecules to mediate signals from other 
molecules. TIR domain recruits two main adaptor proteins, one is MyD88, which 
is recruited to the TLR-TIR domain together with Mal (MyD88 adaptor-like) which 
is also known as TIRAP (TIR-domain-containing adaptor protein). The second 
adaptor is TRIF (Toll-receptor-associated activator of interferon) (Akira, 2006). 
The induction of specific gene expression in MyD88 pathway is mediated by the 
NF-κB transcription factor, AP-1 (activating protein 1) or IRF1, 5 and 7 (interferon-
response factor). TRIF associated pathway is regulated by IRF3 and NF-κB 
(Honda et al., 2006). Except for TLR3, all other TLRs trigger signalling through 
MyD88 whereas TLR4 can trigger downstream signals through both pathways. 
The death domain of MyD88 recruits Interleukin-1 receptor-associated kinase 
(IRAK) family members to the TLR signalling complex, activate them and transmit 
the signal to TNF receptor-associated factor 6 (TRAF6) which allows the 
phosphorylation of IKK. The pathway continues with the activation of NF-κB and 
the recruitment of TGF- P activated protein kinase 1 (TAK1) that induces the 
MAPK pathways. These signalling cascades eventually induce the transcription 
of inflammatory cytokines such as IL-6, IL-8, IL-12 and TNF-α, type I or II 
interferons and chemokines (Akira, 2006).  
1.10 CD180 receptor 
CD180 is the human analogue of the murine surface receptor RP105 sharing 
74% sequence homology. CD180 receptor was originally discovered on murine 
B cells and identified on human B cells by Bgp95 mAb (Valentine et al., 1988). It 
is a membrane-associated orphan receptor with a molecular weight of 105kD. 
The extracellular portion of CD180 consists of tandem repeats of leucine-rich 
motif separated from the single transmembrane domain by a carboxy-flanking 
region thought to be involved in processes such as cell adhesion or receptor-
ligand interaction (Figure 1.13). The presence of conserved cysteine residues in 
the carboxy-flanking region in CD180 is a similarity with TLRs (Chan et al., 1998). 
CD180 is expressed on antigen presenting cells such as human B lymphocytes, 
monocytes (Zarember and Godowski, 2002) and dendritic cells (Kadowaki et al., 
2001). Histological studies have shown RP105 is mainly expressed on mature B 
cells in mantle zones whereas its expression in germinal centre cells is either very 
low or negative (Miuro et al., 1998). RP105 forms a complex with MD-1 to elicit 
responses to bacterial LPS which is structurally related to TLR4/MD-2 complex. 
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The importance of MD1 for RP105 activity has been demonstrated by showing 
that MD-1 null mice had impairment in LPS induced B-cell proliferation, antibody 













Figure 1.13: Schematic diagram to show the structure of CD180 receptor on 
cell surface. The extra-cellular domain consists of tandem repeats of leucine-rich motif 
and conserved cysteine residues and is associated with MD-1. The intra-cellular domain 
consists of 6 amino acids and is not associated with adaptor molecules. 
 
CD180 is homologous to TLR4 but lacks its intracellular TLR-like domain with 
61% sequence similarity in the extracellular domain (Chappell et al., 2013). These 
two receptors use two distinct signalling pathways. LPS binding to CD180/MD1 
induces Lyn activation and CD19 phosphorylation whereas LPS binding to 
TLR4/MD-2 activates MyD88/IRAK and MyD88-independent Toll-interleukin 1 
receptor (TIR) domain-containing adapter protein (TIRAP) pathways to activate 








Figure 1.14: Schematic diagram to show expression of TLR4/MD2, 
RP105/MD1 and BCR receptor complexes on cell membrane. RP105 signalling 
is unclear, but the involvement of Lyn and Vav, was envisaged by the activation of Lyn 
by RP105 stimulation and downstream defects in RP105 signalling between Lyn–/– and 
Vav1–/–Vav2–/– B cells in mice (Kurosaki, 2005).  
Although CD180 regulates B cell sensitivity to LPS in mice, its natural ligand is 
yet unknown since CD180 molecule lacks LPS-binding pockets, unlike TLR4. 
Stimulation of RP105 with an antibody protects B cells from irradiation or 
dexamethasone-induced apoptosis in murine B cells and activates proliferation 
(Miyake et al., 1994). Chaplin et al., (2011) reported that CD180 signals could 
induce B cells for strong polyclonal B cell proliferation and Ig production. Our 
group demonstrated that CD180 involves in B cell activation, proliferation, and 
survival from apoptosis (Porakishvili et al., 2005, 2011). CD180 was shown to 
increase in cell size, expression of the costimulatory molecule CD80 and DNA 
synthesis upon stimulation (Miuro et al.,1998). Roshak et al., (1999) 
demonstrated for the first time that incubation of human peripheral blood 
leukocytes with anti-RP105 sera induced proliferation. CD180 expression in mice 
B cells was analysed by Nagai et al., (2002) and showed it is 3-fold higher on 
marginal zone B cells than follicular and B1 cells and was down regulated on 
germinal centre cells. Valentine et al., (1998) showed that ligation of CD180 with 
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mAb could trigger B cell activation and proliferation. Another study has reported 
that anti-CD180 increased both transitional and mature B cells, marginal zone B 
cell proliferation and CD86, but not CD80 expression. Anti-CD180 had no effect 
on cytokine production from B cells, but it increased IL-6, IL-10, and TNF-α 
production in combination with LPS or CpG in mice (Chaplin et al., 2011). 
It was also reported that after 24 hours LPS stimulation, CD180 expression was 
significantly decreased in normal and leukaemic CD19+ cells (Antosz et al., 
2009)., LPS stimulation has shown to 100-fold down regulate CD180 expression 
in monocytic leukaemia cell line THP-1 (Zarember and Godowski, 2002). 
Nevertheless, reduction of CD180 expression in unstimulated peripheral blood 
CD19+ CLL cells was four-times lower than that of normal CD19+ lymphocytes 
suggesting constant stimulation of CD180 receptor in CLL by unknown antigen 
or autoantigen. It can also be suggested that unknown antigen resembles the 
structure of LPS of gram-negative bacteria (Antoz et al., 2009). This observation 
may provide evidence to suggest that repeated polyclonal activation of leukaemic 
B cells by microbial molecule during natural infection or inflammation is 
responsible for initiating oncogenic process of CLL (Chiron et al.,2008).  
CD180 is expressed heterogeneously on CLL cells, and predominantly on M-CLL 
(Porakishvili et al., 2005). Although approximately 60% of CLL clones expressed 
CD180, only half responded to ligation with anti-CD180 mAb by activation, 
cycling, and reduced basal apoptosis. This was comparable or superior to that 
induced by anti-CD40 mAb or IL-4. These CLL clones were termed responders 
(R-CLL). In contrast, CD180+ CLL samples that failed to respond to anti-CD180 
mAb were termed non-responders (Porakishvili et al., 2005). Furthermore, 
CD180 ligation led to a strong upregulation in phosphorylation of ZAP70, 
p38MAPK, ERK and particularly AKT protein kinases in normal B cells and R-CLL 
cells (Porakishvili et al., 2011), which is an indication of its pro-survival function 
in responder CLL (Chiorazzi and Ferrarini, 2003). B-cell activation decreases 
expression of CD180 inas germinal centre (GC) B cells, and most B-cell lines do 
not express CD180 (Otipoby et al.,2002) and many activated B cells from patients 







1.11 CD180 mediated signalling in normal B cells 
Several studies have supported the importance of CD180 in B-cell survival, 
activation, proliferation and/or differentiation. However, the mechanisms or 
pathways of signalling are not yet fully understood. Although TLRs have an 
intracellular TIR domain and an adaptor molecule Myd88 which activates the 
various downstream PTKs, CD180 does not have a functional cytoplasmic 
signalling domain, and it cannot independently propagate an intracellular signal. 
It must, therefore, recruit or converge with other receptor pathways. RP105 
mediated signalling pathway was independent of MyD88 expression, and its 
functioning is regulated by CD19. In mice, RP105 ligation recruits CD19 into lipid 
rafts and induces the phosphorylation of CD19 which in turns amplifies Src kinase 
Lyn activity (Chan et al.,1998). Phosphorylated CD19 recruits Vav, which is 
important to act upstream of JNK pathway. Therefore, CD19 may mediate the 
interaction between Lyn and Vav in RP105 mediated signalling. This was 
confirmed by the fact that CD19 deficient human B cells showed diminished 
phosphorylation of Vav following RP105 ligation. In fact, this study has 
demonstrated that PI3K and NF-κB activation by CD180 ligation were shown to 
be independent of CD19 (Figure 1.15) (Yazawa et al., 2003).  
It was also demonstrated that Vav1/2-mutant B cells failed to proliferate in vitro 
in response to LPS or CD180 in mice whereas deficiency of Vav1 alone 
prevented CD180- driven proliferation. Nevertheless, activation of ERK in 
response to CD180 and induction of CD86 and CD25 by anti-CD180 also 
required both Vav1 and Vav2 (Hebeis et al., 2005). Involvement of Lyn, BTK, 
PKCβI/II and MAP kinases in both sIgM- and CD180 mediated activation suggest 
a common signalling pathway(s) for both receptors. Activation of Lyn kinase by 
anti-IgM stimulation is relatively stronger than by anti-CD180 causing more 
efficient recruitment of Lyn to BCR complex. This results in blocking of CD180 




Figure 1.15: Model to represent the mediation of LPS signalling in B 
lymphocytes. B cells are activated by LPS through B-cell specific RP105 and 
universally expressed TLR4. Binding of LPS to RP105 induces Lyn activation and CD19 
phosphorylation. Phosphorylated CD19 augments Lyn kinase activity and mediates the 
Lyn and Vav interaction, which is needed for JNK activation. PI3-kinase and BTK are 
activated independent of CD19 and regulate [Ca2+] responses. LPS binding to TLR4 
activates MyD88/IRAK and MyD88-independent TIRAP pathways to activate JNK and 
NF-β (Yazawa et al., 2003).  
 
Src-family protein tyrosine kinase Lyn, Protein kinase C β I/II (PKCβI/II) and 
ERK2-specific mitogen-activated protein (MAP) kinase (MEK) are essential for 
CD180 mediated signalling cascade (Chan et al.,1998). Involvement of these 
molecules in both sIgM and CD180 mediated activation suggest the existence of 
common signalling pathway(s) for both receptors since BTK and PKC βI/II 
contribute to anti-CD180 and IgM-mediated B cell activation. 
 
1.12 Cross-talk between CD180 and B cell receptor (BCR) 
Previous reports suggested that sequential engagement of the BCR and 
intracellularly expressed TLR9 (Leadbetter et al., 2002) and TLR7 (Lau et al., 
2005) can augment B-cell activation. CD69 expression in primary B cells is 
upregulated by antigen and LPS whereas co-engagement of these receptors 
induces a synergistic B-cell response (Minguet et al., 2008). It was shown that 
specific Ag must be linked to anti-CD180 to induce IgG Ab responses suggesting 
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the requirement of both BCR and CD180 ligation on the same cell, to produce 
specific Ab (Chappell et al., 2014).  
 
Figure 1.16: Role of CD180 and TLR4 in promoting B cell activation and 
differentiation together with BCR. The extracellular domains of CD180 and TLR4 
have 61% sequence similarity and 29% sequence identity and interact with 25 kDa 
molecules MD-1 and MD-2, respectively. CD180 can activate PI-3K and Vav-1, and 
synergise with BCR signalling via an unidentified pathway to induce B-cell activation and 
differentiation (Chappell et al.,2014). 
Interaction of R-CLL cells with the microenvironment through CD180 may 
contribute to expansion of leukaemic clones in vivo, in lymph nodes and bone 
marrow within "proliferation centres" (PCs). The ligand(s) for CD180, soluble or 
cell bound, in the PCs, could act as co-stimulatory molecules to BCR signalling 
together with CD40/CD40L and cytokines to provide signals for CLL cell 
expansion and survival. The classical BCR pathway is regulated by the 
signalosome proteins (PI3K, BTK, BLNK, PLCγ and PKC) and leads to the 
elevation of phosphorylated ERK (Mizuno and Rothstein, 2005). Therefore, other 
pro-survival signals such as those from CD180 may rewire the BCR signalling in 
CLL cells. Roshak et al., (1999) observed B lymphocyte proliferation in humans 
after inducing it with anti-human RP105 sera. Exposure to anti-CD180 sensitised 
murine B cells to anti-IgM-mediated apoptosis and growth arrest (Yamashita et 
al., 1996). Porakishvili et al., (2009) demonstrated for the first time that CD180 
modulates BCR-signalling. It is important therefore to study the effect of CD180 
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ligation on regulation of apoptosis of CLL cells and how it impinges on BCR 
mediated signalling. 
Since the microenvironment plays a significant role in development and 
progression of CLL, this study was focussed on to understand the role of local 
microenvironment of CLL through interaction of surface molecules such as BCR 
and CD180. CD180 plays a major role in CLL cells in interacting with their 
microenvironment. Thus, the interaction of R-CLL cells with the microenvironment 
through CD180 may contribute to expansion of leukaemic clones, in vivo, in 
lymph nodes and bone marrow within "proliferation centres" (PCs). CD180 
ligation with putative endogenous or exogenous ligand would, therefore, 
contribute to the pro-survival intracellular signalling in CLL cells. Hence, it was a 
major interest to study the effect of CD180 ligation on protecting CLL cells from 
apoptosis and how it impinges on BCR mediated signalling.  This project would, 
therefore, help to define mechanisms leading to the expansion of the leukaemic 
cells and progression of the disease through interaction of CLL cells with its 
microenvironment and thus to contribute to developing new therapies of CLL.  
 
The major aims of the research 
Aim 1. To study CD180-mediated intracellular signalling pathways in CLL 
To define transduction pathways of CD180-mediated signal downstream of 
ZAP70/Syk, the phosphorylation of intracellular protein kinases BTK, AKT and 
p38MAPK was assessed upon stimulation with anti-CD180. This will be discussed 
in chapter 3.  
Aim 2. To evaluate the modulatory effect of CD180 ligation on sIgM-mediated 
signalling pathways 
To assess whether CD180 ligation can modulate the intensity of BCR signalling 
and whether the two pathways are functionally linked, CLL cells were pre-treated 
with anti-CD180 mAb followed by the sIgM ligation and vice versa and 
phosphorylation of intracellular protein kinases was assessed as described in Aim 
1. This will be discussed in chapter 3.  
Aim 3. To assess regulation of apoptosis of CLL cells following CD180 
ligation 
Specific inhibitors of the CD180-mediated signalling pathways as in Aim 1 (BTK, 
AKT and p38MAPK), were used to block specific intracellular pathway alone and 
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in combination to study their involvement in CD180-mediated regulation of 
apoptosis. This will be discussed in chapter 4. 
 
Aim 4. To assess the spontaneous modulation of CD180 expression and 
modulation of CD180 expression upon anti-IgM stimulation 
To evaluate modulation of expression patterns of CD180 on unstimulated CLL 
cells and when stimulated with anti-IgM, cells were immunophenotyped at 
baseline hour and following 24, 48 and 72 hours anti-IgM stimulation. At the same 
time, CLL cells were left unstimulated in medium to immunophenotype for CD180 

















































2.1 Patients and CLL samples 
90 patients with CLL, aged between 47-89 years (median age 67.9 years) were 
included in the study. Patients were mainly Binet stage A and Rai stage- Low risk. 
The stages and white blood cell count of patients are shown in the table 1. From 
this cohort, 44 patients have been identified as IGHV M-CLL and 37 patients as 
IGHV unmutated U-CLL. The genotype of the remaining 9 patients was unknown. 
Patients were considered as untreated if they had received no treatment during 
the 6 months prior to the study. Twenty-four patients during the course of the 
study underwent treatment with a variety of therapeutic agents including 
chlorambucil (n=8), fludarabine (n=7), Ofatumumab + CAL101 (n=2), rituximab 
(4), Campath (2) and Ibrutinib (n=1). Ten age-matched (50-78 years, median age 
63.5 years) healthy volunteers served as controls. 
 
Ethical approval was obtained from the ethical committee at University College 
London Hospital (UCLH, 08/H0714/6), NHS trust. Prior to the study, the informed 
consent was obtained from the patients under the care of Professor Amit 
Nathwani, UCL CLL clinic. The University of Westminster ethical committee 
approval was obtained regarding MTA Material Transfer Agreement (MTA) with 
UCL. 
 
Table 2.1: CLL stages of the patient cases studied and the corresponding 
WBC counts 
Binet stage Number of patients WBC count ×109/L  
Range 
Rai-Low Risk 




Rai-Intermediate Risk 20 6.6–196.0 
Rai-High Risk 13 1.1-200.4 
 
2.2 Isolation of peripheral blood mononuclear cells (PBMC) 
Six to ten ml of whole blood were taken from CLL patients into heparinised test 
tubes by specially qualified staff at UCLH CLL clinic. Hanks’ buffered salt solution 
(HBSS) and Histopaque 1077 (Sigma, UK) density medium were allowed to 
equilibrate to room temperature before the experiment. After dilution of the 
samples in an equal volume of HBSS, 6-8 ml of blood sample was carefully 
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layered onto 3 ml density medium. Upon centrifugation (5810 R centrifuge 
Eppendorf, UK) at 400 g for 30 min at 22 oC, PBMCs were collected by aspiration 
of the interphase. The cells were washed twice with 5 ml of HBSS, by centrifuging 
for 10 min, 400 g at 4 oC. The cells were resuspended in 1ml of Roswell Park 
Memorial Institute 1640 (RPMI) medium supplemented with 10% w/v foetal 
bovine serum (FBS) (both from Sigma-Aldrich, UK). The lymphocytes were 
counted using a haemocytometer (Millipore, UK) and cell concentration was 
adjusted to 106 cells/ml by resuspending in RPMI-1640.   
2.3 Immunophenotyping 
200µl of PBMC suspension was added into each well of a 96 well round bottom 
microplate (Corning, VWR UK) at a concentration of 106/ml. The plate was 
centrifuged for 5 min, 400 g at 4 oC. The supernatant was discarded and the pellet 
was vortexed (Rotamixer, UK).  In order to prevent non-specific binding of the 
specific monoclonal antibodies (mAb) via Fc receptors, 20 µl of 2 mg/ml human 
immunoglobulin (Ig) (ImmunoReagents, UK) was added into each well and the 
plate was incubated for 30min on ice. The plate was centrifuged for 5 min, 400 g 
at 4 oC, supernatant was removed and vortexed. 20 µl of the following mouse 
anti-human mAbs at a final concentration 20 µg/ml was added into designated 
wells: IgG1 isotype control, anti-CD180 (IgG1 clone G28-8), anti-IgM, anti-
CD79b, anti-CD38, anti-CD86 and anti-CD40 (all - BD Pharmingen, UK), and 
anti-IgD (Sigma, UK). Cells were incubated for 30 min on ice and washed twice 
with 200 µl HBSS for 5 min, 400 g at 4 oC. As the secondary antibody, 20 μl of 
fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse Ig (Dako, UK), at 
an optimal dilution 1:15 in Phosphate Buffered Saline solution (PBS) (Sigma, UK) 
was added into each well. The plate was incubated in the dark on ice for 30 min, 
centrifuged at 400 g and cells were washed twice as before. The cells were further 
incubated with 20 μl of mouse serum (Dako, UK) for 30 minutes on ice in the dark 
(1:15 diluted in PBS) to block any free rabbit anti-mouse F(ab) sites and 
centrifuged for 5 min, 400 g at 4 oC. The supernatant was removed, vortexed and 
5 µl of phycoerythrin cyanine 5 conjugated (PE-Cy5) mouse anti-human CD19 
monoclonal antibody (mAb) (BD Pharmingen, UK) and 5 µl of phycoerythrin 
cyanine 5 conjugated (PE-Cy5) mouse anti-human CD5 monoclonal antibody 
(mAb) (BD Pharmingen, UK) were added and incubated for 30 min on ice in the 
dark. Cells were washed twice as before and fixed with 200 μl of 2% w/v 
paraformaldehyde (PFA) (Sigma, UK) in PBS and stored (no more than 4 days) 
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at 4 oC until analysis by flow cytometry using Cyan (Beckman Coulter, UK) flow 
cytometer and Summit software v4.3. The results were expressed as 
percentages of positive cells as well as antibody relative binding sites (RBS)/cell 
as previously described (Guyre et al., 1989; Porakishvili et al., 2005). This is a 
method of evaluating the level of a cell surface molecule, reflecting its density on 
the cell membrane. Briefly, the number of secondary antibody-binding sites (RBS) 
per cell versus isotype control was determined by comparison with the mean 
fluorescence intensities to a standard curve generated with fluorescent 
microspheres (Dako Cytomation, UK) containing beads with five different levels 
of fluorochrome molecules per bead as described earlier (Porakishvili et al., 
2005). In some cases, the relative mean fluorescence intensity (RMFI) was used 
as a measure of positivity (RMFI = MFI of sample/MFI of isotype control). CLL 
clones were then categorised as CD180+ and CD180- for future studies, or 




















Figure 2.1: Representative flow cytometry image of dot plots, histograms 
and the overlay of phenotyping of PBMCs from a CLL patient. The CLL sample 
was incubated with human immunoglobulin (Ig), stained with mouse IgG1κ isotype 
Negative 
control 
Positive cell population 
expressing CD180 
(D)Mouse anti-human 
CD180 (primary mAb) 
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Live 
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control or mouse anti-human CD180 (primary mAb). Following the incubation with mouse 
serum, the sample was stained with FITC-conjugated rabbit anti-mouse Ig (secondary 
mAb), PE-Cy5-conjugated-mouse-anti-human-CD19 and PE-conjugated mouse anti-
human CD5. The sample was analysed by CYAN flow cytometer and Summit (4.3) 
analytical software. The gating of the first dot plot represents live cells (Panel A) and the 
second gating represents CD19 and CD5 positive CLL cells (Panel B). The first 
histogram shows the negative population of cells (Panel C) and the second histogram 
shows CD180+ cell population (Panel D). The overlay plot shows the CD180 positive CLL 
cells compared with the negative control cells inside CD19+ gated population (Panel E).   
 
2.4 Phosphorylation of intracellular protein kinases  
200 µl of isolated PBMCs from CD180+sIgM+ CLL samples and PBMCs from 
healthy volunteers (concentration of 1x106 cells/ml in RPMI+10% w/v FBS) were 
added to 96 well flat bottom microplates (Corning, VWR UK) and incubated with 
8µl of sodium azide free anti-CD180 mAb (BD Pharmingen, UK) or goat anti-
human IgM F(ab)2 (Southern Biotech, Birmingham, USA) under sterile conditions 
at a final concentration of 20 µg/ml and incubated at 37 °C, 5% CO2 for 30 min 
(short-term cultures) or 24 hours (long-term cultures). In separate experiments, 
cells were sequentially incubated with anti-CD180 for 20 min followed by anti-IgM 
F(ab)2  for 10 min or vice versa. The optimal stimulation time for short-term 
cultures has been identified in previous experiments of our research group 
(Porakishvili et al., 2011). Unstimulated cells were used as negative controls. 
Upon stimulation, cells were transferred into 96 well round bottom plates, 
centrifuged at 400 g, 5 min at 4 oC and the supernatant was removed. Cells were 
washed twice with HBSS as before, the supernatant was discarded, vortexed and 
cells were stained with 5 µl of PE-Cy5-conjugated anti-CD19 mAb and incubated 
for 30 min on ice in dark. After two washes, as before, cells were fixed with 50 µl 
of solution A of Fix/Perm kit (ADG, Kaumberg, Austria) by incubating in the dark 
at room temperature for 15 min. The cells were washed once with HBSS as 
before and permeabilised with 50 µl solution B of the Fix/Perm kit. Cells were 
incubated for another 15 min at room temperature in the dark and centrifuged at 
400 g, 5 min at 4 oC. The supernatant was discarded, vortexed and cells were 
further stained with either of the following anti-human antibodies to 
phosphorylated (P) intracellular protein kinases: anti-AKT-P Alexa Fluor-488 
(FITC conjugated) rabbit mAb, anti-p38MAPK-P Alexa Fluor-488 (FITC 
conjugated) mouse mAb (Cell Signaling, Danvers, MA, USA), anti-BTK-P Alexa 
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Fluor-647 (PE-conjugated) mouse mAb (BD Pharmingen, UK) and incubated at 
room temperature for 30 min in the dark. After incubation, the cells were washed 
once with HBSS as above, fixed with 200µl 2% v/v paraformaldehyde (PFA) and 
stored in the dark (for ≤ 24h) at 4 oC for flow cytometry. The results of the 



























Figure 2.2: Representative flow cytometry image of dot plots, histograms 
and the overlay of Phosphorylation of AKT protein kinase of PBMCs from a 
AKT-S CLL patient. CLL cells were left unstimulated in medium or incubated with anti-
CD180 mAb for 20 min (CD180 mAb), washed, stained with anti-CD19 mAb, fixed, 
permeabilised, stained with anti-AKT(Ser473)-P as described in 2.4 of Materials and 
methods, analysed by CYAN flow cytometer and Summit 4.3 analytical software and 
expressed as percentages of positive cells inside gated CD19+ population. The gating of 
the first dot plot represents live cells (Panel A) and the second gating represents CD19 
positive B lymphocytes (Panel B). The first histogram shows CLL cell population with 
phosphorylated AKT (p-AKT) when unstimulated (Panel C) and the second histogram 
shows CLL cell population with p-AKT when stimulated with anti-CD180 mAb (Panel D). 
The overlay plot shows CLL cell population with p-AKT when stimulated with anti-CD180 
mAb compared with unstimulated cells (Panel E).   
 
2.5 Analysing the effect of protein kinase inhibitors on phosphorylation of 
corresponding protein kinases by flow cytometry 
200 µl of isolated PBMCs (concentration of 1x106 cells/ml in RPMI+10% FBS) 
were added to 96 well flat bottom microplates. In order to assess the optimal 
concentrations of protein kinase inhibitors, pilot experiments were carried out with 
range of concentrations. Final concentration of 5 µM,10 µM and 20 µM was tested 
for SB203580, 2 µM, 5 µM and 10 µM was tested for Akti1/2 and 2 µM, 5 µM and 





(D).CLL cells stimulated 
with anti-CD180 mAb 
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10 µM was tested for Ibrutinib inhibitor (data not shown). CD180+ CLL cells from 
CD180+ patients were treated with protein kinase inhibitors as follows; 4 µl of p38 
MAPK inhibitor, SB203580 (4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-
pyridyl)-1H-imidazole) (Sigma, UK) was added at a final concentration of 20 µM 
(Wilk-Blaszczal et al., 1998) and incubated at 37°C, 5% CO2 for 2 hours (Young 
et al., 1997).  
2 µl of AKT 1/2 kinase inhibitor (1,3-Dihydro-1-(1-((4-(6-phenyl-1H-imidazo[4,5-g] 
quinoxalin-7-yl) phenyl) methyl)-4-piperidinyl)-2H-benzimidazol-2-one 
trifluoroacetate salt hydrate, Akt Inhibitor VIII trifluoroacetate salt hydrate, Akti-1/2 
trifluoroacetate salt hydrate) (Sigma, UK) was added at a final concentration of 5 
µM and incubated at 37°C, 5% CO2 for 2 hours (Frias  et al., 2009). 2 µl of BTK 
kinase inhibitor, Ibrutinib (PCI-32765), (Selleckchem, UK) was added at a final 
concentration of 10 µM and incubated at 37°C, 5% CO2 for 2 hours (Herman et 
al., 2011).  Cells were transferred into 96 well round bottom plates centrifuged at 
400 g, for 5 min at 4 oC, the supernatant was removed and vortexed. Cells were 
washed twice with HBSS as before, the supernatant was discarded and vortexed. 
The pellet was resuspended in 200 µl of RPMI and transferred into a 96 well flat 
bottom microplate. Non-treated CLL cells were used as negative controls. Both 
treated and untreated CLL cells were incubated with 8 µl of sodium azide free 
anti-CD180 mAb under sterile conditions at a final concentration of 20 µg/ml and 
incubated at 37°C, 5% CO2 for 30 min. Unstimulated CLL cells were used as 
negative controls.  After the stimulation, the rest of the experiment was carried 







Figure 2.3: Representative flow cytometry image of dot plots, histogram 
and the overlay of Phosphorylation of AKT protein kinase of PBMCs from a 
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incubated with Akti1/2 inhibitor for 2 hrs, washed and left unstimulated in medium or 
incubated with anti-CD180 mAb for 20 min (CD180 mAb). The sample was washed, 
stained with anti-CD19 mAb, fixed, permeabilised, stained with anti-AKT(Ser473)-P as 
described in 2.4 of materials and methodology, analysed by CYAN flow cytometer and 
Summit 4.3 analytical software and expressed as percentages of positive cells inside 
gated CD19+ population. The gating of the first dot plot represents live cells (Panel A) 
and the second gating represents CD19+ B lymphocytes (Panel B). The histogram shows 
the CLL cell population with phosphorylated AKT (p-AKT) when untreated with Akti1/2 
and unstimulated (Panel C). The overlay plot shows the comparison of CLL cell 
population with p-AKT, stimulated with anti-CD180 mAb when untreated/treated with 
Akti1/2 and CLL cell population with p-AKT when unstimulated and untreated/treated 
with Akti1/2 (Panel D).   
 
2.6 Apoptosis assay 
2.6.1 Assessment of apoptosis by the changes in mitochondrial 
membrane potential 
3,3'-dihexyloxacarbocyanine Iodide (DiOC6) is a fluorescent dye that 
discriminates between bright fluorescent viable and dim fluorescent apoptotic 
cells upon exposure to blue light (482nm) which excites DiOC6 to fluoresce green 
(504nm) (Koning et al., 1993). Mitochondrial membrane potential (Δψm) is an 
important parameter of mitochondrial function and an indicator of cell health. 
Depletion of Δψm suggests the loss of mitochondrial membrane integrity and thus 
the initiation of the proapoptotic signal. A cell-permeant, lipophilic dye, DiOC6 
accumulates in mitochondria due to their large negative membrane potential and 
can be applied to monitor the mitochondrial membrane potential using flow 
cytometric detection (Chang et al., 2013). The optimum concentration of DiOC6 
was previously determined by our research group (Porakishvili et al., 2005). 
DiOC6 is reported to be a useful probe for labelling endoplasmic reticulum and 
our research group has confirmed the validity of assessing mitochondrial 
membrane potential of CLL cells usin DiOC6 compared to annexin V-FITC (data 
not shown). 
200 µl of PBMCs at a concentration 106 cells/ml in RPMI+10% FBS were 
stimulated with 8 µl of sodium azide free anti-CD180 mAb as above for 24 h in 
96 well flat bottom microplates. Non-stimulated cells were used as negative 
controls. Upon stimulation, cells were transferred into 96 well round bottom 
microplates, centrifuged, washed once as described above, stained with 5 µl of 
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PE-Cy5 conjugated anti-CD19 mAb and incubated for 30 min on ice in the dark. 
Cells were washed twice with HBSS as before, supernatant was removed and 
vortexed. Cells were resuspended in 200 µl of HBSS and transferred into 96 well 
flat bottom microplates and probed with 20 µl (0.2 µmol/l) of DiOC6 (3,3'-
dihexyloxacabocyanine iodide; Molecular Probes, Eugene, USA). Cells were 
incubated for 20 min at 370C, washed twice with HBSS, resuspended in HBSS 
and analysed by flow cytometry immediately. The level of apoptosis was 
determined by the percentages of DiOC6dim cells gated on the CD19+ population 




Figure 2.4: Representative flow cytometric profiles of 24 h CLL cell cultures 
without CD180 antibody (A) and after incubating with anti-CD180 mAb (B) 
showing the percentages of DiOC6 bright cells gated on CD19+ lymphocytes. 
PBMC from CD180+ CLL patients were cultured in the absence and presence of 10 
μg/mL anti-CD180 mAb for 24h. Cells were stained with PE-Cy5 conjugated mouse anti-
human CD19 mAb and loaded with 0.4 μM of DiOC6 Dye for 20 min at 370C. Flow 
DiOC6 bright cells 
(24.96%) 
DiOC6 bright cells 
(49.79%) 
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cytometric analysis was performed immediately. DiOC6 bright cells were counted gating on 
CD19+ population and identified as viable cells (Porakishvili et al., 2011). 
 
2.6.2 Assessment of apoptosis by the loss of phospholipid asymmetry in 
cell membranes 
The annexins are a group of proteins which bind to phospholipids in the presence 
of calcium (Pigault et al., 1994; Trotter et al., 1995). Annexin V-FITC is a 
fluorescent probe which binds to phosphatidylserine in the presence of calcium. 
The Mg-ATP-dependent enzyme, aminophospholipid translocase transports 
phosphatidylserine to the inside of the lipid bilayer in living cells (Trotter et al., 
1995) (Figure 2.5a).  At the onset of apoptosis, phosphatidylserine, which is 
normally found on the internal part of the plasma membrane, becomes 
translocated to the external portion of the membrane and becomes available to 
bind to the annexin V-FITC conjugate in the presence of calcium. Therefore, the 
binding of annexin V-FITC to phosphatidylserine in the membrane of cells is an 
indication of the beginning of the apoptotic process (Figure 2.5b) and the binding 
of PI to the cellular DNA in cells indicates that the cell membrane has been totally 
















Figure 2.5: Binding of Annexin V-FITC and Propidium Iodide (PI) at different 
stages of apoptosis. In apoptotic cells, the membrane phospholipid 
phosphatidylserine (PtdSer) is translocated from the inner to the outer leaflet of the 
plasma membrane thereby exposing PtdSer to the external cellular environment. 
Annexin V binds to cells with exposed PtdSer in the presence of Ca2+  thus acting as a 
sensitive probe for flow cytometry analysis of cells that are in the earliest stage of 
apoptosis. Viable and early apoptotic cells exclude PI, whereas the membranes of dead 
and damaged cells are permeable to PI hence acting as a probe to analyse cells that are 
in the end stage of apoptosis or necrosis (Givan, 2000). 
 
200 µl of PBMCs at a concentration 106 cells/ml in RPMI+10% FBS were 
stimulated with 8 µl of sodium azide free anti-CD180 mAb as above for 24h in 96 
well flat bottom microplates. Unstimulated cells were used as negative controls. 
Upon stimulation, cells were transferred into 96 well round bottom microplate, 
centrifuged, washed twice as described above, stained with 5 µl of PE-Cy5 
conjugated anti-CD19 mAb and incubated for 30 min on ice in the dark. Cells 
were washed twice with HBSS as before, the supernatant was removed and 
vortexed. Cells were resuspended in 200 µl of binding buffer (diluted 1:10 in 
deionized water) and transferred into 96 well flat bottom microplates. Each well 
was incubated with 1 μl of propidium iodide (PI, 100µg/ml in 10 mM potassium 
phosphate buffer, pH 7.4, containing 150 mM NaCl) and 2 μl of annexin V-FITC 
conjugate (~50 µg/ml in 50 mM Tris-HCl, pH 7.5, containing 100 mM NaCl). The 
optimum concentration of PI and Annexin V-FITC was previously determined in 
our laboratory (data not shown). Cells were incubated for exactly 10 min at room 
temperature in the dark and analysed by flow cytometry immediately. The level of 
a b c 
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apoptosis was determined by the percentages of PI and Annexin V-FITC positive 
cells gated on the CD19+ population versus unstimulated cultures. 
 
Figure 2.6: Representative flow cytometry image of a dot plot of CLL cells 
at different stages of apoptosis. CLL samples were stained with 5µl of PE-Cy5 
conjugated anti-CD19 mAb, 1 μl of propidium iodide (PI) and 2 μl of annexin V-FITC 
conjugate upon stimulation with anti-CD180 mAb and incubated at 37°C, 5% CO2 for 30 
min. The sample was analysed by CYAN flow cytometer and Summit (4.3) analytical 
software. Viable cells are negative to both Annexin V-FITC and PI, early apoptotic cells 
are positive to Annexin V-FITC while negative to PI and cells that are in late apoptosis or 
already dead are positive to both Annexin V-FITC and PI. 
 
2.7 Analysing the spontaneous and IgM ligated modulation of CD180 level 
of expression in CD180+ and CD180neg CLL cells  
In order to assess the level of CD180 expression ex vivo, 200 µl of isolated 
PBMCs from CD180+ CLL samples (concentration of 1x106 cells/ml in RPMI+10% 
FBS) were added to 4 wells of 96 well flat bottom microplates. The plate was 
centrifuged for 5 min, 400 g at 4 oC. The supernatant was discarded and the pellet 
was vortexed.  In order to prevent non-specific binding via Fc receptors, 20 µl of 
2 mg/ml human immunoglobulin (Ig) was added into each well and incubated for 
30 min on ice. The plate was centrifuged for 5 min, 400g at 4 oC, supernatant was 
removed and vortexed. 5 µl of PE-conjugated mouse IgG1 isotype control and 
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UK) was added (n=2). 5 µl of PE-Cy5 conjugated anti-CD19 mAb was added into 
all 4 wells. Cells were incubated for 30 min on ice in the dark and washed twice 
with 200 µl HBSS for 5 min, 400g at 4 oC. Cells were fixed with 200 μl of 2% PFA 
in PBS and stored (no more than 4 days) at 4 oC until analysis by flow cytometry 
using Cyan flow cytometer and summit software v4.3. The results of the 
experiment were expressed as percentages of CD180 positive cells gated on the 
CD19+ population. In some experiments cells were incubated for 24, 48 and 72 
hours at 37 °C, 5% CO2 in 96 well flat bottom microplates, transferred into 96 well 
round bottom microplates, centrifuged at 400 g, 5 min at 4 oC and the supernatant 
was removed. Cells were washed twice with HBSS as before, the supernatant 
was discarded and vortexed. The same staining and analysis procedure was 
carried out as in the ex vivo experiment to analyse the percentages of CD180 
positive cells gated on the CD19+ population.  Same procedure was followed 
again for CD180- CLL samples in order to compare the level of expression of 
CD180 ex vivo and after 24, 48 and 72 hr incubation.  
 
In order to analyse the effect of IgM ligation on expression of CD180 on the CLL 
cells, 200 µl of isolated PBMCs from IgM positive CLL samples (concentration of 
1x106 cells/ml in RPMI+10% w/v FBS) were added to 96 well flat bottom 
microplates. Cells were stimulated with goat anti-human IgM F(ab)2 under sterile 
conditions at a final concentration of 20 µg/ml and incubated at 37 °C, 5% CO2 
for 24, 48 and 72 hours in 96 well flat bottom microplates, transferred into 96 well 
round bottom microplates, centrifuged at 400 g , 5 min at 4 oC and the supernatant 
was removed. Cells were washed twice with HBSS as before, the supernatant 
was discarded and vortexed. The same staining and analysis procedure was 







Figure 2.7: Representative flow cytometry image of dot plots, histograms 
and the overlay of phenotyping by direct staining for CD180 expressed on 
PBMCs from a CLL patient. CLL sample was incubated with human immunoglobulin 






(C) PE- Mouse IgG1 
isotype control 
(D).PE- mouse anti-human 
CD180 mAb 
(E) Overlay  






anti-human CD180 mAb and PE-Cy5-conjugated-mouse-anti-human-CD19. The sample 
was analysed by CYAN flow cytometer and Summit (4.3) analytical software. The gating 
of the first dot plot represents live cells (Panel A) and the second gating represents CD19 
positive B lymphocytes (Panel B). The first histogram shows the negative population of 
cells (Panel C) and the second histogram shows CD180+ cell population (Panel D). The 
overlay plot shows the CD180 positive CLL cells compared with the negative control cells 
inside CD19+ gated population (Panel E). 
2.8 Statistical analysis 
The results obtained during the course of the project were analysed statistically 
using appropriate methods. The following statistical methods were applied where 
required; 
Standard parametrical tests: 
Pearson’s correlation coefficient using SPSS software (provided by the 
University of Westminster, IT systems, UK)  
Student t-test (MS excel) 
 
Non-parametrical tests: 
Man-Whitney U-test using MINITAB software (provided by the University of 
Westminster, IT systems, UK) 
Wilcoxon’s signed-rank test suning SPSS software  
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Our group has previously shown that CD180 is expressed heterogeneously in 
CLL cells whilst its expression in the majority of CD19+ control B cells is high 
(5548±2271 RBS/cell, range 2392-13870 RBS/cell) compared to CD180+ CLL 
cells (1500±932 RBS/cell, range 499-4287 RBS/cell). Classification of CLL cells 
as either CD180 positive or negative was based on the levels of anti-CD180 
antibody RBS on a small CD180 negative population seen in the control CD19+B 
cells: 316 ± 88 RBS/cell, range 201–470 RBS/cell. The upper limit for the negative 
population was determined as mean + 2SD (Porakishvili et al., 2005). The 
percentages of CD180-negative B cells in control B cell population was recorded 
as [mean ±SD (range)] 2.6 ±1.5% (0.8-7.3%) (Koarada et al., 2001). The ratio 
between CD180+ versus CD180neg CLL cell samples obtained from individual 
patients was approximately 2:1.  
In the initial study, no difference between CD180 expression was detected 
between untreated patients, patients who have been treated 6 months prior to 
the research or those undergoing various treatments (Porakishvili et al., 2005). It 
was also reported that the expression of CD180, sIgM, CD79b and CD40 on both, 
M-CLL and U-CLL cells was significantly lower than in control B cells. Whilst there 
were no significant differences in the expression of CD79b, CD38, CD86 or CD40 
on U-CLL and M-CLL cells it was interesting to note that CD38+ U-CLL samples 
expressed a higher density of CD180 compared with CD38neg U-CLL samples, 
but this was not observed in M-CLL samples (Porakishvili et al., 2005). Most 
importantly in this publication, it was demonstrated that U-CLL samples were 
characterised by the significantly higher expression of sIgM and significantly 
lower expression of CD180, compared to M-CLL cells. 
Porakishvili et al., (2005) further subdivided CD180+ CLL samples into two 
groups depending on their responsiveness to CD180 ligation reflected in their 
activation and proliferation. Those CD180+ CLL clones which responded to 
CD180 ligation by a significant increase in the expression of CD86 and Ki-67 
were termed as responders, (R) whereas CD180+ CLL cells which failed to 
respond to anti-CD180 mAb by elevation of CD86 and Ki-67 were termed non-
responders, (NR).   
These results on activation and cycling of CLL cells upon stimulation with anti-
CD180 mAb were consistent with previous studies which demonstrated the ability 
of anti-CD180 mAb to activate normal human B lymphocytes and murine B cells 
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(Valentine et al., 1988; Chan et al., 1998). CD180 ligation led to comparable or 
even greater levels of activation and proliferation of normal B cells and R-CLL 
cells than optimal concentrations of anti-CD40 mAb or recombinant IL-4 (rIL-4) 
(Porakishvili et al., 2005). The role of CD40 ligation in CLL has been reported in 
previous studies. CD40 ligation has been shown to both stimulate proliferation of 
CLL cells and protect against apoptosis by inducing cMyc (Clark et al., 1989; 
Mentz et al., 1996). CD40 ligation also led to upregulation of anti-apoptotic 
proteins of the B-cell lymphoma (Bcl) family and cellular FADD-like IL-1β-
converting enzyme (FLICE)-inhibitory protein c-FLIP (Liu et al., 1989; Tuscano et 
al., 1996). IL-4 protects B cells and CLL cells from spontaneous-, cytokine-, drug-
induced (Dancescu et al., 1992; Mentz et al., 1996; Mainou-Fowler et al., 2001) 
and Fas-mediated (Foote et al., 1996) apoptosis.  
Since CD180 lacks the TIR intracellular signalling domain and has only 11 
intracellular amino acids (Miyake et al., 1995; Miura et al., 1996; Fugier-Vivier et 
al., 1997; Roshak et al., 1999), it may either recruit an unidentified B cell specific 
protein for upstream signalling (Yazawa et al., 2003) or cooperate/converge with 
other signalling pathways. In order to identify the signalling pathway(s) utilized by 
CD180 in CLL and the possible defect in NR-CLL clones, Porakishvili et al., 
(2011) determined the phosphorylation of several important enzymes involved in 
signalling and they were the first to demonstrate that normal B cells and R-CLL 
cells, but not NR-CLL cells responded to CD180 ligation by significant increase 
in the phosphorylation of protein kinases ZAP70/Syk, p38MAPK, ERK and AKT 
as well as the relative fluorescence intensity (RFI) of antibody binding which 
indicating the level of phosphorylation/cell. However, the responses were quite 
heterogeneous and here, using a larger cohort of patients, R-CLL cells could be 
divided into two categories as AKT signallers (AKT-S) and AKT non-signallers 
(AKT-NS) based on increased levels of phosphorylation of AKT (Ser 473) 
compared with the basal levels. It was important to determine the characteristics 
of the two categories of cells in terms of other signalling molecules, and this has 









3.2.1 CD180 ligation leading to alternative phosphorylation of either AKT or 
p38MAPK  
Stimulation with anti-CD180 mAb of 24 CLL samples which are CD180+ led to a 
significant increase in the percentages of cells expressing phosphorylated AKT, 
and these cells were termed, as previously, AKT-signallers (AKT-S) (p=0.000012, 
Figure 3.1A). Importantly, simultaneously CD180 ligation in the same cells 
induced significant downregulation of p38MAPK-P basal levels (p=0.0026, Figure 
3.1B). Whereas 16 CLL samples previously identified as AKT-NS showed a 
significant increase in p38MAPK-P (p=0.001, Figure 3.1B) accompanied by the 
drop in AKT-P below basal levels (p=0.0027, Figures 3.1A). This group of CLL 
samples was therefore re-categorised by us as p38MAPK signallers (p38MAPK-
S). These data support the hypothesis that CD180 ligation leads to two possible 
alternative pathways as indicated by the elevation of AKT-P or p38MAPK-P. Only 
six out of 60 CLL samples responded to CD180 ligation by increasing levels of 
both AKT-P and p38MAPK-P as did all control B cells (p=0.02 and p=0.0032 
respectively). They were marked as double-signallers (DS) (Figures 3.1A and B). 
The remaining 14 CLL samples showed a significant decrease in percentages of 
both AKT-P and p38MAPK-P expressing cells and were categorised as non-
signallers (NS) (p=0.028 and p=0.03 respectively, Figures 3.1A and B). 
Therefore, four patterns of CD180-mediated signalling in CLL cells were 
identified: AKT-signallers (AKT-S), p38MAPK-signalers (p38MAPK-S), non-
signallers (NS) and a minor subset of double AKT/p38MAPK signallers (DS).  The 
dichotomy of CD180-induced signalling by elevation of AKT-P or p38MAPK-P 
could be related to the surface density of CD180. However, no significant 
differences in CD180, CD38 or CD79b expression were observed between AKT-
S, p38MAPK-S or NS cells, although DS CLL cells surprisingly expressed the 
lowest levels of CD180. Porakishvili et al. (2011) previously reported that CD180 
ligation of control B cells resulted in simultaneous activation of protein kinases 
ZAP70/Syk, ERK, p38MAPK and AKT. This was further confirmed by the present 
study showing phosphorylation of both, AKT and p38MAPK protein kinases in 
control B cells (p=0.000005 and p=0.00022 respectively in Figures 3.1A and 
3.1B). Therefore, the dichotomy of AKT versus p38MAPK activation appears to 




Figure 3.1: Phosphorylation of (A) AKT protein kinase (B) p38MAPK protein 
kinase in control B cells, AKT-signaller (AKT-S), p38MAPK signaller 
(p38MAPK-S), double signaller (DS) and non-signaller (NS) cells following 
stimulation with anti-CD180 mAb. CLL cells and control B cells were incubated with 
anti-CD180 mAb for 20 min (CD180 mAb) or left unstimulated in medium (M), washed, 
stained with anti-CD19 mAb, fixed, permeabilised and stained with anti-AKT(Ser473)-P 
(A) or with anti-p38MAPK-P (B) mAbs as described in the Materials and methods, 
analysed by flow cytometry and expressed as percentages of positive cells. P values 








3.2.2 CD180-induced AKT-mediated signalling in CLL cells involves BTK 
and leads to the survival of CLL cells, while the p38MAPK pathway favours 
apoptosis 
Zhuang et al., (2010) demonstrated that CLL clones consistently express 
activated AKT which plays a pivotal role in maintaining cell survival. This was in 
accord with previous studies showing the significance of AKT in cell survival upon 
stimulation via soluble anti-IgM (sol-IgM) (Petlickovski et al., 2005) and anti-CD40 
(Cuni et al., 2004). Herman et al., (2011) demonstrated that BTK protein and its 
mRNA are significantly overexpressed in CLL cells compared with normal B cells 
suggesting the importance of BTK in CLL cell survival mediated through the BCR. 
Therefore, it was important to determine whether CD180-mediated survival of 
CLL cells involved BTK as well as AKT pathway.  
CD180 ligation of all 13 AKT-S CLL samples induced upregulation of BTK-P 
(p=0.0039, Figure 3.2). This was accompanied by a substantial survival from 
apoptosis shown by a significant decrease in DiOC6dim apoptotic cells in 15 AKT-
S CLL samples (p=0.0058, Figure 3.3). Control B cells also exhibited increased 
survival following CD180 ligation which was shown by a significant decrease in 
DiOC6dim apoptotic cells (p=0.016, Figure 3.3 and [Porakishvili et al., 2011]). 
In contrast, there was a significant decrease in the percentages of BTK-P+ cells 
below the basal level in 11 out of 12 p38MAPK-S CLL samples, following the 
treatment with anti-CD180 mAb (p=0.036, Figure 3.2). Most importantly, a 
significant (if heterogeneous) increase in DiOC6dim apoptotic p38MAPK-S cells 
after CD180 ligation in 14 p38MAPK-S CLL samples analysed was observed 
(p=0.0064, Figure 3.3).  
BTK phosphorylation and associated apoptosis in a small cohort of 6 DS CLL 
samples was analysed and there was a decrease in BTK-P in DS (p=0.048, 
Figure 3.2) whilst there was no CD180-mediated change in the cell survival as 




Figure 3.2: Percentages of BTK-P+ cells in AKT-S, p38MAPK-S and DS 
categories of CLL cells. Cells were incubated with anti-CD180 mAb for 20 min 
(CD180 mAb) or left unstimulated (Medium), washed, stained with anti-CD19 mAb, fixed, 
permeabilised and stained with anti-BTK-P mAb as described in the Materials and 
methods and analysed by flow cytometry. P values were calculated using the paired t-
test. 
 
Figure 3.3: The percentages of DiOC6dim (apoptotic) cells in control B cells, 
AKT-S, p38MAPK-S and DS CLL cells, compared to unstimulated cultures 
(Medium). Cells were stimulated with anti-CD180 mAb for 24h, washed, stained with 
anti-CD19 mAb, loaded with DiOC6 for 20 min and analysed by flow cytometry as 
described in the Materials and methods. The values are means ± SD, p values were 
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calculated using a non-parametrical U-test. White colour bars represent % of dead cells 
in unstimulated cultures (Medium) and grey colour bars represent% of dead cells in 
stimulated cultures.  
3.2.3 sIgM-induced activation favours the pro-survival signalling pathway 
in AKT-S CLL cells, but not a pro-apoptotic pathway in p38MAPK-S CLL 
cells 
Several studies reported the significance of AKT in CLL survival, by playing a vital 
role in BCR-mediated pro-survival signalling (Packham et al., 2010; 
Wickremasinghe et al., 2011; Scuppoli et al., 2012). Bichi et al., (2002) 
demonstrated that activation of sIgM is associated with higher expression levels 
of T-cell leukaemia/lymphoma 1 (TCL1) protein which is an AKT activator and 
increased phosphorylation of AKT. Overexpression of TCL1 causes expansion of 
CD5+ B cells which develop into CLL-like disease in transgenic mice showing the 
importance of AKT phosphorylation in development of CLL upon sIgM activation. 
Hence, it was important to study and compare sIgM induced signalling pathways 
with CD180 mediated signalling patterns which were identified in the major 
categories of CLL cells defined above. Double positive CD180+sIgM+ CLL 
samples were selected for this study. 
In the AKT-S category of cells, striking similarities between CD180 and sIgM-
mediated signalling could be observed. There was a significant increase in 
phosphorylation of AKT (p= 0.00063, Figure 3.4A) and BTK (p=0.0006, Figure 
3.4C) above the basal level in AKT-S CLL samples upon treatment with anti-IgM 
whereas downregulation of the basal levels of p38MAPK-P (p=0.019, Figure 
3.4B). However, anti-CD180 induced activation of BTK/AKT was observed in all 
AKT-S CLL samples studied (Figures 3.1 and 3.2), anti-IgM effect on this 
BTK/AKT circuit was more heterogeneous. 4/20 (20%) AKT-S CLL samples 
responded to anti-IgM by downregulation of AKT-P (Figure 3.4A) and 2/15 (13%) 
AKT-S samples responded by phosphorylation of p38MAPK (Figure 3.4B). 
However, overall 70% of AKT-S CLL samples responded to anti-CD180 and anti-
IgM similar pattern and led to activation of BTK/AKT whilst downregulation of 
p38MAPK-P. 
The anti-IgM effect on survival of AKT-S CLL cells was studied by analysing 
DiOC6dim apoptotic cells upon stimulation. Interestingly, anti-IgM protected AKT-S 
CLL cells from apoptosis in 9 CLL samples as shown by a significant reduction in 
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DiOC6dim apoptotic AKT-S cells (p=0.020, Figure 3.5) similar to the result shown 
by CD180 ligation in this category of cells.  
By contrast, sIgM ligation resulted in an increase in phosphorylation of p38MAPK 
in only 3/13 p38MAPK-S samples (23%) (p=0.26, Figure 3.4B) suggesting 
phosphorylation of p38MAPK upon stimulation with anti-IgM is a less frequent 
event compared to CD180 ligation. However, there was a significant decrease in 
expression of BTK-P in all 9 p38MAPK-S CLL samples studied (p=0.016, Figure 
3.4C). 
Effect of sIgM ligation on the survival of p38MAPK-S cells was assessed by 
analysing the changes in mitochondrial membrane potential and there was no 
significant difference in DiOC6dim apoptotic p38MAPK-S cells upon stimulation 
with anti-IgM (p=0.104, Figure 3.5). Therefore, new data indicate that 
phosphorylation of p38MAPK is vital for the induction of apoptosis in p38MAPK-
S category of cells that has not been observed after sIgM ligation compared to 
CD180 ligation. As similar to CD180 ligation, sIgM ligation also resulted in 
phosphorylation of both AKT and p38MAPK protein kinases in control B cells 
(p=0.0000005 and p=0.000017 respectively, Figures 3.4A and B).  
Hence, these data suggest that a pro-survival signalling pathway operating via 
BTK/AKT in CLL cells can be activated by both sIgM and CD180 ligation whereas 
only anti-CD180 mAb can activate an alternative pathway mediated via 
p38MAPK which leads to apoptosis in p38MAPK-S cells. This p38MAPK 





Figure 3.4: Anti-IgM mediated phosphorylation of AKT, p38MAPK and BTK. 
(A, B and C) Control B cells or CLL cells from the AKT-S and p38MAPK-S groups were 
incubated with anti-IgM F(ab)2 for 10 minutes (anti-IgM) or left unstimulated in medium 
(Medium), washed, stained with anti-CD19 mAb, fixed, permeabilised and stained with 
anti-AKT-P, anti-p38MAPK-P and anti-BTK-P mAbs as described in the Materials and 
methods. The results were analysed by flow cytometry and expressed as percentages 
of positive cells. P values were calculated using the paired t-test. 
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Figure 3.5: The percentages of DiOC6dim apoptotic cells in control B cells, 
AKT-S, p38MAPK-S and DS upon stimulation with anti-IgM F(ab)2. Control B 
cells and CLL cells were stimulated with anti-IgM F(ab)2 or left unstimulated (Medium) for 
24 h, washed, stained with anti-CD19 mAb, loaded with DiOC6 for 20 min and analysed 
by flow cytometry as described in the Materials and methods. The values represent mean 
± SD, p values were calculated using the non-parametrical U-test. White colour bars 
represent % of dead cells in unstimulated cultures (Medium) and grey colour bars 
represent % of dead cells in stimulated cultures.  
 
3.2.4 Rewiring of sIgM-mediated intracellular signalling from pro-survival 
BTK/PI3K/AKT to a pro-apoptotic p38MAPK Pathway 
Yamashita et al., (1996) showed that pretreatment of murine B cells with anti-
CD180/RP105 led to anti-IgM-induced apoptosis. Hence, it was interesting to 
study whether pre-engagement of CD180 on CLL would affect BCR mediated 
signalling in CLL. CLL samples which are CD180+sIgM+ were selected for this 
study. In all 15 AKT-S CLL samples, pre-treatment with anti-CD180 mAb, followed 
by anti-IgM F(ab)2, led to a significant decrease in the percentages of AKT-P+ 
cells (Figure 3.6A, p=0.000013) albeit not to the baseline level, compared with 
anti-IgM alone. Simultaneously, a decrease in BTK-P+ cells from 44.3±11.4% 
(anti-IgM alone) to 32.6±13.5% (anti-CD180+anti-IgM, n=11, p=0.02) with 
baseline levels of 38.3±6.5% was observed. Most interestingly, in 14 out of 15 of 
these AKT-S samples, reduction in BTK/AKT phosphorylation was accompanied 
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by a significant increase in the phosphorylation of p38MAPK following sequential 
ligation of CD180 and IgM (p=0.0057 Figure 3.6A).  
The effect of pre-treatment of AKT-S CLL cells with anti-CD180 mAb on their 
survival was also studied. Importantly, there was a significant increase in 
apoptotic cells compared with the engagement of IgM alone (p = 0.025) and 
above baseline apoptosis (p = 0.026, Figure 3.7). Therefore, these data show 
that sensitization of AKT-S CLL cells with anti-CD180 leads to rewiring of anti-IgM 
mediated pro-survival signalling via BTK/AKT to the pro-apoptotic p38MAPK 
pathway. However, a similar result was not observed in control B cells as there 
was no significant difference in the percentages of AKT-P+ cells (p=0.193, Figure 
3.6B) and p38MAPK-P+ (p=0.561, Figure 3.6B) following sequential ligation of 
CD180 and IgM. Hence, the modulation appears to be a characteristic of CLL 
cells. Differences in the optimal stimulation time for anti-CD180 and anti-IgM 
antibodies did not affect the redirection phenomenon described in this study. The 
percentages of cells expressing AKT-P following stimulation with anti-IgM for 30 
min were somewhat lower than those after 10 min (49.3 ± 8.9% versus 59.4 ± 
11.0%, p = 0.09). However, this did not affect an outcome of pre-stimulation with 
anti-CD180 where the numbers of AKT-P cells further dropped down to 26.4 ± 
13.5%, p =0.028. The percentages of p38MAPK-P expressing cells did not differ 
in the range of 10 to 30 min stimulation with anti-IgM (data not shown). 
It was important to study the effect of sensitization with anti-IgM antibodies in 
AKT-S CLL samples. Striking similarities between the modulation caused by the 
sensitization with anti-CD180 mAb and anti-IgM antibodies could be observed. In 
all 12 AKT-S CLL samples, there was a significant downregulation of CD180-
mediated expression of AKT-P to basal levels (p=0.0039, Figure 3.8A) 
accompanied by a significant increase in the expression of p38MAPK-P 
compared to CD180 ligation alone (p=0.016, Figure 3.8A). In addition, pre-
treatment with anti-IgM led to downregulation of percentages of cells expressing 
BTK-P from 45.0 ± 15.8% (anti-CD180) down to 35.8.4 ± 11.3% (anti-IgM + anti-
CD180, n = 11, p = 0.019) with the baseline levels of 38.6 ± 7.1%. 
Although pretreatment of control B cells with anti-CD180 did not make a 
significant difference in percentages of cells with AKT-P and p38MAPK-P, 
pretreatment of control B cells with anti-IgM had an additive effect with anti-
CD180 which led to a significant increase in expression of AKT-P in all 8 control 
samples (p=0.00006, Figure 3.8B). However, there were no changes in the levels 
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of p38MAPK-P in control B cells (p=0.278, Figure 3.8B). These data support the 
conclusion that there is cross-talk between the BCR and CD180 in the AKT-S CLL 
samples, leading to rewiring of BTK/AKT pro-survival signalling pathway to 
p38MAPK pro-apoptotic pathway.  
It was decided to study the effect of pretreatment of p38MAPK-S CLL samples 
with anti-CD180 and anti-IgM antibodies next. Interestingly, in all eleven 
p38MAPK-S samples, pretreatment with anti-CD180 had an additive effect with 
anti-IgM mediated levels of AKT-P (p=0.0063, Figure 3.6C) whilst there was no 
significant difference in p38MAPK-P upon sequential ligation of anti-CD180 mAb 
and anti-IgM antibodies (p=0.18, Figure 3.6C). This was accompanied by 
increased survival of p38MAPK-S CLL cells as shown by a significant decrease 
in percentages of DiOC6dim apoptotic cells compared to sIgM ligation alone 
(p=0.001, Figure 3.7). Similarly, pretreatment of p38MAPK-S CLL cells with anti- 
IgM amplified the CD180-mediated percentages of AKT-P expressing cells in 8/10 
samples (p=0.019, Figure 3.8C) but decreased the expression of p38MAPK-P 
compared to CD180 ligation alone (p=0.022, Figure 3.8C).  Hence these data 
show that in contrast to AKT-S cells, pretreatment of p38MAPK-S cells with either 
anti-CD180 or anti-IgM often leads to additive phosphorylation of AKT. Therefore, 
it can be concluded that in AKT-S CLL cells, ligation of either sIgM or CD180 lead 
to a substantial activation of the pro-survival BTK/AKT pathway and 
presensitization of the other receptor redirected intracellular signalling towards 
the potentially pro-apoptotic p38MAPK pathway, whereas in p38MAPK-S CLL 




Figure 3.6: Modulation of sIgM-mediated signalling by sensitisation with 
anti-CD180 mAb. (A-C) Control B cells or CD180+sIgM+ CLL samples were treated 
with anti-CD180 mAb or anti-IgM F(ab)2 alone or first with anti-CD180 for 20 minutes 
followed with anti-IgM F(ab)2 for another 10 minutes as described in the Materials and 
methods. Unstimulated cultures (Medium) were used as controls. The cells were then 
stained with anti-CD19~Cy5-PE mAb, fixed, permeabilised and stained with antibodies 
to AKT-P and p38MAPK-P. p values were calculated using the paired t-test. 
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Figure 3.7: The percentages of DiOC6dim (apoptotic) cells in unstimulated 
CLL cells (Medium) or stimulated with anti-IgM F(ab)2 alone or first with anti-
CD180 followed by anti-IgM F(ab)2 for 24 h, stained with anti-CD19 mAb, 
loaded with DiOC6 and analysed by flow cytometry. The values represent 





Figure 3.8: Modulation of CD180-mediated signalling by sensitisation with 
anti-IgM F(ab)2. (A-C) Control B cells or CD180+sIgM+ CLL samples were treated with 
anti-CD180 mAb or anti-IgM F(ab)2 alone or first with anti-IgM F(ab)2 for 10 minutes 
followed by anti-CD180 for 20 minutes as described in the Materials and methods. 
Unstimulated cultures (Medium) were used as controls. The cells were then stained with 
anti-CD19~Cy5-PE mAb, fixed, permeabilised and stained with antibodies to AKT-P and 








3.3.1 CD180 ligation on B-CLL cells leads to alternative phosphorylation of 
either AKT or p38MAPK 
Four patterns of CD180-mediated signalling in CLL cells have been identified: 
AKT-signallers (AKT-S); p38MAPK signallers (p38MAPK-S); nonsignallers (NS); 
and a minor subset of double AKT/p38MAPK signallers (DS). 24 out of the 60 
CD180+ CLL samples, responded to CD180 ligation by a significant upregulation 
of AKT-P (AKT-S) (Figures 3.1A). It was reported that activation of AKT is 
essential for the BCR-mediated growth and survival of B lymphocytes (Woodland 
et al., 2008) as well as the survival of CLL cells (Longo et al., 2008; Packham et 
al., 2010; Downward, 2014). CD180 ligation resulted in increased 
phosphorylation of p38MAPK in 16 out of 36 remaining samples (p38MAPK-S) 
(Figures 3.1B) and only in a small cohort of 6 CLL samples showed activation of 
both AKT-P and p38MAPK-P(DS) upon stimulation with anti-CD180 mAb 
(Figures 3.1A and B). The use of specific inhibitors of AKT and p38MAPK 
signalling pathways to confirm that, activation of AKT and p38MAPK pathways is 
exclusive will be discussed in chapter 4. Activation of alternative pathways 
appears to be a feature of CLL cells, and not of normal B cells as they responded 
to CD180 ligation by increasing both AKT-P and p38MAPK-P (Figures 3.1A, B). 
CD180 ligation led to significant drop in p38MAPK-P basal levels in the AKT-S 
cells (Figures 3B) and AKT-P basal levels in p38MAPK-S cells (Figures 3A). 
Petlickovski et al., (2005) reported that BCR stimulation causes a decrease in 
signal intensity of p38MAPK, rather than an increase, but not linked to AKT 
activation. This data suggests the regulatory influence of one pathway on another. 
14 CD180+ CLL samples did not respond to CD180 ligation by activating either 
of the two pathways (NS, Figures 3.1 A and B). It is possible to suggest that those 
NS CLL cells may use an alternative pathway or that they are totally refractive to 
ligation of CD180. Interestingly, those CD180 NS CLL samples remained 
unresponsive to the ligation of sIgM suggesting their anergic status (Packham et 
al., 2014). The distribution of CD180-mediated signalling categories of CLL cells 
which was identified is shown in Figure 3.8 below.  
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Figure 3.9: Proportion of CLL samples exhibiting four different patterns of 
signalling. Treatment with anti-CD180 mAb of CD180+ CLL samples or treatment with 
anti-IgM F(ab)2 of CD180+sIgM+ CLL samples. AKT-S, AKT-signallers; p38MAPK-S, 
p38MAPK signallers; DS, double AKT/p38MAPK signallers; NS, nonsignallers 
(Porakishvili et al., 2015) 
Porakishvili et al., (2005) have demonstrated that more U-CLL samples (71%) 
are CD180+sIgM+ than CD180+sIgMneg/low attributing U-CLL samples mostly to the 
AKT-S and NS signalling categories. However, in this study M-CLL samples were 
found to be evenly distributed between AKT-S, p38MAPK-S and NS categories. 
Interestingly, all six DS CLL samples belonged to M-CLL group, which is 
associated with increased anergy (Packham et al., 2014). There were no 
differences in surface expression of the CD180, sIgM, CD79b or CD38 between 
the four signalling groups (data not shown). However, p38MAPK-S cells 
expressed significantly higher ex vivo levels of sIgD compared to AKT-S cells: 
83.5±15.1% versus 48.5±33.0%, p=0.0055, n=10. Although the relevance of this 
is currently unclear, it is possible to suggest that sIgD could be involved in the 







3.3.2 CD180-mediated AKT-signalling pathway in CLL involves activation of 
BTK and is pro-survival, while p38MAPK activation favours apoptosis 
There are several studies showing that BTK plays an important role in BCR 
signalling pathway (Burger et al., 2010). Moreover, its role in CLL cell survival has 
also been reported (Ponader et al., 2012). As per this data, CD180 ligation in 
AKT-S CLL samples activated pro-survival BTK kinase while suppressing 
p38MAPK pathway.  Activation of BTK led to the reduction in apoptosis in this 
category of CLL samples (Figure 3.2). However, recruitment of BTK in p38MAPK-
S samples was not observed, resulting in the increased apoptosis (Figure 3.2). 
The role of p38MAPK-mediated signalling in CLL is so far unclear. Activation of 
p38MAPK has been associated with proliferation of various cells in response to 
CpG-ODN. Takeshita et al., (2004) reported that CpG DNA/TLR9-mediated 
cellular signalling involves in activation of p38MAPK in macrophages. CPG-DNA 
driven activation of p38MAPK in murine macrophage cell line, RAW264.7 has 
been reported by Ahmad-Nejad et al., (2002). Moreover, in mice dendritic cells, 
CpG DNA induced survival signals via activation of PI3K and p38MAPK (Park et 
al., 2002). Peng (2005) showed the importance of activation of p38MAPK in TLR4 
signalling in B cells for transcription of inflammatory genes and in TLR9 signalling 
for activation, proliferation and Ig secretion. CpG DNA augmented BCR-mediated 
signals for the activation of p38MAPK which lead to synergistic production of 
cytokines and induction of splenic mature B cells proliferation (Kyung-Ae et al., 
2003). On the contrary, Ntoufa et al., (2012) demonstrated that p38MAPK 
activation led to tolerant status in CLL cells.  
Moreover, it has been documented that p38MAPK is associated with regulation 
of cell survival in CLL (Grumont et al.,1998; Furman et al., 2000; Piatelli et al., 
2004).  p38MAPK has been shown to induce apoptosis in murine splenocytes 
and human lymphoma B-cell lines (Graves et al., 1998: Yan et al., 2008). Later 
Negro et al., (2012) demonstrated the significance of p38MAPK in apoptosis of 
CLL cells. Current data strongly confirm that CD180-mediated activation of 
p38MAPK is associated with apoptosis of CLL cells. This might suggest the 
potential use of p38MAPK-signalling as a new profiling tool for those patients who 
are unresponsive to BTK inhibitors. 
To summarise, current data show that CD180 ligation activates BTK/AKT 
signalling pathway in AKT-S cells leading to their survival but not in p38MAPK-S 
or NS CLL samples (Figures 3.1, 3.2 and 3.3). Therefore, considering that CLL 
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cells receive various stimuli from their microenvironment in vivo, including via 
CD180, these findings suggest that BTK inhibitors might be limited to AKT-S CLL 
cells. 
3.3.3 sIgM ligation favours pro-survival BTK/AKT signalling pathways in 
AKT-S CLL cells 
Since CD180 may play a significant role in interacting with microenvironmental 
ligands in CLL, it was important to compare the sIgM-mediated signalling patterns 
with CD180-mediated signalling in the major categories of CLL cells as defined 
above. Current data show a striking similarity of CD180- and sIgM-mediated 
signalling in AKT-S CLL samples by activation of pro-survival BTK/AKT pathway 
following the ligation of either receptor (Figures 3.1 and 3.4A) leading to 
increased survival of CLL cells (Figures 3.3 and 3.5). In contrast to CD180 
activation, BCR engagement did not show an activation of p38MAPK in 
p38MAPK-S (Figure 3.4B) or DS CLL samples. This could be explained by a 
significant drop of BTK-P+ cells below the basal levels following stimulation of 
sIgM in p38MAPK-S cells since it has been previously shown that BCR signalling 
was abrogated in the absence of BTK activation (Petro et al.,2000). Moreover, 
Efremov et al., (2007) also failed to detect p38MAPK activation in CLL cells 
following BCR ligation. This suggests that the lack of BTK phosphorylation 
abrogates both “arms” of BCR signalling (via AKT and via p38MAPK), whilst 
leaving CD180-mediated p38MAPK activation intact.  
Recent data indicate that CD180 is able to bypass BTK and carry signals 
downstream to p38MAPK favouring apoptosis over survival. Therefore, it 
suggests that although there is a substantial overlap of CD180 and sIgM 
mediated activation of BTK/AKT pro-survival signalling circuit, only ligation of 
CD180 can lead to activation of an alternative pro-apoptotic pathway mediated 
via p38MAPK. Hence, it was important to study how sequential ligation of CD180 
and BCR would impact signal transduction through the AKT and p38MAPK 
pathways. 
3.3.4 Pretreatment of CLL cells with Anti-CD180 antibodies rewires the sIgM 
signalling pathway from pro-survival to pro-apoptotic 
Yamashita et al., (1996) demonstrated that anti-IgM induced murine B cells can 
be sensitised for apoptosis by treatment with anti-CD180 mAb, whereas 
combining signalling of CD180 and BCR induced rapid proliferation and antigen-
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specific antibody responses in mice in vivo (Chaplin et al., 2013). Recent data 
clearly indicate that pretreatment of AKT-S CLL cells with anti-CD180 mAb 
significantly reduced the pro-survival pathway operated via BTK/AKT circuit 
induced via subsequent ligation of sIgM and redirected it towards p38MAPK 
pathway which leads to apoptosis (Figure 3.6 and 3.7). Similar results were 
observed when AKT-S CLL cells were stimulated with by ligating two receptors in 
the reverse order (Figure 3.8).  
There was no rewiring of signalling from pro-survival to pro-apoptotic pathway in 
control B cells (Figure 3.6B and 3.8B), although the reasons for absence of a 
cross-talk between CD180 and BCR in normal cells is unclear, recent data show 
that modulation is unique to CLL.  
Since CLL cells are believed to express BCR in proliferation centres (Ferrarini et 
al., 2014) and pilot experiments using immunohistochemical staining of our 
research group has shown that CD180 is expressed in bone marrow and lymph 
nodes (data not shown), it is possible to suggest that CD180+sIgM+ CLL cells may 
receive simultaneous signals through both receptors in vivo. Continuous BCR 
mediated signalling in CLL has been reported (Burger et al.,2013) and it is 
possible to hypothesise that CD180-mediated activation of CLL cells by an 
unknown microenvironmental ligand such as generated soluble ligand may mimic 
this continuous BCR-mediated signalling. Rewiring of intracellular signals from 
BTK/AKT pro-survival circuit to p38MAPK pro-apoptotic pathway in AKT-S CLL 
cells may suggest a possible cross-talk between CD180 and BCR in AKT-S. Such 
modulation of signalling could influence blood cell counts, long-term disease 
progression and could provide a basis for therapy. In order to understand the 
significance of these pathways for prognosis and clinical criteria, future 
experiments will be carried out.  
In conclusion, current data help to hypothesise that interaction between CD180 
and sIgM leads to convergence of certain key signalling pathways. Whereas the 
pro-survival pathway appears to be operating through the BTK/AKT circuit, the 
pro-apoptotic pathway is activated via p38MAPK perhaps leading to inhibition of 
the BTK/AKT. The elements of the pro-apoptotic pathway upstream to p38MAPK 
have yet to be identified. This New data suggest that in a substantial number of 
CLL samples preengaging of CD180 could prevent further pro-survival signalling 
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mediated via sIgM and, instead, induce CLL cell apoptosis, which opens the door 




















Chapter 4  
Modulation of CD180-mediated 
signalling and survival of CLL 












4.1.1 AKT Inhibitors 
The Phosphatidylinositol-3-kinase (PI3K) pathway was described in chapter one 
as the most critical pathway in the survival of CLL cells. AKT (serine-threonine 
kinase) also known as protein kinase B (PKB) is one of the important targets of 
PI3K products.  Low-activity conformation of AKT resides in the cytosol and it is 
activated by phosphorylation at Thr308 and Ser473 through recruitment to cell 
membranes. When activated, AKT is capable of promoting cell survival via 
phosphorylation and inactivation of components of apoptotic cascade. Substrates 
of AKT include the members of the forkhead family of transcription factors and 
glycogen synthase kinase-3 (GSK-3) (Maurer et al., 2006). Inhibition of GSK-3 
induces the up-regulation of the anti-apoptotic protein MCL-1.  Moreover, 
inhibition of PI3K induces a loss of cell viability, dephosphorylation of FoxO3a 
and GSK-3, and a subsequent decrease in the level of MCL-1 protein. CLL 
patients with progressive disease have shown a higher capacity for cell cycle 
progression in CLL cells upon stronger activation of AKT (Longo et al., 2007). 
The AKT inhibitors reduce phosphorylation of downstream targets such as 
GSK3α/β, FOXO3, TSC2 and mTOR in a dose-dependent manner. 
Phosphorylation of further downstream signalling molecules in the AKT pathway 
such as S6 protein are also reduced by AKT inhibitors (Luo et al., 2005). 
The three AKT isoforms: AKT1, AKT2 and AKT3 are closely related and consist 
of a conserved amino-terminal (N-terminal) pleckstrin homology (PH) domain 
which involves with intracellular signalling, a central kinase catalytic domain and 
a carboxy-terminal (C-terminal) regulatory hydrophobic motif (HM) (Hanada et al., 
2004). The three AKT isoforms are highly homologous. However, it is unclear 
whether they are functionally redundant (Datta et al., 1999). 
Studies on tissue expression patterns of AKT isoforms revealed that AKT1 and 
AKT2 are ubiquitously expressed, whereas AKT3 expression is mainly limited to 
brain, testis, lung, heart, kidney, mammary gland and fat (Brodbeck et al., 1999; 
Masure et al., 1999; Yang et al., 2003). Knockout of AKT isoforms in mice 
revealed distinct phenotypes: deficiency of AKT1 resulted in a smaller animal with 
significant growth defects (Cho et al., 2001). AKT2 deficient mice were unable to 
maintain glucose homeostasis (Cho et al., 2001) and AKT3 knockout mice had a 
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smaller brain, but were otherwise normal (Yang et al., 2004). Overexpression of 
AKT2, but not AKT1 and AKT3, increased the phosphatidylinositide 3-kinases 
(PI3K)‑ dependent effect on adhesion, invasion and metastasis of breast and 
ovarian cancer cells (Arboleda et al., 2003). AKT has been proposed as a 
potential therapeutic target for cancer (Bellacosa et al., 2005). Downregulation of 
AKT1 by antisense oligonucleotides inhibited anchorage-independent cell growth 
and induced apoptosis in cancer cells (Liu et al., 2001). It was shown that the 
targeted decrease of AKT3 levels with siRNA or by expressing active 
phosphatase and tensin homolog (PTEN) protein stimulated apoptosis and 
inhibited melanoma tumour development (Stahl et al., 2004). Jetzt et al., (2003) 
demonstrated that adenovirus-mediated expression of an AKT kinase-dead 
mutant of AKT induces apoptosis selectively in tumour cells and suppresses 
tumour growth in mice. It is a commonly held perception that tumour cells are 
dependent upon activated AKT for survival and sensitive to inhibition of AKT, 
particularly those cells with PTEN mutations and/or a high basal level of activated 
AKT (Bellacosa et al., 2005). 
Akti-1/2  
It is an ATP non-competitive AKT inhibitor blocking AKT1 and AKT2, but not 
AKT3 activity. Akti-1/2 also prevents phosphorylation at Ser308 by 
phosphoinositide-dependent protein kinase (PDK)1 in vitro and at Ser308 and 
Thr473 in cells without inhibiting PDK1 activity (Barnet et al., 2005). It was also 
reported that Akti-1/2 could sensitise tumour cells to induce apoptosis when 
combined with some chemotherapeutic agents and biological agents, such as 
TNF-related apoptosis-inducing ligand (TRAIL) (Lindsley et al., 2005). The 
chemical structure of Akti1/1 is shown in Figure 4.1.  
 
Figure 4.1: Chemical structure of AKTi-1/2 (Gilot et al., 2010) 
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Akti-1/2 inhibits Ca2+/CaM-dependent protein kinase (CaMK) Iα activity. The 
efficiency of inhibition of recombinant CaMKIα activity is the same as the CaMK 
inhibitor KN-93. Moreover, Akti-1/2 prevents the nuclear translocation of aryl 
hydrocarbon receptor (AhR) in MCF-7 cells in response to 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) exposure, which has been demonstrated to 
require CaMKI activity. This shows that Akti-1/2 has off-target effects at 
concentrations equipotent with AKT inhibition which should be considered in 
therapeutic applications (Gilot et al., 2010). Akti-1/2 could induce dose-
dependent apoptosis in CLL cells, and the Akti1/2 mediated apoptosis was also 
confirmed by induction of Poly (ADP-ribose) polymerase (PARP) cleavage 
demonstrating that activated AKT in CLL cells play a role in the survival of the 
malignant cells. It was also reported that Akti-1/2 at the concentration inducing 
substantial apoptosis in CLL cells did not induce apoptosis in normal cells 
suggesting normal PBMC cells are less dependent on AKT for survival than CLL 
cells. AKT inhibitor-induced apoptosis was associated with rapid loss of induced 
myeloid leukaemia cell differentiation protein (MCL1) through proteasome 
degradation and increased expression of p53 (Zhuang et al., 2010).  
Induction of apoptosis in CLL cells by akt1/2 is dose-dependent and it is 
irrespective of TP53 mutational status. Furthermore, B cells from patients with 
CLL were more sensitive to AKT inhibitors than T cells from leukemic patients, 
and B or T cells from healthy donors. Apoptosis induced by AKT inhibitors was 
not blocked by CLL survival factors such as IL-4 and stromal cell-derived factor-
1α (SDF-1α). Interestingly, inhibition by Akti-1/2 did not lead to any change in the 
mRNA expression profile of genes involved in apoptosis. However, it induced p53 
upregulated modulator of apoptosis (PUMA) and NADPH oxidase activator 
(NOXA) proapoptotic protein levels, and decreased MCL-1 anti-apoptotic protein 
level (Frias et al., 2009).  
Zhuang et al., (2010) also demonstrated that activated AKT in CLL cells can be 
inhibited by selective inhibitors can induce apoptosis in CLL cells. Furthermore, 
some AKT inhibitors such as AiX induce apoptosis preferentially in U-CLL cells 
(Hofbauer et al., 2009). Hence AKT inhibitors have been tested as a treatment 
for CLL. Presently, the allosteric AKT inhibitor MK-2206 (an analog of Akti-1/2) is 
under investigation at the phase II level in advanced ovarian, fallopian tube and 
peritoneal carcinomas (NCT01283035) (Correa et al., 2014). 
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4.1.2 p38MAPK inhibitors 
SB203580 
P38MAPK is a Ser/Thr protein kinase activated by various inflammatory cytokines 
and a variety of stress stimuli. It is activated by dual phosphorylation of Thr180 and 
Tyr182 in a Thr-Gly-Tyr activation loop by a dual specificity MAP kinase kinase 6 
(MKK6) (Kumar et al.,1999). SB203580 (4-(4-fluorophenyl)2,2-(4-
methylsulfinylphenyl)25-(4-pyridyl) Imidazole) is a pyridinyl imidazole inhibits p38 
kinase catalytic activity by binding to the ATP site. It has the ability to bind to both 
the inactive and activated forms of p38 kinase and it is a highly selective inhibitor 
of the p38 family of MAPKs (Wilson et al., 1997; Young et al., 1997). SB203580 
was originally discovered as an inhibitor of LPS-induced cytokine synthesis in the 
human leukaemia monocytic cell line, THP-1 (Laydon et al., 1994). Kumar et al., 
(1999) demonstrated that SB203580 inhibits only the activity of p38 but not its 
activation by MKK6 using THP-1 monocytes because the binding of SB203580 
in the ATP binding pocket of p38 MAPK does not interfere with the ability of MKK6 
to phosphorylate and activate p38 (Kumar et al., 1999). 
MAP kinase-activated protein (MAPKAP) kinase-2 (MAPKAP kinases-2) which is 
activated by p42 or p44 isoforms of MAP kinase, promotes phosphorylation of 
heat shock protein27 (HSP27). It is suggested that HPS27 may be involved with 
cell survival and SB203580 has shown inhibitory effect on MAPKAP kinase-2 and 
hence on HPS27 on pheochromocytoma (PC12) cells (Cuenda et al., 1995). Due 
to the high selectivity, the inhibitor did not show inhibition of Jun N-terminal 
kinase, ERK or other kinases (Cuenda et al., 1995, 1997; Kumar et al., 1997). It 
was demonstrated that SB203580 do not act distally by blocking calcium 
channels or altering their voltage dependency (Wilk-Blaszczak et al., 1998).  
The melanoma differentiation associated gene-7 (mda-7) is a gene induced 
during terminal differentiation in human melanoma cells and classified as IL-24. 
Administration of mda-7/IL-24 by means of a replication-incompetent adenovirus 
(Ad.mda-7) induced apoptosis selectively in diverse human cancer cells without 
affecting normal fibroblast or epithelial cells. It was demonstrated that treatment 
of melanoma cells with SB203580 inhibited Ad.mda-7-induced apoptosis as well 
as Ad.mda-7-mediated induction of the GADD family of genes in a time and dose-
dependent manner, and Ad.mda-7-mediated down-regulation of the anti-
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apoptotic protein BCL-2 (Sarkar et al., 2002). The chemical structure of 
SB203580 is shown in Figure 4.2.  
 
Figure 4.2: Chemical structure of SB203580 (Young et al., 1997) 
Erythroleukaemic SKT6 cells respond to glycoprotein hormone erythropoietin 
(Epo) and induce haemoglobinization and Epo-dependent cell growth. All MAP 
kinases ERK1, ERK2, p38, JNK1 and JNK2 are activated by Epo stimulation in 
SK6 cells and SB203580 inhibited Epo-dependent differentiation and 
haemoglobinization. In Epo-dependent FD-EPO cells, inhibition of p38 
suppressed cell growth (Nagata et al., 1998). 
The activation of p38 in Epo-dependent HCD57 cells in response to EPO 
suggests a role for p38 in EPO-induced proliferation or survival. SB203580 
suppressed proliferation of Epo-induced HCD57 cells. However, the treatment 
with this inhibitor neither caused apoptosis in the presence of EPO nor protected 
these cells from apoptosis when EPO was withdrawn (Jacobs-Helber et al., 
2000). In contrast, Shan et al., (1999) reported that inhibition of p38 protected 
HCD57 cells from apoptosis following EPO withdrawal for 4 days. In CD40 
stimulated CLL cells, treatment with SB203580 diminished the levels of NOXA 
and MCL-1. Therefore, SB203580 had not shown significant alteration in 
Noxa/MCL-1 ratio (Tromp et al., 2011). The ability of r-IL-24 and LPS, MAPK 
activators to reverse SB203580-mediated apoptosis in CLL cells was reported by 
Sainz-Perez et al., (2006). 
Korus et al., (2002) demonstrated elevated levels of p38MAPK in the breakpoint 
cluster region (BCR)-transfected COS-7 cells, which is a gene associated with 
the Philadelphia chromosome and pathogenesis of CML and ALL. Elevated 
levels of p38 MAPK were not observed in control cells, or in the presence of the 
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inhibitor suggesting that BCR can activate endogenous p38 MAPK and that the 
inhibitor can block this activation. SB203580 affects NF-κB activation since, in the 
presence of the inhibitor, activation of both the NF-κB-luc and Gal4-p65 by BCR 
was substantially reduced (Korus et al.,2002)  
4.1.3 BTK inhibitors 
Ibrutinib 
BTK is a key signalling molecule that plays a significant role in the BCR mediated 
signalling pathway (Burger et al., 2010) and in the survival and proliferation of 
malignant B cells (Maas et al., 2012). Moreover, its significance in CLL cell 
survival has also been reported (Ponader et al., 2012). BTK is overexpressed in 
CLL cells compared with normal B cells suggesting its involvement in CLL cell 
survival mediated through the BCR (Herman et al., 2011). 
Ibrutinib which was originally named as PCI-32765 is a BTK inhibitor that binds 
specifically and irreversibly to cysteine residue in the BTK kinase domain and 
hence blocks its enzymatic activity. Ibrutinib is the first BTK-targeting agent to 
secure approval by the US Food and Drug Administration (FDA) and other health 
authorities globally (Gaykoet al., 2014). The chemical structure of Ibrutinib is 
shown in Figure 4.3. 
  
 
Figure 4.3: Chemical structure of Ibrutinib (Woyach et al., 2012) 
Ibrutinib binds covalently to the amino acid cysteine at position 481 (Cys-481) in 
the BTK active site and prevents adenosine triphosphate from binding to BTK 
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active site and thus its activation (Figure 4.4). It has a short half-life, and due to 
the formation of covalent bonds, provides a high degree of pharmacologic 
selectivity (Gaykoet al., 2014) 
 
Figure 4.4: Mechanism of action of Ibrutinib via B cell receptor pathway. 
When the B cell receptor binds to its specific antigen, BTK is phosphorylated (activated) 
by Syk/Lyn. Ibrutinib blocks the downstream signalling by forming a covalent bond with 
Cys481 at the active site of BTK (Gayko et al., 2014). 
Some CLL patients show Ibrutinib resistance, and it was suggested that the 
C481S mutation disrupts the formation of covalent bonds between Ibrutinib and 
BTK leading to loss of inhibition of BTK enzymatic activity and finally Ibrutinib 




Figure 4.5: Mechanism of BTK inhibition by Ibrutinib is compared with the 
effect of resistant mutations. Ibrutinib covalently binds to a cysteine at position 481 
(Cys481) in the ATP binding pocket of BTK which leads to irreversible inhibition of the 
kinase molecule. In patients with Ibrutinib resistance, mutations that result in 
replacement of Cys481 by another amino acid have been identified. In the absence of 
Cys481, Ibrutinib cannot form a covalent bond and inhibition of the kinase is reversible 
and short-lived, consistent with the rapid clearance of Ibrutinib (Wiestner, 2015). 
Inhibitory action of Ibrutinib was recorded in several preclinical studies on 
numerous processes including ERK signalling, NF-κB DNA binding, cytosine-
phosphate-guanine (CpG)-mediated CLL cell proliferation and tumour cell 
migration. Byrd et al., (2013) demonstrated that the response in patients with CLL 
as evaluated according to the criteria of the International Workshop on Chronic 
Lymphocytic Leukaemia (IWCLL) (Hallek et al., 2008) is greater in patients with 
U-CLL cells than in those with M-CLL cells (77% partial or complete response 
and 13% partial response with lymphocytosis versus 33% partial or complete 
response and 42% partial response with lymphocytosis). Although lymph node 
shrinkage and clinical benefit occur in patients with both CLL cells subsets, 
lymphocytosis tends to persist in patients with M-CLL (Woyach et al., 2014). 
Ibrutinib expressed several mechanisms of action in CLL cells in vitro: induction 
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of apoptosis, blocking signalling and activation in response to BCR and CD40 
pathway stimulation, as well as disrupting the protective effect of stromal cell co-
incubation (Herman et al., 2011). Point of inhibition of Ibrutinib in BCR signalling 
pathway is shown in Figure 4.6.  
Figure 4.6: Point of inhibition for Ibrutinib. Ibrutinib inhibits the ability of BTK to 
phosphorylate and activate PLCᵞ2 (Slupsky, 2014). 
Ibrutinib is also effective in blocking integrin α(4)β(1)-mediated adhesion to 
fibronectin and VCAM-1 in CLL cells, as well as signalling and homing in 
response to CXCL12 and CXCL13 (De Rooji et al., 2012; Ponader et al., 2012). 
It also could reduce secretion of the BCR-dependent chemokines such as CCL3 
and CCL4 (Ponader et al., 2012). 
In this experiment, specific inhibitors of the CD180-mediate signalling pathways 
were used to block specific intracellular pathways alone and in combination to 
confirm their involvement in CD180-mediated signalling. 
4.2 Results  
CD180+ CLL samples were categorised into two groups as AKT-S and p38MAPK-
S according to alternative phosphorylation of AKT or p38MAPK protein kinases 
following CD180 ligation with mAb as described in Chapter 3 and Porakishvili et 
al., (2015). In this study, AKT-S and p38MAPK-S CLL samples were pre-treated 
with specific protein kinase inhibitors as explained in Materials and methods. 
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4.2.1 Effect of Akti1/2 on AKT phosphorylation and cell survival in AKT-S 
and p38MAPK-S CLL cells 
To assess the effect of Akti-1/2 on AKT activation in CLL samples, the 
phosphorylation status of AKT (after treating with inhibitor followed by mAbs) was 
studied. In all six AKT-S CLL samples, the percentage of cells with pAKT were 
significantly increased following CD180 ligation compared with basal levels 
(p=0.019, Figure 4.7). Interestingly, pre-treatment of unstimulated AKT-S cells 
with Akti1/2 did not exert an apparent effect on spontaneous phosphorylation of 
AKT, when untreated and treated (p=0.118, Figure 4.7). As expected, in all six 
AKT-S CLL samples stimulated with anti-CD180 mAb, Ser473 phosphorylation 
was significantly reduced when pre-treated with Akti1/2 compared to untreated 












Figure 4.7: Percentages of cells expressing p-AKT in unstimulated and anti-
CD180 mAb stimulated AKT-S CLL samples untreated or treated with 
Akti1/2 inhibitor: Bar chart (A) and scatter plot (B). CLL cells were incubated 
with AKTi1/2 inhibitor or left untreated, washed and stimulated with anti-CD180 mAb for 
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20 min (CD180 mAb) or left unstimulated in medium, then washed, stained with anti-
CD19 mAb, fixed, permeabilised and stained with anti-AKT(Ser473)-P as described in 
the Materials and methods. Samples were analysed by flow cytometry and expressed 
as percentages of positive cells. P values were calculated using the paired t-test. 
Importantly, pre-treatment of p38MAPK-S CLL cells with AKT inhibitor Akti1/2 had 
no effect on phosphorylation of AKT as there was no reduction in basal (p=0.397, 
Figure 4.8), or anti-CD180-stimulated percentages of pAKT cells (p=0.266, 
























Figure 4.8: Percentages of cells expressing p-AKT in unstimulated and anti-
CD180 mAb stimulated p38MAPK-S CLL samples untreated or treated with 
AKTi1/2 inhibitor: Bar chart (A) and scatter plot (B). P38MAPK-S CLL cells were 
incubated with AKTi1/2 inhibitor or left untreated, washed and stimulated with anti-
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CD180 mAb for 20 min (CD180 mAb) or left unstimulated in medium, washed, stained 
with anti-CD19 mAb, fixed, permeabilised and stained with anti-AKT(Ser473)-P as 
described in the Materials and methods. Samples were analysed by flow cytometry and 
expressed as percentages of positive cells. P values were calculated using the paired t-
test. 
Since it has been documented that AKT activation is essential for the survival of 
CLL cells (Ringshausen et al., 2002; Petlickovski et al., 2005; Longo et al.,2007) 
evaluating possible changes in the survival of CLL cells following CD180 ligation 
with and without AKT inhibitors was important. The percentages of viable cells 
were measured by assessing changes in mitochondrial membrane potential 
using DiOC6 dye. These recent data confirmed previous observations that 
stimulation of CLL cells with anti-CD180 mAb enhanced their survival 
(Porakishvili et al., 2005). Indeed, there was a significant increase in the 
percentages of viable cells (p=0.045) following CD180 ligation compared with 
basal levels confirming AKT-mediated anti-apoptotic activity in CD180-induced 
AKT-S cells. Interestingly, pre-treatment of unstimulated AKT-S cells with Akti1/2 
did not exert any effect on apoptosis (p=0.220, Figure 4.9). As expected, in all six 
AKT-S CLL samples stimulated with anti-CD180 mAb, percentages of viable cells 
were significantly reduced when pre-treated with Akti1/2 compared to untreated 
samples (p=0.007, Figure 4.9), down to the basal levels confirming the inhibitory 






Figure 4.9: Percentages of DiOC6 bright viable cells in unstimulated and anti-
CD180 mAb stimulated AKT-S CLL cells untreated or treated with Akti1/2 
inhibitor: Bar chart (A) and scatter plot (B). Cells were incubated with Akti1/2, 
washed and stimulated with anti-CD180 mAb for 24h, washed, stained with anti-CD19 
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mAb, loaded with DiOC6 for 20 min and analysed by flow cytometry as described in the 
Materials and methods. The p values were calculated using a non-parametrical U-test.  
In some AKT-S CLL samples, changes in the survival of CLL cells following 
CD180 ligation with and without AKT inhibitors were assessed using the 
annexin/PI method which detects the loss of phospholipid asymmetry in cell 
membranes during apoptosis (Terasaki, 1989; Koning et al., 1993).  Indeed, there 
was a significant decrease in the percentages of annexinposPIneg cells (p=0.011) 
following CD180 ligation compared with basal levels confirming AKT-mediated 
anti-apoptotic activity in CD180-induced AKT-S cells. Similar to the results seen 
with DiOC6, pre-treatment of unstimulated AKT-S cells with Akti1/2 did not exert 
any effect on the level of apoptosis (p=0.359, Figure 4.10). As expected, in all 
four AKT-S CLL samples stimulated with anti-CD180 mAb, percentages of 
AnnexinposPIneg cells were significantly increased when pre-treated with Akti1/2 
compared to untreated samples (p=0.023, Figure 4.10), further confirming the 









Figure 4.10: Percentages of early apoptotic cells in unstimulated and anti-
CD180 mAb stimulated AKT-S CLL cells untreated or treated with Akti1/2 
inhibitor: Bar chart (A) and scatter plot (B). CLL cells were incubated with Akti1/2 
inhibitor or left untreated, washed and stimulated with anti-CD180 mAb for 24h or left 
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unstimulated, washed, stained with anti-CD19 mAb, washed, resuspended in binding 
buffer, loaded with PI and Annexin V-FITC for 10 min and analysed by flow cytometry as 
described in the Materials and methods. The p values were calculated using a non-
parametrical U-test. 
Interestingly, AKT inhibitor elevated percentages of apoptotic cells to the level 
characteristic for unstimulated CLL cells suggesting that a fraction of CLL cells 
was susceptible to plasticity of a survival vs. apoptosis. 
The effect of Akti1/2 on the survival of p38MAPK-S CLL cells was assessed by 
using Annexin-PI assay. In line with the previous data in all four p38MAPK-S CLL 
samples, the percentages of early apoptotic cells were significantly increased 
following CD180 ligation compared with basal levels (p=0.011, Figure 4.11) 
confirming p38MAPK- mediated pro-apoptotic effect of CD180 ligation in 
p38MAPK-S CLL cells. As expected pre-treatment of p38MAPK-S CLL cells with 
AKT inhibitor Akti1/2 had no effect on survival in all 4 p38MAPK-S CLL samples 
as there were no significant changes in basal (p=0.161, Figure 4.11), or anti-
CD180-stimulated percentages of early apoptotic cells (p=0.077, Figure 4.11) 








Figure 4.11: Percentages of early apoptotic cells in unstimulated and anti-
CD180 mAb stimulated p38MAPK-S CLL cells untreated or treated with 
Akti1/2 inhibitor: Bar chart (A) and scatter plot (B). CLL cells were incubated 
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with Akti1/2 inhibitor or left untreated, washed and stimulated with anti-CD180 mAb for 
24h or left unstimulated, washed, stained with anti-CD19 mAb, washed, resuspended in 
binding buffer, loaded with PI and Annexin V-FITC for 10 min and analysed by flow 
cytometry as described in the Materials and methods. The p values were calculated 
using a non-parametrical U-test. 
4.2.2 Effect of SB203580 on p38MAPK phosphorylation and cell survival in 
p38MAPK-S and AKT-S CLL cells 
In line with the previous publications of our research group (Porakishvili et al., 
2011) in all four p38MAPK-S CLL samples, a significant increase in the 
percentages of cells with p38MAPK-P was observed, compared with basal levels 
following stimulation with anti-CD180 mAb (p=0.022, Figure 4.12). To assess the 
effect of SB203580 on p38MAPK activity in CLL cells, the phosphorylation status 
of p38MAPK after pre-treating cells with the p38 inhibitor, SB203580 was studied.  
In contrast to the effect shown by Akti1/2 inhibitor, pre-treatment of unstimulated 
p38MAPK-S cells with SB203580 significantly reduced spontaneous 
phosphorylation of p38MAPK compared to untreated samples (p=0.040, Figure 
4.12). As expected, in all four p38MAPK-S CLL samples stimulated with anti-
CD180 mAb, phosphorylation of p38MAPK was significantly reduced when pre-
treated with SB203580 compared to untreated samples, down to the basal levels 





Figure 4.12: Percentages of cells expressing p38MAPK-P in unstimulated 
and anti-CD180 mAb stimulated p38MAPK-S CLL samples untreated or 
treated with SB203580 inhibitor: Bar chart (A) and scatter plot (B). CLL cells 
were incubated with SB203580 inhibitor or left untreated, washed and stimulated with 
anti-CD180 mAb for 20 min (CD180 mAb) or left unstimulated in medium, washed, 
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stained with anti-CD19 mAb, fixed, permeabilised and stained with anti-p38MAPK-P as 
described in the Materials and methods. Samples were analysed by flow cytometry and 
expressed as percentages of positive cells. P values were calculated using the paired t-
test. 
Assessing the effect of SB203580 on AKT-S CLL cells has shown that 
pretreatment with SB203580 had no effect on phosphorylation of p38MAPK 
protein kinase in all 6 AKT-S CLL cells as there was no substantial reduction in 
basal (p=0.063, Figure 4.13) or anti-CD180-stimulated percentages of 














Figure 4.13: Percentages of cells expressing p38MAPK-P in unstimulated 
and anti-CD180 mAb stimulated AKT-S CLL samples untreated or treated 
with SB203580 inhibitor: Bar chart (A) and scatter plot (B).  CLL cells were 
incubated with SB203580 inhibitor or left untreated, washed and stimulated with anti-
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CD180 mAb for 20 min (CD180 mAb) or left unstimulated in medium, washed, stained 
with anti-CD19 mAb, fixed, permeabilised and stained with anti-AKT(Ser473)-P as 
described in the Materials and methods. Samples were analysed by flow cytometry and 
expressed as percentages of positive cells. P values were calculated using the paired t-
test. 
Although the role of p38MAPK-mediated signalling in CLL is yet unclear, it has 
been documented that p38MAPK activation is associated with proliferation of 
various cells in response to CpG-ODN (Ahmed-Nejad et al., 2002; Park et al., 
2002; Takeshita et al., 2004; Peng et al., 2005). In CLL it seems that p38MAPK 
is involved in the regulation of cell survival (Grumont et al., 1998; Piatelli et al., 
2004), establishment of cell tolerance status (Ntoufa et al., 2012) and apoptosis 
(Negro et al., 2012). Therefore, it was essential to assess possible changes in 
the survival of CLL cells following CD180 ligation with and without SB203580 
inhibitors. As described in chapter 3 and the previous publication (Porakishvili et 
al., 2015), current data confirmed that CD180-mediated activation of p38MAPK 
could induce apoptosis in CLL cells. 
The percentages of viable cells were measured using DiOC6 dye and this data 
yet again confirmed that stimulation with anti-CD180 mAb led to apoptosis of 
p38MAPK-S CLL cells. Indeed, there was a significant decrease in the 
percentages of DiOC6bright, viable cells (p=0.001, Figure 4.14) following CD180 
ligation compared with basal levels confirming p38MAPK mediated pro-apoptotic 
activity. However, pre-treatment of unstimulated p38MAPK-S cells with 
SB203580 did not exert a significant effect on survival of p38MAPK-S CLL cells 
(p=0.102, Figure 4.14). As expected, in all four p38MAPK-S CLL samples 
stimulated with anti-CD180 mAb, percentages of viable cells were significantly 
increased when pre-treated with SB203580 compared to untreated samples 
(p=0.018, Figure 4.14), confirming the inhibitory action of SB203580 on 





Figure 4.14: Percentage of viable cells in unstimulated and anti-CD180 mAb 
stimulated p38MAPK-S CLL cells treated or untreated with SB203580 
inhibitor: Bar chart (A) and scatter plot (B). Cells were pretreated with SB203580 
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or left untreated, washed and then stimulated with anti-CD180 mAb for 24h, washed, 
stained with anti-CD19 mAb, loaded with DiOC6 for 20 min and analysed by flow 
cytometry as described in the Materials and methods. The p values were calculated 
using a non-parametrical U-test.  
 
Moreover, the effect of SB203580 on the survival of AKT-S CLL cells was 
assessed. Importantly, pre-treatment of AKT-S CLL cells with p38MAPK inhibitor 
SB203580 had no appreciable effect on survival in all 6 AKT-S CLL cells as there 
was no significant change in basal (p=0.115, Figure 4.15), or anti-CD180-
stimulated percentages of viable cells (p=0.132, Figure 4.15) following pre-












Figure 4.15: Percentage of viable cells in unstimulated and anti-CD180 mAb 
stimulated AKT-S CLL cells untreated or treated with SB203580 inhibitor: 
Bar chart (A) and scatter plot (B). Cells were pretreated with SB203580, washed 
and then stimulated with anti-CD180 mAb for 24h, washed, stained with anti-CD19 mAb, 
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loaded with DiOC6 for 20 min and analysed by flow cytometry as described in the 
Materials and methods. The p values were calculated using a non-parametrical U-test.  
4.2.3. Effect of Ibrutinib on BTK Phosphorylation and cell survival in 
p38MAPK-S and AKT-S CLL cells 
The effect of Ibrutinib on BTK activation in both AKT-S and p38MAPK-S 
categories of CLL cells were assessed by the phosphorylation status of BTK after 
treatment with this specific BTK inhibitor. In all five AKT-S CLL samples analysed, 
the percentages of cells with phosphorylated BTK were significantly increased 
compared to basal levels after ligating with anti-CD180 mAb (p=0.005).   
Interestingly, in four out of five samples, pretreatment with Ibrutinib significantly 
reduced CD180 mediated phosphorylation of BTK down to the basal levels 
(p=0.008, Figure 4.16). Similar to the results obtained for Akti1/2, pre-treatment 
of unstimulated AKT-S cells in those four samples did not show any significant 
change in spontaneous phosphorylation of BTK, when untreated and treated 








Figure 4.16: Percentages of cells expressing BTK-P in unstimulated and 
anti-CD180 mAb stimulated AKT-S CLL samples when untreated or treated 
with Ibrutinib: Bar chart (A) and scatter plot (B). CLL cells were incubated with 
Ibrutinib inhibitor or left untreated, washed and stimulated with anti-CD180 mAb for 20 
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min (CD180 mAb) or left unstimulated in medium, washed, stained with anti-CD19 mAb, 
fixed, permeabilised and stained with anti-BTK-P as described in the Materials and 
methods. Samples were analysed by flow cytometry and expressed as percentages of 
positive cells. P values were calculated using the paired t-test. 
Since it has been documented that BTK activation is an essential contributor to 
the survival of CLL cells (Petro et al., 2000, 2001; Honigberg et al., 2010) the 
possible changes in the survival of CLL cells caused by Ibrutinib treatment were 
studied and compared, followed by CD180 ligation. Percentages of early 
apoptotic cells were measured by analysing the percentages of AnnexinposPIneg 
cells. This data yet again confirmed that stimulation of AKT-S CLL cells with anti-
CD180 mAb involves phosphorylation of BTK which leads to the CLL cell survival.   
Indeed, there was a significant decrease in the percentages of early apoptotic 
cells in all five samples analysed (p=0.001) following CD180 ligation compared 
with basal levels confirming BTK mediated pro-survival activity in CD180-induced 
AKT-S cells. Interestingly, pre-treatment of unstimulated CLL cells with Ibrutinib 
did not exert a noticeable effect on apoptosis, (p=0.268 Figure 4.17). In four out 
of five AKT-S CLL samples, pretreatment with Ibrutinib significantly increased 
anti-CD180 stimulated percentages of early apoptotic cells (p=0.013, Figure 







Figure 4.17: Percentages of early apoptotic cells in unstimulated and anti-
CD180 mAb stimulated AKT-S CLL cells untreated or treated with Ibrutinib: 
Bar chart (A) and scatter plot (B). CLL cells were incubated with Ibrutinib or left 
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untreated, washed and stimulated with anti-CD180 mAb for 24h or left unstimulated, 
washed, stained with anti-CD19 mAb, washed, resuspended in binding buffer, loaded 
with PI and Annexin V-FITC for 10 min and analysed by flow cytometry as described in 
the Materials and methods. The p values were calculated using a non-parametrical U-
test.  
 
To assess the effect of Ibrutinib on BTK activation in p38MAPK-S CLL samples, 
the phosphorylation status of BTK was examined after treating with inhibitor 
followed by anti-CD180 mAb. In all four p38MAPK-S CLL samples, the 
percentages of cells with pBTK were significantly decreased following CD180 
ligation compared with basal levels (p=0.0002) confirming the previous results in 
Chapter 3 and the previous publication (Porakishvili et al., 2015), which is the 
reduction in phosphorylation of BTK in p38MAPK-S when stimulated with CD180 
mAb. Importantly, pre-treatment of p38MAPK-S CLL cells with BTK inhibitor 
Ibrutinib had no effect on phosphorylation of BTK protein kinase in all 4 
p38MAPK-S CLL cells as there was no substantial reduction in basal (p=0.114, 
Figure 4.18) or anti-CD180-stimulated percentages of BTK-P cells (p=0.127, 







Figure 4.18: Percentages of cells expressing BTK-P in unstimulated and 
anti-CD180 mAb stimulated p38MAPK-S CLL samples when untreated or 
treated with Ibrutinib: Bar chart (A) and scatter plot (B).  CLL cells were 
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incubated with Ibrutinib inhibitor or left untreated, washed and stimulated with anti-
CD180 mAb for 20 min (CD180 mAb) or left unstimulated in medium, washed, stained 
with anti-CD19 mAb, fixed, permeabilised and stained with anti-BTK-P as described in 
the Materials and methods. Samples were analysed by flow cytometry and expressed 
as percentages of positive cells. P values were calculated using the paired t-test. 
It was necessary to assess the effect of Ibrutinib on the survival of p38MAPK-S 
CLL cells. Indeed, there was a significant increase in the percentages of early 
apoptotic cells in all four samples analysed (p=0.003) following CD180 ligation 
compared with basal levels confirming CD180- mediated signalling in p38MAPK-
S can lead to pro-apoptotic pathway although there is no recruitment of BTK 
kinase in signalling of this category of cells. Interestingly, pre-treatment of 
Ibrutinib had no appreciable effect on survival in all 4 p38MAPK-S CLL samples 
as there was no significant change in basal (p=0.193, Figure 4.19), or anti-
CD180-stimulated percentages of early apoptotic cells (p=0.119, Figure 4.19) 









Figure 4.19: Percentages of early apoptotic cells in unstimulated and anti-
CD180 mAb stimulated p38MAPK-S CLL cells untreated or treated with 
Ibrutinib: Bar chart (A) and scatter plot (B).   CLL cells were incubated with 
Ibrutinib or left untreated, washed and stimulated with anti-CD180 mAb for 24h or left 
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unstimulated, washed, stained with anti-CD19 mAb, washed, resuspended in binding 
buffer, loaded with PI and Annexin V-FITC for 10 min and analysed by flow cytometry as 
described in the Materials and methods. The p values were calculated using a non-
parametrical U-test.  
 
4.3 Discussion 
4.3.1 AKTi1/2 inhibited CD180-mediated phosphorylation of AKT protein 
kinase and AKT-S CLL cell survival  
In all CLL samples, a significant increase in the percentages of cells with 
phosphorylated AKT was observed after stimulating with anti-CD180 mAb 
compared to unstimulated cells. CD180 mediated phosphorylation of AKT in CLL 
was previously reported by our group (Porakishvili et al., 2011, 2015). Although 
it has been shown by some authors that CLL cells constitutively express 
phosphorylated AKT (Cuni et al., 2004; Petickovski et al., 2005; Ticchioni et al., 
2007; Zhuang et al., 2010), a significant change in the constitutive 
phosphorylation of AKT following the treatment with AKTi1/2 inhibitor was not 
observed in this study (Figure 4.7). Current data indicate that AKT protein kinase 
is not activated (at least in AKT-S category of CLL cells) without receiving a 
specific stimulation, the opinion also shared by others (Bernal et al., 2001; 
Barragan et al., 2002; Ringshausen et al., 2002; Muzio et al., 2008). In all six 
AKT-S CLL samples stimulated with anti-CD180 mAb Ser473 phosphorylation of 
AKT was significantly reduced when pre-treated with Akti1/2, down to the basal 
levels (Figure 4.7). This confirms that CD180 mediated signalling recruits AKT 
protein kinase in its signalling pathway. Inhibition of AKT by AKTi1/2 in a dose-
dependent manner in CLL has been reported by several other studies (Frias et 
al., 2009; Zhuang et al., 2010) linking it with the induction of PUMA and NOXA 
proteins the well-known p53-inducible pro-apoptotic members of the Bcl-2 family 
and a decrease in anti-apoptotic MCL-1 protein.   
As expected there was no effect on phosphorylation of AKT seen in p38MAPK-S 
CLL cells in both unstimulated and anti-CD180 mAb stimulated cells when 
comparing untreated and AKTi1/2 pre-treated cells (Figure 4.8). This confirms 
our previous findings (Porakishvili et al., 2015) regarding the dichotomy of 
CD180-mediated signalling pathways recruiting either AKT or p38MAPK. 
Although the direct substrates affected by AKT inhibition were not assessed, the 
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effect of AKTi1/2 on apoptosis of CLL cells was examined. Using both, DiOC6 
and Annexin/PI staining assays, a significant increase in the percentages of 
viable CLL cells following CD180-ligation was observed compared to basal levels 
confirming anti-apoptotic activity of CD180 mediated signalling in AKT-S CLL 
cells (Figure 4.9). That the pre-treatment of AKT-S CLL samples with AKTi1/2 
inhibitor significantly reduced the percentages of viable cells upon CD180-ligation 
and inhibited the CD180 mediated anti-apoptotic activity confirms the hypothesis 
that CD180-mediated CLL cell survival is operating via AKT (Figures 4.9 and 
4.10). Several earlier studies have shown that inhibition of AKT induces apoptosis 
in CLL cells and inhibit the expression of anti-apoptotic proteins (Frias et al., 
2009; Zhuang et al., 2010). 
Interestingly, pre-treatment of unstimulated AKT-S cells with Akti1/2 did not exert 
any effect on apoptosis, indicating as above a lack of spontaneous recruitment of 
AKT in CLL cells. Importantly, pre-treatment of p38MAPK-S CLL cells with AKT 
inhibitor Akti1/2 had no effect on the survival of p38MAPK-S CLL cells 
unstimulated or stimulated with anti-CD180 mAb as there was no reduction in 
basal or anti-CD180-stimulated percentages of early apoptotic cells (Figure 4.11) 
confirming that CD180 ligation in AKT-S CLL cells does not recruit p38MAPK 
protein kinase. Up to my knowledge, our research group was the first to report on 
a dichotomy of CD180-mediated signalling pathways in CLL cells. 
4.3.2 SB203580 inhibited CD180 mediated phosphorylation of p38MAPK 
protein kinase and p38MAPK-S cell apoptosis 
In all four p38MAPK-S CLL samples analysed, a significant increase in the 
percentages of cells with phosphorylated p38MAPK was observed after 
stimulating with anti-CD180 mAb, compared to the basal levels (Figure 4.12). 
CD180 mediated phosphorylation of p38MAPK in CLL cells was previously 
reported by our group (Porakishvili et al., 2011; 2015).  
Contrary to the data shown for AKT above, pre-treatment of unstimulated 
p38MAPK-S cells with SB203580 significantly reduced spontaneous 
phosphorylation of p38MAPK compared to untreated samples. This suggests the 
presence of constitutively phosphorylated p38MAPK in unstimulated CLL cells. 
Similar results regarding the presence of phosphorylated p38MAPK in all fresh 
CLL cells but not in normal B cells were reported others (Ringshausen et al., 
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2004; Sainz-Perez et al., 2006; Blix et al., 2012). It has been proposed that 
constitutive activation of the p38MAPK, observed in the majority of CLL cases 
was critical for matrix metalloproteinase-9 (MMP-9) production, which plays an 
important role in tumour-angiogenesis and tumour homing (Molica et al., 2003). 
As expected, in all four p38MAPK-S CLL samples stimulated with anti-CD180 
mAb, phosphorylation of p38MAPK was significantly reduced when pre-treated 
with SB203580 compared to untreated samples, down to the basal levels 
confirming that CD180-mediated signalling recruits p38MAPK in p38MAPK-S 
cells (Figure 4.12). It was suggested that SB203580 has no effect on activation 
of p38MAPK by mitogen-activated protein kinase 6 (MKK6), which is an essential 
component of the MAP kinase signal transduction pathway, but the continuous 
presence of SB203580 blocks the ability of p38MAPK to phosphorylate its 
downstream substrates (Kumar et al., 1999), the question we might address in 
our future studies. That SB203580 had no effect on phosphorylation of p38MAPK 
in AKT-S CLL cells (Figure 4.13) further confirmed the hypothesis that CD180 
ligation operates via two alternative signalling pathways in AKT-S and p38MAPK-
S categories of CLL cells.  
p38MAPK-mediated apoptosis only in p38MAPK-S category of CLL cells is a 
phenomenon first detected by us. Conflicting data has been published previously 
regarding the role of p38MAPK in apoptosis. Earlier on it was demonstrated that 
p38MAPK inhibitor, SB203580 could significantly inhibit BCR-induced apoptosis 
in B104 cells, human B lymphoma line (Graves et al., 1998). It was further 
reported that Rituximab activates a CD20-mediated signalling pathway to induce 
apoptosis of the CLL cells in p38MAPK activation-dependent manner (Pederson 
et al., 2002). p38MAPK was shown to be a key mediator of glucocorticoid-induced 
apoptosis in all lymphoid cells (Miller et al., 2005). However, Sainz-Perez et al., 
(2006) have demonstrated a paradoxical effect of p38MAPK which acts as an 
important intermediate for the function of Mda-7/IL-24, tumour suppressor 
proteins by inducing apoptosis in diverse cancer cells, whereas promoting the 
survival in CLL through p38MAPK activation. Also, Sarkar et al., (2002) 
demonstrated SB203580 mediated inhibition of mda-7 induced apoptosis in 
human melanoma cells.  In the light of these contradictory data, it was important 
to study the effect of SB203580 on the survival of CLL cells. The current data 
strongly indicate that p38MAPK selective inhibitor abrogates CD180-mediated 
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pro-apoptotic action of this protein kinase (Figure 4.14) in p38MAPK-S CLL cells, 
as suggested earlier (Porakishvili et al., 2011). Interestingly, any significant 
changes in the percentages of viable cells in unstimulated p38MAPK-S CLL cells 
were not observed when pre-treated with SB203580 (Figure 4.14), although pre-
treatment of unstimulated p38MAPK-S cells with SB203580 significantly reduced 
spontaneous phosphorylation of p38MAPK compared to untreated samples 
(Figure 4.12). This might indicate that although SB203580 inhibits 
phosphorylation of constitutively activated p38MAPK, the latter is not a sole 
contributor to the induction of apoptosis of p38MAPK-S CLL cells, and some 
complementary upstream or downstream events are required which can only be 
initiated upon stimulation with anti-CD180. As I mentioned above, these signalling 
molecules are still to be identified.  
That, similar to the results seen with AKTi1/2 inhibitor, pre-treatment of AKT-S 
CLL cells with p38MAPK inhibitor SB203580 had no effect on survival of AKT-S 
CLL cells (Figure 4.15) once more confirming the existence of two alternative 
signalling pathways upon ligation of CD180. 
4.3.3 Ibrutinib inhibited CD180 mediated phosphorylation of BTK protein 
kinase and cell survival in AKT-S CLL cells while not affecting CD180-
mediated BTK phosphorylation or cell apoptosis in p38MAPK-S CLL cells 
In line with our previous publications (Porakishvili et al., 2011; 2015) in all five 
AKT-S CLL samples analysed, there was a statistically significant increase in the 
percentages of cells with phosphorylated BTK, compared with basal levels 
following stimulation with anti-CD180 mAb (Figure 4.16). This validates the 
previous findings that BTK is involved in CD180 mediated signalling in AKT-S 
CLL cells (Porakishvili et al., 2015). The significance of BTK activation for BCR-
mediated signalling has been previously demonstrated. Upon BCR activation, 
BTK becomes activated by other tyrosine kinases, such as Lyn and SYK, 
resulting in activation of transcription factors needed for B-cell proliferation and 
differentiation (Petro et al., 2000). BTK is involved in signalling pathways of other 
receptors related to B cell migration and adhesion, such as chemokine receptors 
(CXCR4 and CXCR5) and adhesion molecules. It seems that BTK is critical for 
the development and function of normal B lymphocytes, and its expression 
appears to be required for CLL development (Kil et al., 2013). However, the 
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precise role of the kinase function of BTK in the initial development of CLL, as 
well as the disease expansion phase, remains unclear (Woyach et al., 2014).  
There were no significant changes in spontaneous phosphorylation of BTK, 
confirmed by other studies with Ibrutinib (Figure 4.16). It appears that BTK is 
preferentially activated after receiving signals via BCR or CD40 (Herman et al., 
2011). In this study, the stimulation for the activation of BTK is driven by anti-
CD180 mAb. Interestingly, in four out of five CLL samples stimulated with anti-
CD180 mAb, phosphorylation of BTK was significantly reduced when pre-treated 
with Ibrutinib compared to untreated samples, down to the basal levels confirming 
that Ibrutinib inhibits CD180 mediated signalling via BTK in AKT-S cells (Figure 
4.16). Current data also indicate that some of the key signalling PKs contributing 
to BCR-mediated signalling pathways are shared by CD180, as it has been 
suggested in Chapter 3. 
Importantly, although four out of five AKT-S samples demonstrated a significant 
reduction in the levels of BTK-P induced by Ibrutinib, one sample showed 
resistance towards Ibrutinib. It has been recently reported that 5.3% of CLL 
patients have disease progression following the treatment with Ibrutinib, 
suggesting resistance of those CLL cells to the inhibitor. The mechanism of 
resistance to Ibrutinib is thought to be associated with C481S mutation of BTK 
active site which prevents covalent binding between Ibrutinib and BTK (Furman 
et al., 2014; Wiestner, 2015).  
It is well documented that BTK is involved in pro-survival signalling in both, normal 
B lymphocytes and CLL cells (Woyach et al., 2014) as well as CLL-cell trafficking 
(Spaargaren et al., 2003; de Gorter et al., 2007; Byrd et al., 2013;2014). Herman 
et al. (2011) reported that Ibrutinib induces apoptosis in CLL cells stimulated by 
pro-survival factors such as CD40L, BAFF, IL-6, IL-4, TNF-α, fibronectin, stromal 
cell contact. Burger et al., (2010) demonstrated the inhibitory action of Ibrutinib 
on CLL cell survival, proliferation and leukaemic cell migration towards the tissue 
homing chemokines such as CXCL12 and CXCL13. They have also reported that 
Ibrutinib downregulated secretion of BCR-dependent chemokines such as CCL3 
and CCL4 in vitro and in CLL patients receiving Ibrutinib suggesting Ibrutinib may 
work in part by modulating the CLL cell interaction with the microenvironment 
rather than by direct cytotoxicity. Recently, Guo et al., (2016) showed that U-CLL 
cells display higher proliferative capacity correlated with higher BTK-P levels 
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compared to M-CLL. However, they failed to detect any differences in the Ibrutinib 
mediated apoptosis between U-CLL and M-CLL samples. 
Since our group has previously shown that BTK phosphorylation upon CD180 
ligation led to the survival of CLL cells (Porakishvili et al., 2011; 2015), analysing 
the effect of Ibrutinib on CD180-mediated survival of CLL cells was important. 
Current data have shown that in four AKT-S samples stimulated with anti-CD180 
mAb, Ibrutinib treatment has significantly increased the percentages of early 
apoptotic cells (Figure 4.17).  This confirms that CD180-induced pro-survival role 
of BTK is effectively inhibited by Ibrutinib in AKT-S. However, no significant 
change in the number of apoptotic cells observed in the sample which was 
resistant to Ibrutinib treatment. 
Moreover, the effect of Ibrutinib on phosphorylation of BTK in p38MAPK-S CLL 
cells was studied and interestingly, in all four samples there was no significant 
change in basal or anti-CD180 mAb stimulated percentages of BTK-P cells 
(Figure 4.18). This confirms that BTK is not recruited in p38MAPK-S category of 
cells for CD180-mediated apoptosis (Figure 4.19) as proposed in Chapter 3 and 
the previous publication Porakishvili et al., (2015).  That Ibrutinib had no effect on 
phosphorylation of BTK in p38MAPK-S CLL cells (Figure 4.18) further confirmed 
the hypothesis that CD180 ligation operates via two alternative signalling 
pathways.   Similarly, Ibrutinib had no effect on survival of p38MAPK-S CLL cells 
as there was no reduction in basal or anti-CD180-stimulated percentages of early 
apoptotic cells (Figure 4.19) confirming the hypothesis that CD180 ligation in 
p38MAPK-S CLL cells does not recruit BTK protein kinase. Nevertheless, this 
suggests that therapeutic application of the BTK inhibitors might be limited to the 
AKT-S CLL cells 
In conclusion, specific inhibitors of p-AKT, p-p38MAPK and p-BTK were used to 
confirm the involvement of these protein kinases in CD180-mediated signalling. 
As expected, pretreatment of AKT-S CLL cells with AKT inhibitor Akti1/2 resulted 
in a significant decrease in the number of p-AKT cells, while no effect was seen 
for p38MAPK-S cells. Likewise, p38MAPK inhibitor SB2035804 suppressed 
CD180-stimulated levels of p-p38MAPK in p38MAPK-S, but not in AKT-S cells. 
Moreover, pBTK inhibitor, ibrutinib could suppress phosphorylation of BTK and 
survival only in AKT-S CLL cells. Thus, the current data suggest that CD180- 
mediated intracellular signalling in CD180+ CLL cells can engage two major 
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pathways, either via BTK/AKT favouring survival or via p38MAPK favouring 
apoptosis. Application of specific inhibitors confirmed that, in many of the CLL 
samples, activation of AKT and p38MAPK pathways is exclusive. This appears 
to be a feature of CLL cells, and not of normal B cells that responded to CD180 
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CD180, previously called RP105, contains a leucine-rich extracellular domain but 
also possesses an 11-amino acid cytoplasmic domain with no homology to Toll-
like receptor 4 (TLR4) or other known proteins (Miyake et al., 1995). Nagai et al., 
(2002) demonstrated that CD180 is associated with a small molecule called MD1 
which is needed for recognition of lipopolysaccharide (LPS) which are found in 
outer membrane of gram-negative bacteria, surface expression and intracellular 
distribution of CD180. MD-1-null mice showed impairment in LPS-induced B cell 
proliferation, antibody production and B7.2/CD86 up-regulation (Nagai et al., 
2002). As previously described, the CD180 mediated signalling mechanism is 
less studied, however it seems that cross-linking of CD180 by antibody leads to 
activation of extracellular signal-regulated kinase (ERK), Jun amino(N)-terminal 
kinase(JNK) and p38-Mitogen activated protein kinase (p38MAPK) (Miyake et al., 
1994: Chan et al., 1998: Porakishvili et al., 2011). Current evidence suggests that 
MyD88 does not participate in CD180 mediated signalling as B cells deficient in 
MyD88 have shown proliferation following CD180 crosslinking. However, cells 
deficient in protein kinase C β (PKCβ) or from X-linked immunodeficient (xid) mice 
lacking normal Bruton tyrosine kinase (BTK) function, responded poorly to CD180 
ligation suggesting the importance of these proteins in CD180 mediated 
signalling (Chan et al., 1998). It was also reported that optimal proliferative 
signals after CD180 cross-linking require that the B cell co-receptor CD19 forms 
a complex with the Lck/Yes novel tyrosine kinase (Lyn) and Vav following CD180 
ligation (Yazawa et al., 2003).  
Stimulation of cells with LPS could significantly affect expression of CD180 on 
CD19+ cells and there was a significant decrease in expression of CD180 after 
24hr LPS stimulation in normal and leukaemia CD19+ cells suggesting that 
chemical structure of unknown antigen for CD180 resembles the 
lipopolysaccharide of gram- negative bacteria (Antosz et al., 2009) and it was 
correlated with reduced expression of CD180 mRNA (Zarember et al., 2002).  
This provided confirmation of previous studies which showed 100-fold down-
regulation of CD180 expression in the monocytic leukaemia cell line, THP-1 after 
LPS stimulation (Zarember and Godowski., 2002). Nagai et al. (2005) 
demonstrated that in CD180 knockout (KO) mice, B cell responses to LPS are 
impaired, and the level of constitutive serum IgG3 is reduced. This supported a 
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model of CD180 as a required coreceptor for B cell responses to bacterial cell 
wall components, to bind with LPS and form heterodimers with TLR4 to enhance 
signalling. Porakishvili et al., (2005) demonstrated that control B cells express 
higher levels of CD180 than do CLL cells. Similarly, Antosz et al., (2009) studied 
the expression patterns of CD180 receptor on the CD19+ subpopulation of normal 
and CLL lymphocytes and demonstrated that CD180 expression in unstimulated 
normal B cells is four times higher than in unstimulated CLL cells suggesting 
constant stimulation of CD180 receptor in CLL by unknown antigen or auto-
antigen. Ogata et al., (2000) demonstrated the functional interaction between 
CD284 and CD180 in LPS-mediated nuclear factor κB (NFκB) activation and 
confirmed that CD180 protein plays a significant role in B cell development acting 
both as LPS sensor and regulator of B cell proliferation. However, the natural 
ligand of CD180 is yet unknown. In contrast, Divanovic et al., (2005) reported that 
the antigen for CD180 is not LPS as CD180 does not bind with this antigen and 
CD180 complex does not contain the required LPS-binding pocket (Tsuneyoshi 
et al., 2005). They suggested that although CD180 regulates B cell sensitivity to 
LPS, the mechanism of CD180 to support TLR4 signalling remains unknown. Two 
opposing functions of CD180 have been reported; an essential co-receptor for 
LPS/stimulator of B cells (Nagai et al., 2005) and a specific TLR4 inhibitor in 
dendritic cells (DCs) with no physiological effect on B cells (Divanovic et al., 
2007).  
As previously described, the human myeloid differentiation factor 1 (MD-1) 
molecule has 66% and 38% amino acid sequence similarity to mouse and 
chicken MD-1 respectively and interacts with CD180 to play a significant role in 
cell surface expression (Miura et al., 1998). MD-1 and MD-2 are both members 
of group I of the MD-2- related lipid-recognition (ML) family that is characterized 
by a lipid binding function (12). MD-1 shares ~20% sequence identity with MD-2 
which is an adaptor molecule needed by TLR4 for the recognision of bacterial 
lipopolysaccharides on the cell surface. MD-1 is associated with and functions 
with radioprotective 105 (RP105). It was reported that without MD-1, the majority 
of human CD180 was held in the cell and CD180 was not able to undergo 
intracellular maturation or traffic to cell surfaces (Miura et al., 1998). Nagai et al., 
(2005) demonstrated that CD180/MD-1 that may not directly recognise 
lipoproteins and LPS, is displayed at high levels on marginal zone (MZ) B cells 
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and is essential for both polyclonal and specific IgG3 Ab responses to T-
independent (TI) type 1 vaccines. 
Arvaniti et al., (2011) also reported the high level of expression of CD180 in a 
large cohort of 192 CLL patients by gene expression profiles, suggesting CD180 
may promote the activation of both CLL and normal B cells. Good et al., (2009) 
demonstrated that CD180 is highly expressed on naïve and memory B cells 
however, memory cells show 2-5-fold higher expression compared to naïve cells. 
Moreover, signalling through CD180 in combination with CD40L decreased the 
time taken to enter division for naive and memory B cells compared with CD40L 
alone, and it had a more potent effect on naive B cells than on memory B cells 
(Good et al., 2009).   
Roshak et al., (1999) reported that anti-human CD180 sera could induce 
proliferation of lymphocytes in humans in a concentration-dependent manner and 
this proliferative response was equal to the response given by anti-CD40 
induction. Moreover, anti-CD180 induction in murine cells leads to proliferation of 
murine splenocytes and it was reported that anti-CD180 activates >85% both 
human and mouse B cells in vitro causing them to proliferate (Miyake et al., 
1994). Kulikova et al., (2013) studied CD180 expression patterns in the CLL cell 
line, MEC1 and reported that there was a decrease in CD180+ cells number 
during the activation and a negative correlation with the number of cells 
expressing CD180 and CD86 intensity.  
It was reported that the number of CD180-negative B cells is significantly 
increased in PBMCs from systemic lupus erythematosus (SLE) patients and is 
positively associated with the disease activity (Koarada et al., 2011). These 
CD180neg B cells from SLE patients could produce IgG and IgM in vivo 
spontaneously, suggesting that only CD180neg B cells can produce auto-
antibodies. Interestingly in SLE, ligation of CD180 inhibited the tyrosine 
phosphorylation of signal transducer and activator of transcription 2 (STAT-2) 
induced by IFN-α via a Lyn-PI3K-BTK-dependent pathway. Moreover, TLR7 and 
TLR9 signalling could downregulate CD180 expression and attenuate the 
inhibitory effect of anti-CD180 on the activation of IFN- α signalling in murine B 
cells (You et al., 2015). In SLE, the percentages of CD180+ B cells decreased as 
the disease turned inactive and disappeared in the peripheral blood from inactive 
patients treated with corticosteroids. Moreover, CD180neg B cells underwent 
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spontaneous and dexamethasone-induced apoptosis in contrast to CD180+ B 
cells. They have also shown that CD180neg B cells in SLE can produce IgG and 
IgM antibodies in vitro suggesting at least partially the CD180neg B cells may 
include pathogenic autoreactive B cells subset(s) in SLE (Koarada and Tada, 
2011). 
As previously described elsewhere, histological studies have shown that CD180 
is expressed mainly on mature B cells in mantle zones whereas germinal centre 
cells are either dull or negative (Miuro et al., 1998). Mestrallet et al., (2016) 
reported a high expression of CD180 by neoplastic follicular lymphoma (FL) cells 
when they reside in lymph nodes (LNs). As the expression of the CD180 may 
support interaction between lymphoma cells and their microenvironment, their 
findings suggest that CD180 could potentially be playing a role in FL 
pathogenesis. They also demonstrated that the expression of CD19 is conserved 
by neoplastic FL B cells, whereas the expression of the negative BCR regulator, 
CD22 is down-regulated suggesting the importance of BCR signalling in FL 
pathogenesis and significant overlap between the TLR and BCR pathways. 
Similar to the role of CD180 in CLL, the TLR/CD180 pathway and its interaction 
with CD19 signalling were reported to be involved in the enhanced BCR activity 
via the tyrosine kinase Syk in FL (Leseux et al., 2006). 
Chaplin et al., (2011) demonstrated that anti-CD180 mAb in vivo induces rapid 
polyclonal B cell expansion and immunoglobulin production, especially IgG1 and 
IgG3 subclasses and it was inhibited by co-administration of diverse TLR ligands. 
However, anti-CD180 synergizes with ligands for all MyD88-dependent TLRs to 
increase B cell proliferation. Combining activity of anti-CD180 with TLR signals 
increased cytokine production from purified B cells; however, it does not, by itself, 
induce cytokine production. Yamashita et al., (1996) demonstrated that exposure 
to anti-RP105 sensitised murine B cells to anti-IgM-mediated apoptosis and 
growth arrest.  
Previous studies by our group on surface expression of CD180 on CLL cells have 
shown that CD180 is heterogeneously expressed on CLL cells.  However, the 
majority of control CD19+ B cells express a high density of CD180 (5548±2271 
RBS/cell) compared to CD180+ CLL cells (1500±932 RBS/cell) (Porakishvili et 
al., 2005). This could be related to activation, as CD180neg B cells increased in 
patients with SLE and showed higher levels of activation markers than CD180+ B 
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cells (Kadowaki et al., 2001). CLL cells were classified as CD180neg based on a 
small CD180neg population seen in the control B cells (316±88 RBS/cell). It was 
reported that the ratio of the CD180+ versus CD180neg CLL patients was about 
2:1 (50 and 28 respectively). However, there was no difference in CD180 
expression between the untreated patients, those treated six months prior to the 
investigation or those who were receiving treatment during the research as well 
as there was no relationship with disease stage or WBC counts (Porakishvili et 
al., 2005). Interestingly, the level of CD180 expression in those CLL cells with 
high expression of CD180 remained high and those with low density stayed low 
for up to 24 months suggesting that CLL using UM-IGVH genes might be 
continuously maintained in a more heightened state of BCR mediated activation, 
consistent with lower levels of CD180 (Porakishvili et al., 2005). Our previous and 
current data have also shown that there is no relationship between CD180 and 
sIgM, CD79b or CD38 expression in CLL patients. However, the expression of 
sIgM and the BCR-associated molecule, surface CD79b is variable from patient 
to patient, but significantly lower on CLL cells compared with control B cells (Zupo 
et al., 1996; Thompson et al., 1997; Damle et al., 1999). CD180 expression level 
is higher in M-CLL group than UM-CLL group in contrast to sIgM levels. Although 
most of the UM-CLL cells were negative for CD180, positive cells have shown an 
increased expression of CD38 (Porakishvili et al., 2005).  
Interactions between CD180- and BCR mediated signalling in B cells have been 
reported in several studies. Chan et al., (1998) demonstrated that both CD180 
and BCR mediated signalling in mice use Lyn protein and BCR can recruit Lyn 
more efficiently to the BCR complex compared to the putative CD180 signalling 
complex suggesting the simultaneous ligation of BCR and CD180 will reduce the 
amount of Lyn that could be used by CD180 signalling complex and block the 
CD180–induced MAP kinase activation. 
Tsertsvadze et al., (2015) studied the correlation of the expression of CD32 and 
CD180 on CLL cells and the MEC1 cell line, which are derived from a CLL patient 
with M-CLL, and found that expression of CD32 is significantly increased on CLL 
cells throughout 0-96 hours compared to control B cells as well as in long-term 
MEC1 cell culture. In contrast, CD180 expression on MEC1 cells significantly 
decreased throughout 0-96 hours of MEC1 cell culture. The negative correlation 
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between CD180 and CD32 expression on cycling MEC1 cells could be limited to 
M-CLL.  
Instability of CD180 expression could be partially explained by its endocytosis. 
Although dynamics of the ligation-induced CD180 endocytosis in CLL or B cells 
has not been documented, termination of immune responses by receptor 
endocytosis has been reported for other types of receptors such as G-protein-
coupled receptors, which are important in various biological processes. Binding 
of a ligand to their receptor complex induces phosphorylation and conformational 
changes of the different subunits of the receptor activating signals. This is 
followed by internalisation of ligand-receptor complexes and their direction into 
endosomes where the ligand is removed and degraded whereas the receptor is 
either degraded or is recycled back to the cell surface (Kane et al., 2014). Key 
steps in internalisation of receptors are summarised in figure 5.1. 
 
Figure 5.1: Termination of signal transduction by receptor endocytosis. 
Ligand binding to surface receptors transduces activating signals (1) and simultaneously 
initiates signals that cause lateral diffusion of receptor-ligand complexes to clathrin-
coated pits, membrane invagination (2) and generation of coated vesicles (3). The 
vesicles then undergo a process of uncoating (a precondition for vesicles to join to other 
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membranes), fuse with early endosomes and release ligands (4). The ligand undergoes 
proteosomal and/or lysosomal degradation after being transported either to late 
endosome and/or lysosome (5) or is recycled and secreted by transcytosis (6). Similarly, 
receptors may undergo proteosomal degradation or recycle to the cell surface (7) (Kane 
et al., 2014).  
As shown in Figure 5, binding of a ligand to complex receptors induces 
phosphorylation and conformational changes of the different subunits of the 
receptor leading to transduction of activation signals. This is followed by 
internalisation of ligandreceptor complexes and their transport into the 
endosomes. In the endosomes, the ligand is removed and undergoes rapid 
degradation, while the receptor is either degraded or is recycled back to the cell 
surface (Kane et al., 2014).  
Gangloff (2012) proposed a mechanism for TLR4 cellular targeting and signalling 
which involves the formation of ligand-receptor complex leading to endocytosis 
as shown in figure 5.2. Since CD180 is a TLR4 homologue lacking the 
intracellular TLR4 signalling domain, it may be plausible to suggest that CD180 
mediated signalling recruits a similar mechanism which leads to endocytosis of 




Figure 5.2: Proposed mechanism for TLR4 cellular targeting and signalling. 
(i) TLR4 is expressed in the endoplasmic reticulum. (ii) It relies on MD-2 among other 
protein partners for surface targeting. (iii) LPS is transferred from CD14 to TLR4-MD-2. 
(iv) Receptor dimerization after ligand binding (v) Mal has a phosphatidylinositol 4,5-
bisphosphate (PIP2) binding motif (depicted as KKKK) that targets the receptor complex 
to a membrane microdomain. PIP2 is exclusively located at the plasma membrane. 
Surface signalling involves the myddosome and leads to early NF-κB activation. (vi) 
CD14 and TRIF-related adaptor molecule (TRAM) have lipid-raft localization signals and 
are engulfed along the TLR4-MD-2-LPS complex. Mal is not translocated out of the 
membrane. (vii) Endosomal signalling results in the recruitment of TRAM and 
Toll/interleukin (IL)-1 receptor (TIR)-domain-containing adaptor-inducing interferon-β 
(TRIF) in the case of LPS and monophosphoryl lipid A (MPLA). This leads to the 
activation of Interferon-response factor3 (IRF3), IRF7, NF-κB and Fas-associated death 
domain (FADD), respectively. (viii) In the lysosome, all endocytosed complexes are 
targeted for degradation (ix) antigen presentation (Gangloff, 2012).  
Lipid rafts (LRs) are specialised microdomains located in the outer plasma 
membrane of cells that play important roles in various cellular functions, including 
cell signalling, secretory and endocytic pathways. Many surface antigens 
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expressed on CLL cells are localised or translocated into LRs and carry out 
different functions. LRs act as critical binding sites for therapeutic antibodies such 
as anti-CD20 rituximab and anti-CD52 alemtuzumab used for CLL patients. It has 
been reported that rituximab binds to CD20 on CLL cells and translocates it into 
LRs to increase intracellular Ca2+ level to trigger downstream apoptosis signalling 
pathways (Janas et al., 2005). Alomari et al., (2014) have identified 643 proteins 
in LRs of CLL including 30 proteins with no previous known association to the 
LRs.  
Here, the stability of CD180 expression on CD180+ CLL cells in cell cultures up 
to 72 hours was studied. This was important since it would help to understand 
the dynamics of CD180-mediated intracellular signalling, survival or apoptosis, 
discussed in the previous chapters better. Both spontaneous change and change 
of expression of CD180 upon anti-IgM stimulation have been analysed. And also, 
the CD180 expression in CD180neg cells in cell cultures up to 72 hours was 
studied to assess the stability of CD180 expression profile on CLL cells. This 
experiment was carried out to evaluate modulation of expression patterns of 
CD180 on unstimulated CLL cells and when stimulated with anti-IgM which 
helped to suggest a possible link between dynamic expression of CD180 and 
CD180 mediated intracellular signalling. 
5.2 Results 
The surface expression of CD180 receptor on 17 CLL CD180+ CLL samples was 
analysed and three patterns in the dynamics of CD180 expression during 0-72h 
in culture were observed.  
5.2.1 Stable spontaneous expression of CD180 on a fraction of CLL samples 
(Pattern I) 
In 8 out of 17 CLL samples, there were no significant differences in the 
percentages of CD180+ CLL cells after 24, 48 or 72 hours of incubation (p=0.39; 
p=0.20 and p=0.20 respectively, Figure 5.3). Importantly, all of these 8 CLL 
samples belonged to the category of non-signallers (NS) as categorised in 




Figure 5.3: Percentages of CD180+ cells in a fraction of CLL samples with a 
stable spontaneous expression of CD180 up to 72 hours (Pattern I). CD180+ 
CLL cells were taken at 0 hour or incubated for 24, 48 and 72 hours, washed, incubated 
with human immunoglobulin (Ig), stained with PE-conjugated mouse IgG1 isotype control 
or PE-conjugated mouse anti-human CD180 mAb and PE-Cy5-conjugated-mouse-anti-
human-CD19 as described in Materials and methods, analysed by CYAN flow cytometer 
and Summit (4.3) analytical software and expressed as percentages of positive cells. p 
values were calculated using the paired t-test. Percentages of cells binding to the isotype 
control was subtracted from the percentages of cells binding to anti-CD180 mAb.  
 
5.2.2 Cell viability of a fraction of CLL samples with a stable spontaneous 
expression of CD180 
Since the surface expression of CD180 and cell viability may have a functional 
relationship, it was important to measure the percentages of viable cells by 
assessing changes in mitochondrial membrane potential as previously described 
in Materials and methods. There were no significant differences in the 
percentages of viable cells after 24, 48 or 72 hours of incubation (p=0.136; 




Figure 5.4: Percentages of DiOC6dim (apoptotic) cells in a fraction of CLL 
samples with a stable spontaneous expression of CD180 up to 72 hours 
(Pattern I). CD180+ CLL cells were taken at 0 hour or incubated for 24, 48 and 72 hours, 
washed, stained with anti-CD19 mAb, loaded with DiOC6 for 20 min and analysed by 
flow cytometry as described in the Materials and methods. The values are means ± SD, 
p values were calculated using the paired t-test. 
5.2.3 Decreased spontaneous expression of CD180 on a fraction of CLL 
samples (Pattern II) 
Interestingly, in 5 out of 17 CLL samples, the percentages of CD180+ CLL cells 
significantly reduced after 24, 48 or 72 hours of incubation (p=0.019; p=0.002, 
and p=0.001 respectively, Figure 5.5). Moreover, four out of five CD180+ CLL 
samples became completely negative for CD180 expression after 72 hours of 
incubation; one sample remained as CD180+ but with a reduced expression 
compared to 0 hour. Moreover, decrease in CD180 expression was significant 
from 24-48 hours (p=0.029) and 48-72 hours (p=0.017). It was interesting to 





Figure 5.5: Percentages of CD180+ cells in a fraction of CLL samples with a 
decreased spontaneous expression of CD180 up to 72 hours (Pattern II).  
CD180+ CLL cells were taken at 0 hour or incubated for 24, 48 and 72 hours, washed, 
incubated with human immunoglobulin (Ig), stained with PE-conjugated mouse IgG1 
isotype control or PE-conjugated mouse anti-human CD180 mAb and PE-Cy5-
conjugated-mouse-anti-human-CD19 as described in Materials and methods, analysed 
by CYAN flow cytometer and Summit (4.3) analytical software and expressed as 
percentages of positive cells. p values were calculated using the paired t-test. 
Percentages of cells binding to the isotype control was subtracted from the percentages 
of cells binding to anti-CD180 mAb. 
 
5.2.4 Cell viability of a fraction of CLL samples with a decreased 
spontaneous expression of CD180 
Since the reduction of expression of CD180 may be associated with survival of 
cells, it was essential to assess possible changes in the survival of CLL cells in 
cultures up to 72 hours. The viability of cells was measured by using DiOC6 dye 
as previously mentioned. The percentages of DiOC6dim apoptotic cells were 
significantly increased after 24, 48 or 72 hours of incubation (p=0.0026; p=0.0087 
and p=0.0027, Figure 5.6) showing a positive correlation between decrease of 
CD180 expression and apoptosis of those CD180+ CLL cells. Increased 
182 
 
apoptosis was successive from 24-48 hours (p=0.049) and 48-72 hours 
(p=0.006). 
 
Figure 5.6: Percentages of DiOC6dim (apoptotic) cells in a fraction of CLL 
samples with a decreased spontaneous expression of CD180 up to 72 hours 
(Pattern II). CD180+ CLL cells were taken at 0 hour or incubated for 24, 48 and 72 
hours, washed, stained with anti-CD19 mAb, loaded with DiOC6 for 20 min and analysed 
by flow cytometry as described in the Materials and methods. The values are means ± 
SD, p values were calculated using the paired t-test. 
 
5.2.5 Increased spontaneous expression of CD180 on a fraction of CLL 
samples (Pattern III) 
In 4 out of 17 CLL samples, the percentages of CD180+ CLL cells significantly 
increased after 24, 48 or 72 hours of incubation (p=0.010; p=0.019, and p=0.025 
respectively, Figure 5.7). However, there was no significant difference of 
percentages of CD180+ CLL cells between 24 and 48hr cultures (p=0.463) or 48 
and 72hr cultures (p=0.111) confirming although there is a substantial increase 
of CD180 expression up to 24 hours, after 24 hours the expression remains 





Figure 5.7: Percentages of CD180+ cells in a fraction of CLL samples with 
an increased spontaneous expression of CD180 up to 72 hours (Pattern III).  
CD180+ CLL cells were taken at 0 hour or incubated for 24, 48 and 72 hours, washed, 
incubated with human immunoglobulin (Ig), stained with PE-conjugated mouse IgG1 
isotype control or PE-conjugated mouse anti-human CD180 mAb and PE-Cy5-
conjugated-mouse-anti-human-CD19 as described in Materials and methods, analysed 
by CYAN flow cytometer and Summit (4.3) analytical software and expressed as 
percentages of positive cells. p values were calculated using the paired t-test. 
Percentages of cells binding to the isotype control was subtracted from the percentages 
of cells binding to anti-CD180 mAb. 
 
5.2.6 Viability of CD180 positive CLL samples which had an increased 
expression of CD180 up to 72 hours when unstimulated 
It was important to assess whether the increase in CD180 expression up to 24 
hours in those CD180+ CLL cells was associated with cell viability in cultures. 
Interestingly, the percentages of DiOC6dim apoptotic cells were significantly 
decreased after 24,48 or 72 hours of incubation (p=0.0002; p=0.045 and p=0.014, 
Figure 5.8) showing a correlation between increased CD180 expression and 
survival of cells. However, there was no significant difference of percentages of 
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viable cells between 24 and 48hr cell cultures (p=0.356) or 48 and 72hr cell 
cultures (p=0.179).  
 
Figure 5.8: Percentages of DiOC6dim (apoptotic) cells in a fraction of CLL 
samples with an increased spontaneous expression of CD180 up to 72 
hours (Pattern III). CD180+ CLL cells were taken at 0 hour or incubated for 24, 48 and 
72 hours, washed, stained with anti-CD19 mAb, loaded with DiOC6 for 20 min and 
analysed by flow cytometry as described in the Materials and methods. The values are 
means ± SD, p values were calculated using the paired t-test. 
5.2.7 Stable spontaneous expression of CD180 on CD180neg CLL samples  
CD180 expression on 5 CD180neg CLL samples was studied to assess the 
stability of CD180 expression profile in CD180neg CLL cells. As expected there 
were no significant differences in the percentages of CD180+ CLL cells after 24, 






Figure 5.9: Percentages of CD180+ cells in CD180neg CLL samples up to 72 
hours. CD180neg CLL cells were taken at 0 hour or incubated for 24, 48 and 72 hours, 
washed, incubated with human immunoglobulin (Ig), stained with PE-conjugated mouse 
IgG1 isotype control or PE-conjugated mouse anti-human CD180 mAb and PE-Cy5-
conjugated-mouse-anti-human-CD19 as described in Materials and methods, analysed 
by CYAN flow cytometer and Summit (4.3) analytical software and expressed as 
percentages of positive cells. p values were calculated using the paired t-test. 
Percentages of cells binding to the isotype control was subtracted from the percentages 
of cells binding to anti-CD180 mAb.  
 
5.2.8 Viability of CD180 negative cells up to 72 hours of incubation 
Analysis of viability of those CD180neg CLL samples showed strikingly similar 
results shown to those CD180+ samples with a stable spontaneous expression of 
CD180. Indeed, there were no significant differences in the percentages of viable 
cells after 24, 48 or 72 hours of incubation (p=0.153; p=0.070 and p=0.095 




Figure 5.10: Percentages of DiOC6dim (apoptotic) cells CD180neg CLL 
samples up to 72 hours. CD180neg CLL cells were taken at 0 hour or incubated for 
24, 48 and 72 hours, washed, stained with anti-CD19 mAb, loaded with DiOC6 for 20 min 
and analysed by flow cytometry as described in the Materials and methods. The values 
are means ± SD, p values were calculated using the paired t-test. 
5.2.9 Modulation of CD180 expression on CD180+ CLL samples upon anti-
IgM stimulation 
Since several studies have demonstrated that activation could significantly affect 
surface expression of CD180 in different types of cells (Antosz et al., 2009; 
Chankotadze, 2013; You et al., 2015), it was necessary to assess the effect of 
IgM ligation on surface expression of CD180 in CLL cells. CLL samples with 
CD180+IgM+ CLL cells were used for this study and interestingly, in all 11 
samples, the percentages of CD180+ cells significant decreased following anti-
IgM ligation compared with basal levels after 24, 48 and 72 hours of incubation 
(p=0.013; p=0.006 and p=0.039, Figure 5.11). Moreover, 7 out of 11 CLL samples 
belonged to the category of p38MAPK-signallers and the rest was AKT-
signallers. Furthermore, the percentages of CD180+ cells significantly decreased 
after 24, 48 or 72 hours of incubation in unstimulated cultures (p=0.021; p=0.014 
and p=0.002).   
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Figure 5.11: Modulation of CD180 expression in CD180+ CLL samples upon 
anti-IgM F(ab)2 stimulation. CD180+ CLL cells were taken at 0 hour or incubated with 
anti-IgM mAb for 24, 48 and 72 hours, washed, incubated with human immunoglobulin 
(Ig), stained with PE-conjugated mouse IgG1 isotype control or PE-conjugated mouse 
anti-human CD180 mAb and PE-Cy5-conjugated-mouse-anti-human-CD19 as 
described in Materials and methods, analysed by CYAN flow cytometer and Summit (4.3) 
analytical software and expressed as percentages of positive cells. p values were 
calculated using the paired t-test. Percentages of cells binding to the isotype control was 
subtracted from the percentages of cells binding to anti-CD180 mAb. 
5.2.10 Effect of anti-IgM stimulation on viability of CD180 positive CLL cells 
Since the decrease of expression of CD180 upon anti-IgM stimulation may be 
associated with survival of cells, it was essential to assess possible changes in 
the survival of CLL cells in anti-IgM stimulated cultures up to 72 hours. The 
viability of cells was measured by determining changes in mitochondrial 
membrane potential as previously mentioned. There were no significant 
differences in the percentages of viable cells following anti-IgM ligation compared 
with basal levels after 24, 48 and 72 hours of incubation (p=0.314; p=0.084 and 
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p=0.111 respectively, Figure 5.12) in all 11 CLL samples. However, the 
percentages of DiOC6dim apoptotic cells were significantly increased after 24, 48 
or 72 hours of incubation in unstimulated cultures (p=0.047; p=0.00016 and 
p=0.00007). 
Figure 5.12: The percentages of DiOC6dim (apoptotic) cells in anti-IgM F(ab)2 
stimulated CD180+ CLL cells compared to unstimulated cultures. CD180+ 
CLL cells were taken at 0 hour or incubated with anti-IgM for 24, 48 and 72 hours, 
washed, stained with anti-CD19 mAb, loaded with DiOC6 for 20 min and analysed by flow 
cytometry as described in the Materials and methods. The values are means ± SD, p 












5.3.1 Stable spontaneous expression of CD180 on a fraction of CLL samples 
with no change in cell survival  
Current data has shown that on a fraction of CD180+ CLL samples (8 out of 17), 
the surface expression of CD180 did not significantly change from 0 to 72 hours 
(Figure 5.3). Analysis of a possible correlation between modulation of CD180 
expression and survival of cells has confirmed that CLL cells with a stable 
spontaneous CD180 expression had a stable cell viability throughout 0- 72 hours 
in cultures (Figure 5.4). As previously described in Chapter 3 and the previous 
publication Porakishvili et al., (2015), there are four patterns of CD180-mediated 
signalling in CLL cells and here, all 8 CLL samples belonged to the non signallers 
(NS) category.  It has been previously demonstrated that NS CLL samples are 
unresponsive to CD180 ligation suggesting that NS may use an alternative 
pathway or they are totally refractive to ligation of CD180. Moreover, NS samples 
were unresponsive to the ligation of sIgM suggesting their anergic state (Packhan 
et al., 2014).  Two explanations for instability of CD180 expression in cultures 
might be either internalisation of ligand-receptor complex (endocytosis) as shown 
by TLR4 and other biologically important receptors or change of the percentages 
of CD180+ cells due to activation of either pro-apoptotic or anti-apoptotic 
pathways upon stimulation of cells by a specific ligand. Interestingly, all 8 samples 
which showed a stable expression of CD180 were NS and this suggests that 
either a natural ligand was not present in the body or those NS CLL cells did not 
respond to the intrinsic ligand which was present in the body at the time of the 
samples taken due to their anergic state. Therefore no triggering of endocytosis 
or activation of either pro-survival or pro-apoptotic signalling pathway has been 
taken place. 
5.3.2 The level of CD180 surface expression decreased on a fraction of CLL 
samples with a significant increase in cell viability 
A fraction of CD180+ CLL samples showed a significant decrease of CD180 
surface expression from 0 to 72 hours (Figure 5.5) while the percentages of 
apoptotic cells in cultures significantly increased (Figure 5.6). Similar results were 
reported by Tsertsvadze et al., (2015) showing a decrease in CD180 expression 
in MEC1 cells throughout 0-96 hours. Current data on downmodulation of CD180 
expression suggest that CD180 was already stimulated by an intrinsic ligand 
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causing further endocytosis of the receptors in cultures. Although dynamics of the 
ligation-induced CD180 endocytosis in CLL or B cells has not been reported yet, 
lipid raft formation of many of the surface antigens aberrantly expressed on CLL 
(Janas et al., 2005; Alomari et al.,2014) and ligation-induced endocytosis of other 
receptors have been reported by others (Ferguson, 2001; Spat et al., 2004; 
Takayama et al., 2005; Nakayama et al., 2013 and Kane et al., 2014) including 
endocytosis of TLR4 (Gangloff, 2012). Interestingly, all five CLL samples with 
decreased CD180 expression were p38MAPK-signallers. Although the role of 
p38MAPK-mediated signalling in CLL is unclear, previous data in Chapter 3 
confirm that CD180-mediated activation of p38MAPK is associated with 
apoptosis in CLL cells. In line with previous findings, there was an increase in the 
percentages of apoptosis cells throughout 0-72 hours further supporting the 
hypothesis that those cells were already stimulated by an intrinsic ligand, and 
therefore, p38MAPK-mediated pro-apoptotic pathway is activated. This may have 
led to increasing the percentages of CD180neg cells in cultures. As previously 
described in Chapter 3 and the previous publication Porakishvili et al., (2015), 
CD180 ligation can redirect sIgM-mediated signalling from the pro-survival to the 
pro-apoptotic pathway. Hence the reduction in the expression of CD180 on 
cycling CLL cells suggests that this may lead to a weakening of redirection effect 
and enhance further survival and expansion of CLL cells in proliferative centres 
of lymphoid tissues.  
5.3.3 The level of CD180 surface expression increased on a fraction of CLL 
samples with a significant increase in cell viability  
Moreover, a fraction of CD180+ CLL samples showed a significant increase of 
CD180 surface expression from 0 to 24 hours spontaneously followed by a  stable 
expression from 24 to 72 hours in cultures (Figure 5.7). Interestingly, all 4 CLL 
samples were AKT-signallers.  Previous signalling data have demonstrated that 
CD180 ligation on AKT-S CLL cells activates the pro-survival pathway. Hence it 
is credible to suggest that these AKT-S CLL cells were already stimulated by a 
putative CD180 antigen which was present in its microenvironment and activated 
pro-survival pathway thereby increasing the number of CD180+ CLL cells in 
cultures. Confirming this, the viability of cells of all four samples significantly 
decreased from 0 to 24 hours. However, the signal generated by receptor ligation 
might not be robust enough to continue its pro-survival effect in long-term cultures 
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as the viability did not change significantly after 48 or 72 hours compared with 24 
hours culture (Figure 5.8).    
5.3.4 Stable spontaneous expression of CD180 on CD180neg CLL samples 
while no change in cell survival 
There was no significant change in CD180 surface expression and apoptosis of 
CD180neg CLL cells from 0 to 72 hours of incubation as expected (Figure 5.9). 
Since CD180neg CLL cells possess relatively less CD180 RBS/cell (≤316±88 
RBS/cell) to ligate with antigen and initiate a response, either the level of CD180 
expression or the percentages of apoptotic cells were not affected by any ligand-
receptor interaction (Figure 5.10). Consequently, these CD180neg CLL cells 
remained as a negative population of cells for CD180 expression up to 72 hours.  
5.3.5 The anti-IgM treatment significantly reduced the expression of CD180 
while not affecting survival of cells  
There was a statistically significant decrease in the percentages of CD180+ CLL 
cells when stimulated with anti-IgM for 24, 48 and 72 hours compared to basal 
levels (Figure 5.11) suggesting a functional relationship between CD180- and 
BCR mediated signalling. Preliminary data of our research group indicated that 
CD180 is endocytosed upon ligation with anti-CD180 mAb (data not shown). 
Hence it is possible to suggest that in these samples, CD180 was already 
stimulated by an unknown antigen present in vivo initiating the endocytosis 
process and anti-IgM treatment triggered further endocytosis in cultures. In that 
case, the putative ligand of CD180 and anti-IgM should recognise different 
epitopes on CD180. Hypothesised co-localization of IgM and CD180 receptors in 
the lipid rafts will be assessed in our future studies to understand the interaction 
between the two receptors better. Chappell et al., (2014) suggested that the 
combination of signals via CD180 and antigen-engaged BCRs appears to be 
responsible for effective immunisation in mice. Significantly higher expression of 
CD180 in CD19+ subpopulation of unstimulated normal B cells than in 
unstimulated CLL cells has been previously reported (Porakishvili et al., 2005; 
Antosz et al., 2009) suggesting constant stimulation of CD180 receptor in CLL by 
an unknown antigen or auto-antigen. Furthermore, 7 out of 11 CLL samples were 
p38MAPK-S and 4 out of 11 CLL samples were AKT-S. However, there was a 
significant decrease of CD180 expression and percentages of viable cells in 
unstimulated cultures throughout 0-72 hours (Figure 5.12). This data further 
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confirmed that at least for p38MAPK-S, the intrinsic ligand has already stimulated 
pro-apoptotic pathway.  
In conclusion, current data suggest that at least for p38MAPK-S and AKT-S CLL 
cells, the surface expression of CD180 is dynamic in cultures and this dynamic 
expression might be related to the interaction of CD180 with an unknown ligand 
present in the microenvironment. In my opinion, either the intrinsic ligand of 
CD180 was present in the body at the time of the samples taken, or it could be a 
generated soluble molecule such as a heat shock protein (HSP). Although the 
dynamics of ligation-induced CD180 endocytosis in CLL cells has not been 
documented so far, it is plausible to suggest that upon receiving signals via 
binding of ligands to surface receptors, activating signals are transduced, and 
endocytosis of receptor-ligand complex is initiated. This provides a probable 
elucidation for dynamics of CD180 expression observed in p38MAPK-S and AKT-
S CLL cells. Furthermore, current data suggest that the internalisation is further 
triggered by the activation signals received via BCR ligation. Moreover, a stable 
spontaneous expression of CD180 shown by nonsignallers confirms that the 
dynamics of CD180 expression in cultures is mediated by the signals received 
from their microenvironment. Hence, the anergic state of NS CLL cells for CD180- 
and BCR mediated signalling prevented modulation of CD180 expression in this 
category of cells. In conclusion, current data show that modulation of CD180 
expression in cultures is a characteristic of some categories of CLL cells 
suggesting a possible link between dynamics of the receptor expression and 
































The role of microenvironment in the development and progression of chronic 
lymphocytic leukaemia (CLL) is currently of major interest. Pathogen- and 
damage-associated molecular patterns (PAMPs and DAMPs) represent 
exogenous and endogenous microenvironmental factors. These factors act via a 
range of receptors, including Toll-like receptors (TLR). CD180/RP105 is a 
membrane-associated orphan receptor that belongs to the TLR family, is 
expressed by professional antigen-presenting cells, and drives normal B-cell 
activation and proliferation. It is expressed heterogeneously on CLL cells, and 
predominantly on CLL with mutated IGVH genes (M-CLL). Our group has 
previously shown that approximately 60% of CLL samples expressed surface 
CD180 (Porakishvili et al., 2005), but only half responded to ligation with anti-
CD180 monoclonal antibody (mAb) resulting in activation, cycling, and reduced 
basal apoptosis. This was comparable or superior to that induced by anti-CD40 
mAb or IL-4 (Porakishvili et al., 2011). These CLL samples which upregulated 
CD86 and Ki-67 upon stimulation with anti-CD180 mAb were termed responders 
(R). In contrast, CD180+ CLL samples that failed to respond to anti-CD180 mAb, 
despite expressing a high density of CD180 receptors, were termed non-
responders (NR). Porakishvili et al., (2011) further demonstrated that in R-CLL 
cells and normal B cells, CD180 ligation led to a strong upregulation in 
phosphorylation of ZAP70/Syk, Erk, p38MAPK, and AKT protein kinase (PK) in a 
Ca2+ independent manner, compared to untreated cells. Thus, the interaction of 
R-CLL cells with the microenvironment through CD180 may contribute to the 
expansion of leukaemia cell clones, in vivo, in lymph nodes and bone marrow 
within proliferation centres (PCs). In contrast, CD180-mediated signalling in NR 
CLL cells did not progress downstream from ZAP70/Syk phosphorylation 
indicating a block in activation of downstream protein kinases, and possible 
anergy. 
However, our group has previously noted that although the levels of 
phosphorylated AKT, ERK, and p38MAPK were significantly increased in R-CLL 
compared to NR-CLL samples), there was substantial heterogeneity within both 
anti-CD180 R and NR subsets of CLL. Therefore, to clarify the CD180-mediated 
signalling pathways in CLL, downstream signal transduction was studied and 
samples were recategorized into R and NR through their proximal ability to 
activate AKT. This was more appropriate compared to distal event of CD86 
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upregulation, which may dependent on other factors such as T cell interactions 
and/or cytokines. Although the responses were quite heterogeneous, using a 
larger cohort of patients (n=60), R-CLL cells could be divided into two categories; 
AKT signallers (AKT-S) and AKT non-signallers (AKT-NS) based on the ability to 
increase the level of phosphorylation of AKT (Ser 473) compared to basal levels. 
It was important to determine the characteristics of the two categories of cells in 
terms of other signalling molecules which was one of the major aims of my 
project. Hence the major signalling protein kinases; BTK, AKT and p38MAPK 
which were associated with the BCR signalling pathway were studied during this 
project. 
Summary 
The results of this study helped to establish the following: 
• Activation of alternative pathways appears to be a feature of CLL cells and 
there is a dichotomy in the CD180 mediated signalling pathways in CLL 
cells as BTK/AKT or p38MAPK. 
• This dichotomy in CD180-mediated signalling has opposing effects – 
BTK/AKT signalling pathway in AKT-S cells leads to survival whereas 
CD180-mediated activation of p38MAPK is associated with apoptosis. 
• Based on the differential pathways activated following CD180 ligation, four 
patterns of CD180-mediated signalling in CLL cells were identified: AKT-
signallers (AKT-S); p38MAPK signallers (p38MAPK-S); nonsignallers 
(NS); and a minor subset of double AKT/p38MAPK signallers (DS).  
• Pretreatment of CLL cells with anti-CD180 antibodies rewires the sIgM 
signalling pathway from pro-survival to pro-apoptotic in AKT-S CLL cells 
whereas pretreatment of p38MAPK-S cells with either anti-CD180 or anti-
IgM often leads to additive phosphorylation of AKT.   
• Application of specific inhibitors of AKT and p38MAPK signalling pathways 
confirmed that, in many of the CLL samples, activation of AKT and 
p38MAPK pathways is exclusive. 
• Modulation of CD180 expression studies showed that spontaneous 
expression of CD180 on p38MAPK-S and AKT-S CLL cells is dynamic in 
cell cultures which may be associated with dynamics of CD180-mediated 
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intracellular signalling, whereas spontaneous CD180 expression is stable 
on NS and CD180neg categories of CLL cells. 
• Activation of BCR mediated signalling by anti-IgM ligation, significantly 
reduce the expression of CD180 in CD180+IgM+ CLL cells. 
Signalling experiments included 60 CLL patients and 10 control samples. CD180+ 
CLL samples which responded to CD180 ligation by a significant upregulation of 
AKT-P were termed AKT-signallers (AKT-S, ~40%) and the samples which 
upregulated p38MAPK-P were termed p38MAPK-signallers (p38MAPK-S, 
~27%). Activation of both AKT and p38MAPK was seen in a small cohort of CLL 
samples and they were termed double signallers (DS, ~10%) whereas the 
remaining CD180+ CLL samples which did not respond to CD180 ligation by 
activating either of the two pathways were defined as non-signallers (NS, ~23%). 
This suggests that NS may use an alternative pathway or they are totally 
refractive to ligation of CD180. Therefore, as described elsewhere, four patterns 
of CD180-mediated signalling in CLL cells were identified: AKT-S, p38MAPK-S, 
NS and a minor subset of double AKT/p38MAPK signallers.   
It was important to compare CD180-mediated changes in survival of AKT-S and 
p38MAPK-S categories of CLL cells. CD180 ligation in AKT-S cells, activated 
protein kinase, BTK leading to a significant increase in pro-survival while 
suppressing p38MAPK pathway.  A similar result was observed with control B 
cells. However, CD180 ligation in p38MAPK-S did not recruit BTK and 
importantly, CD180 ligation stimulated pro-apoptotic pathway in this category of 
cells. In conclusion, ligation of CD180 with anti-CD180 mAb on CLL cells can 
activate two alternative signalling pathways; pro-survival: operate through 
activation of protein kinases BTK/AKT (AKT-S) predominantly and pro-apoptotic: 
operate through activation of p38MAPK (p38MAPK-S).  
sIgM induced signalling pathways were studied and compared with CD180 
mediated signalling patterns which were identified in the major categories of CLL 
cells.  Striking similarities were observed between two signalling pathways in 
AKT-S CLL cells.  Anti-IgM treatment increased the phosphorylation of AKT 
whereas downregulated the phosphorylation of p38MAPK in AKT-S category of 
cells. However, CD180 ligation induced activation of BTK/AKT in all AKT-S CLL 
samples, anti-IgM effect on this BTK/AKT circuit was more heterogeneous. 
Similar to anti-CD180 ligation, anti-IgM ligation also protected AKT-S CLL cells 
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from apoptosis. Phosphorylation of p38MAPK was a less frequent event with anti-
IgM stimulation compared to CD180 ligation as only 23% of samples showed 
activation of p38MAPK.  There was no significant difference in apoptosis in this 
category of cells suggesting that phosphorylation of p38MAPK is vital for the 
induction of apoptosis in p38MAPK-S cells. There was a significant decrease in 
expression of BTK-P in all p38MAPK-S CLL samples upon stimulation with anti-
IgM. Similarly, BCR engagement did not show an activation of p38MAPK in DS 
CLL samples.  This could be due the lack of BTK phosphorylation abrogates both 
“arms” of BCR signalling (via AKT and p38MAPK), whilst leaving CD180-
mediated p38MAPK activation intact. Interestingly, the ability of CD180 to bypass 
BTK and carry signals downstream to p38MAPK, favours apoptosis over survival. 
This suggests, although there is a substantial overlap of CD180 and sIgM 
mediated activation of BTK/AKT pro-survival signalling circuit, only ligation of 
CD180 can lead to activation of an alternative proapoptotic pathway mediated via 
p38MAPK. 
Since the previous data indicate that CD180 and IgM operate through similar 
signalling pathways, particularly via BTK/AKT, leading to increased survival of 
CLL cells, it was interesting to investigate the effect of pre-engagement of CD180 
on signalling through sIgM (the BCR) investigated. Whilst sIgM ligation with goat 
anti-human IgM F(ab)2 alone led to a significant activation of pro-survival BTK-
AKT pathway in AKT-S cells, pre-treatment with anti-CD180 mAb redirected pro-
survival signalling mediated through BCR towards pro-apoptotic p38MAPK 
pathway. Rewiring of signalling from pro-survival to pro-apoptotic pathway was 
not observed in control B cells suggesting that modulation is unique for CLL cells. 
Hence it is possible to hypothesise that CD180-mediated activation of CLL cells 
by an unknown microenvironmental ligand may mimic this continuous BCR-
mediated signalling. Therefore, rewiring of intracellular signals from BTK/AKT 
pro-survival circuit to p38MAPK pro-apoptotic pathway in AKT-S CLL cells may 
suggest a possible cross-talk between CD180 and BCR.  A hypothetical scheme 




Figure 6.1: Hypothetical scheme of a cross-talk between CD180 and BCR 
signalling pathways. CD180-mediated pathway can operate via both pro-survival 
BTK/AKT or pro-apoptotic p38MAPK pathway, while sIgM-mediated signalling mostly 
operates through BTK/AKT. Cross-talk between the two receptors redirects signalling 
pathway from BTK/AKT to p38MAPK. Hypothetical precursors of p38MAPK activation 
are suggested (Adapted from Porakishvili et al., 2015). 
However, in contrast to AKT-S cells, pretreatment of p38MAPK-S cells with either 
anti-CD180 or anti-IgM often leads to additive phosphorylation of AKT favouring 
the BTK/AKT antiapoptotic pathway. Although this is a rare event, it emphasises 
the importance of individual tailor-made immunotherapeutic approaches to the 
treatment of CLL.  
Specific inhibitors of AKT, BTK and p38MAPK have been used to confirm the 
exclusivity of activation of AKT and p38MAPK pathways. In all AKT-S CLL 
samples pretreatment with AKT inhibitor, Akti1/2 significantly reduced the CD180 
mediated activation of AKT but did not affect the phosphorylation of AKT in 
p38MAPK-S CLL cells. Moreover, CD180 mediated pro-apoptotic activity in AKT-
S CLL cells was inhibited by Akti1/2 as measured by DiOC6 and Annexin/PI 
staining assays. Pretreatment with inhibitor did not affect the phosphorylation of 
AKT or survival of cells in unstimulated samples, indicating AKT protein kinase is 
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not activated (at least in AKT-S category of CLL cells) without a specific 
stimulation.  Interestingly, Akti1/2 had no effect on CD180-mediated survival of 
p38MAPK-S CLL cells. In contrast, pretreatment of unstimulated p38MAPK-S 
cells with p38MAPK inhibitor, SB203580 significantly reduced spontaneous 
phosphorylation of p38MAPK compared to untreated samples suggesting the 
presence of constitutively phosphorylated p38MAPK in unstimulated CLL cells.  
As expected, SB203580 treatment inhibited CD180 mediated phosphorylation of 
p38MAPK in all p38MAPK-S CLL but did not affect p38MAPK phosphorylation in 
AKT-S CLL cells.  
Recent data strongly indicate that p38MAPK selective inhibitor abrogates CD180-
mediated pro-apoptotic action in p38MAPK-S CLL cells as the pretreatment 
significantly increased the percentages of viable cells compared to unstimulated 
cells. This suggests that although SB203580 inhibits phosphorylation of 
constitutively activated p38MAPK, phosphorylation on its own is not a sole 
contributor to the induction of apoptosis of p38MAPK-S CLL cells, and some 
complementary upstream or downstream events are required which can only be 
initiated upon stimulation with anti-CD180. As expected pre-treatment of AKT-S 
CLL cells with p38MAPK inhibitor had no effect on survival of AKT-S CLL. Hence 
the use of both Akti1/2 and SB203580 confirmed that, in many of the CLL 
samples, activation of AKT and p38MAPK pathways is exclusive.  
CD180 mediated phosphorylation of BTK was inhibited in a majority of AKT-S 
CLL samples when treated with Ibrutinib, a BTK specific inhibitor, suggesting 
sharing of essential protein kinases such as BTK by both CD180 and BCR 
mediated signalling. Only one sample was resistant to Ibrutinib treatment in 
duplicates indicating Ibrutinib resistance in some CLL clones, as reported by 
others (Furman et al., 2014; Wiestner, 2015). That pretreatment with Ibrutinib 
significantly reduced survival of AKT-S CLL cells when stimulated with anti-
CD180 mAb further confirmed that CD180-mediated AKT/BTK pro-survival 
pathway in this category of cells. Confirming previous data in Chapter 3, Ibrutinib 
had no effect on phosphorylation of BTK or survival of p38MAPK-S CLL cells 
suggesting CD180 ligation does not recruit BTK in p38MAPK-S cells.   
Recent data on modulation of surface expression of CD180 in 26 CLL samples 
confirmed the dynamic expression of CD180 in p38MAPK-S and AKT-S 
categories of CLL cells. However, there was a stable spontaneous expression of 
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CD180 on NS and CD180neg CLL cells. Downmodulation of CD180 expression in 
p38MAPK-S suggests that possible endocytosis of CD180 upon ligation of 
putative ligand present in its microenvironment and/or activation of the pro-
apoptotic pathway. Interestingly, the spontaneous increase of CD180 expression 
in AKT-S CLL cells was associated with activation of pro-survival pathway 
suggesting a plausible ligand-receptor interaction in vivo triggering pro-survival. 
NS and CD180neg CLL samples did not modulate surface expression of CD180 
in cultures indicating the significance of ligand-receptor interaction for the 
dynamics of CD180 expression. Moreover, stimulation with anti-IgM significantly 
reduced the surface expression of CD180 in CD180+ CLL samples throughout 0-
72 hours suggesting possible colocalization of both CD180 and BCR into 
membrane lipid rafts and further triggering of CD180 endocytosis by anti-IgM 
ligation. 
There are some restrictions that limit further understanding of the role of 
microenvironmental influences in CLL. For instance, due to the invasiveness of 
the procedure, availability of bone marrow and lymph nodes biopsies is limited 
and in vitro studies classically carried out using peripheral blood-derived tumour 
cells.  Moreover, mimicking the microenvironment in vitro requires further 
understanding of the microenvironment in vivo. Therefore, the majority of studies 
based on the peripheral blood cells only provide a partial image of the real 
interactions in the solid tissues. Thus, the contribution of host microenvironment 
to the proliferation and survival of CLL cells in vivo remains insufficiently defined. 
Issues related to getting enough samples from CLL patients may also limit the 
sturdiness of results and further studies.    
Through the findings of this research project, it was established that CD180 
expression on CLL cells helps to identify different subsets and to delineate their 
physiological status. Since intraclonal diversity plays an important role in the 
clinical outcome of patients with CLL, identification of subsets which respond 
more vigorously to external stimuli is of primary importance. Recent findings on 
modulation of signalling pathways through CD180 and sIgM and the temporal 
effects of their ligation is consistent with multiple ligands in the, in vivo, 
microenvironment playing an important role in the survival of CLL cells. In 
conclusion, sensitisation of AKT-S CLL cells with anti-CD180 leads to re-wiring 
of anti-IgM signalling from pro-survival BTK/AKT to pro-apoptotic p38MAPK 
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pathway, opening the door to new strategies for the treatment of a substantial 
cohort of CLL patients. I anticipate that this study helps to define in detail 
mechanisms leading to the expansion of the leukaemia cells in vivo, the 
progression of the disease and thus leads to the development of novel therapies 
of CLL. 
Future studies 
• Hypothesised co-localization of IgM and CD180 receptors in the lipid rafts 
upon stimulation with anti-CD180 will be assessed to explore the 
interaction between the two receptors. Control and R-CLL cells will be 
stimulated with APC-conjugated anti-CD180 mAb and its co-localisation in 
FITC-conjugated probe for the lipid rafts (FITC-CTB) and sIgM stained with 
PE-conjugated antibody will be studied using confocal analysis.  
• Inhibitors of protein kinases, which are upstream and downstream to 
p38MAPK including for Lyn will be used to understand whether 
complementary upstream or downstream events are required which can 
only be initiated upon stimulation with anti-CD180 and the inhibitors of NF-
κB to determine whether this is the key protein involved in CD180 induced 
survival. 
• Western blotting will be used to confirm the flow cytometry data and to 
assess activation of protein kinases where flow cytometry antibodies are 
not yet commercially available including the effect of PI3K inhibitor 
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